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Chapter 1 
 
Introduction to the subject and outline of the thesis. 
  
   
 
INTRODUCTION 
Urothelial carcinoma is the 6th most common cancer in men and the 10th most common cancer 
in women in The Netherlands as measured in 2014 [1]. Although tumors of the urothelium can 
be seen in the upper urinary tract (pyelum and ureter), about 90-95% of tumors are located 
inside the urinary bladder. 
Bladder cancer is a malignancy of the inner part of the bladder wall. It derives from the mucosa 
layer named urothelium that has special features to resist urine while it is stored awaiting 
micturition. Malignant changes often lead to thickened and fragile tissue in a papillary form. 
The fragility of the tissue can lead to spontaneous bleeding. Therefore, macroscopic 
hematuria without pain or frequency is the most common symptom. 
Following the symptom of macroscopic painless hematuria the patient is referred to the 
urologist who will perform a cystoscopy in an outpatient clinic setting. A bladder tumor can 
easily be recognized in most cases. Only in case of carcinoma in situ (CIS), that gives a slightly 
altered aspect of the bladder mucosa appearing as a flat tumor, it can be more difficult. 
However, CIS usually leads to exfoliation of malignant cells that can be recognized in 
microscopic examination of urine. For that reason, urinary cytology is added to the diagnostic 
armamentarium. After a visual or cytological diagnosis, transurethral resection will be planned 
at the operation theatre. 
With the resection of a bladder tumor we aim two goals [2]. The first is to collect tissue for 
pathological investigation leading to information about tumor stage and grade. The second is 
to remove all potentially cancerous tissue. After resection and pathological examination, 
tumors can be characterised by two important features: the tumor stage and the tumor grade 
[3, 4]. The stage is reflecting information about the anatomical behaviour of the tumor tissue: 
whether it is limited to the layer of tissue from which it originated or it is infiltrating 
surrounding tissue layers. The grade is a reflection of the histological architecture.  Tumors 
that do not invade the detrusor muscle (Stages Tis, Ta or T1) of the urinary bladder are called 
non muscle invasive bladder cancer (NMIBC). In contrast, tumors that invade the detrusor 
muscle or beyond (T2-4) are called muscle invasive bladder cancer (MIBC) (table 1). 
In the curative treatment for NMIBC it is in most cases possible to preserve the bladder and 
its function. In MIBC, standard curative treatment includes removing the urinary bladder as a 
whole, mandating an alternative for storage and passing urine, usually by creating an 
ileocutaneostomy or a neobladder.  
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Table 1. T-stadia according to TNM classification [3] 
Ta Non-invasive papillary carcinoma  
 
Non Muscle Invasive Bladder Cancer 
(NMIBC) 
 
Tis: Non-invasive flat carcinoma (flat carcinoma in situ, 
or CIS) 
T1: The tumor has grown from the layer of cells lining 
the bladder into the connective tissue below. It has 
not grown into the muscle layer of the bladder. 
T2: The tumor has grown into the muscle layer.  
 
 
 
 
 
Muscle Invasive Bladder Cancer 
(MIBC) 
T2a: The tumor has grown only into the inner half of the 
muscle layer. 
T2b: The tumor has grown into the outer half of the 
muscle layer. 
T3 The tumor has grown through the muscle layer of 
the bladder and into the fatty tissue layer that 
surrounds it. 
T3a: The spread to fatty tissue can only be seen by using 
a microscope. 
T3b: The spread to fatty tissue is large enough to be 
seen on imaging tests or to be seen or felt by the 
surgeon. 
T4: The tumor has spread beyond the fatty tissue and 
into nearby organs or structures. It may be growing 
into any of the following: the stroma (main tissue) 
of the prostate, the seminal vesicles, uterus, 
vagina, pelvic wall, or abdominal wall. 
T4a: The tumor has spread to the stroma of the prostate 
(in men), or to the uterus and/or vagina (in 
women). 
T4b The tumor has spread to the pelvic wall or the 
abdominal wall. 
 
In NMIBC, when the urinary bladder is preserved, one of the clinical issues is tumor recurrence 
and progression rate. One explanation for this problem is the biology of this disease: the 
urothelium shows tumor-changes on multiple locations and after resection of one, another 
site can become visible. Another explanation is an incomplete resection. Besides incomplete 
resection of all visible tumor, incomplete resection of non-visible tumor can occur e.g. when 
an invasive growth pattern exists. For these issues, several attributive steps in treatment of 
NMIBC are advocated: 
1. Immediate postoperative chemotherapeutic instillation: within 24 hours of the TUR, a 
chemotherapeutic agent (mitomycin-C or epirubicin) is installed into the bladder to 
prevent early recurrence [5]. A major disadvantage for this strategy is the risk of 
 
complications due to perforation of the bladder wall and subsequent leakage of the 
agent into surrounding tissue [6]. 
2. A re-resection in case of T1 and/ or G3 tumors or in case of initially recognized 
incomplete resection. This proved to lower recurrence and progression rates [7,8,9].  
3. Adjuvant treatment. 
Adjuvant treatment 
In NMIBC, chances of recurrence are varying from 15-61% and of progression from 0,2-17% in 
1 year depending on several aspects of the disease like grade, stage, previous recurrence, 
amount and volume of lesions and presence of carcinoma in situ (CIS) [10]. In the EAU 
guidelines on NMIBC 2015, 3 risk categories are used based on this risk stratification (figure 1) 
[2]. For the intermediate and high risk categories, it is recommended to start adjuvant 
treatment using intravesical instillations with either a chemotherapeutic drug like mitomycin-
C or the immune modulating drug bacillus Calmette-Guérin (BCG) with a one-year 
maintenance schedule. In high risk, BCG for 3 years is advised, although in a subgroup of these 
patients with a very high risk, early cystectomy is advocated.  
 
History of BCG in bladder cancer treatment 
BCG was originally developed as a vaccine for tuberculosis between 1908 and 1921. In 1929, 
the American biostatistician Raymond Pearl described a potential beneficial effect of 
tuberculosis in the incidence of cancer [11]. Already in 1935, Holmgren reported a study using 
BCG in treating stomach cancer [12]. In 1976, Morales described a beneficial effect of BCG 
used as bladder instillation, for which he arbitrarily used 6 weekly instillations [13]. In 1980, 
the first randomised controlled trial on 6 instillations of BCG was published, confirming the 
positive effect of BCG for bladder cancer recurrence rate [14]. The protective effect of BCG 
was even more pronounced when given as a maintenance treatment for a period of three 
years compared to the standard induction of 6 weeks.  As a result of the outcome of this 
publication, maintenance BCG for a period of 3 years became the gold standard. Although BCG 
has been proven to be effective as adjuvant treatment in NMIBC, it can produce moderate to 
severe local and systemic side effects [15].  This has triggered the European Organization for 
Research and Treatment of Cancer Genito-Urinary (EORTC-GU) group to conduct two 
Randomized Controlled Trials (RCT) that focused on reduction of side effects while 
maintaining the efficacy of BCG. Trial 30911 compared maintenance BCG ± isoniazid (INH) to 
epirubicin. In the arms using BCG, INH, an tuberculostatic drug, was added to lower side 
effects. In the final analysis however, it showed not to have any beneficial effect. This has led 
to trial 30962 that compared the effects on both side effects and efficacy of a reduced dose 
and/ or a shorter maintenance period of one year with the normal dose during 3 years. 
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Figure 1. Risk stratification of NMIBC (Derived from EAU guidelines on NMIBC 2015) [5]. 
 
 
Outline of the thesis 
In this thesis, we describe aspects of efficacy and side effects of BCG-treatment based on two 
randomized controlled trials performed by the EORTC-GU group. The final results of trial 
30962 are discussed. The general results of trial 30911 were published between 2003-2010 
[16,17,18,19].  Sub-analyses on the data of trial 30911 are incorporated into this thesis as is 
the analysis on risk factors that used data of both trials. 
 
Part 1 will focus on the efficacy of BCG. 
 
In chapter 2 the results on efficacy will be discussed of EORTC trial 30962. In this trial, patients 
with intermediate to high risk BCG were randomized between 4 study groups that all received 
a certain period of a certain dose of maintenance BCG. Variation in duration (one versus three 
years) and amount (full versus 1/3 dose) determined the four study groups. 
In chapter 3 we focus on another important subject related to efficacy. As BCG is working by 
stimulation of the immune response of the patient, the aging patients may respond differently 
due to a decreased response capacity of their immune system, a phenomenon called 
immunosenescence. We investigated the role of age in the efficacy of the treatment. 
Chapter 4 reflects the statistical exercise to link tumor related factors to the efficacy of BCG, 
based on the study results of both trials 30911 and 30962 leading to the development of a 
nomogram predicting the overall survival of patients treated with BCG. 
 
Part 2 will focus on side effects of BCG. 
 
In chapter 5 the relation of age to the occurrence of side effects of BCG as seen in trial 30911 
are explored. 
In chapter 6 the side effects as reported in trial 30962 are discussed. 
We conclude in chapter 7 with a brief summary of the most important results in regard to 
future developments.  
 
  
13
Ch
ap
te
r 1
 |
 In
tr
od
uc
ti
on
1
 
Figure 1. Risk stratification of NMIBC (Derived from EAU guidelines on NMIBC 2015) [5]. 
 
 
Outline of the thesis 
In this thesis, we describe aspects of efficacy and side effects of BCG-treatment based on two 
randomized controlled trials performed by the EORTC-GU group. The final results of trial 
30962 are discussed. The general results of trial 30911 were published between 2003-2010 
[16,17,18,19].  Sub-analyses on the data of trial 30911 are incorporated into this thesis as is 
the analysis on risk factors that used data of both trials. 
 
Part 1 will focus on the efficacy of BCG. 
 
In chapter 2 the results on efficacy will be discussed of EORTC trial 30962. In this trial, patients 
with intermediate to high risk BCG were randomized between 4 study groups that all received 
a certain period of a certain dose of maintenance BCG. Variation in duration (one versus three 
years) and amount (full versus 1/3 dose) determined the four study groups. 
In chapter 3 we focus on another important subject related to efficacy. As BCG is working by 
stimulation of the immune response of the patient, the aging patients may respond differently 
due to a decreased response capacity of their immune system, a phenomenon called 
immunosenescence. We investigated the role of age in the efficacy of the treatment. 
Chapter 4 reflects the statistical exercise to link tumor related factors to the efficacy of BCG, 
based on the study results of both trials 30911 and 30962 leading to the development of a 
nomogram predicting the overall survival of patients treated with BCG. 
 
Part 2 will focus on side effects of BCG. 
 
In chapter 5 the relation of age to the occurrence of side effects of BCG as seen in trial 30911 
are explored. 
In chapter 6 the side effects as reported in trial 30962 are discussed. 
We conclude in chapter 7 with a brief summary of the most important results in regard to 
future developments.  
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ABSTRACT 
Background: The optimal dose and duration of intravesical bacillus Calmette-Guérin (BCG) in 
the treatment of non muscle invasive bladder cancer (NMIBC) are controversial. 
Objectives: To determine if one third dose (1/3D) is not inferior to full dose (FD), if 1 year (1yr) 
maintenance is not inferior to 3 years (3yrs) maintenance and if 1/3D and 1yr maintenance 
are associated with less toxicity. 
Design, Setting, Participants and Intervention:  After transurethral resection, intermediate and 
high risk NMIBC patients were randomized to one of four BCG groups: 1/3D-1 yr, 1/3D-3 yr, 
FD-1 yr, FD-3 yr. 
Outcome Measurements and Statistical Analysis: The trial was designed as a noninferiority 
study with the null hypothesis of a 10% decrease in the disease-free rate at 5 yr.  Times to 
events were estimated using cumulative incidence functions and compared using the Cox 
proportional hazards regression model. 
Results: In an intent-to-treat analysis of 1355 patients with median follow up 7.1 yr, there 
were no significant differences in toxicity between 1/3D and FD. The null hypotheses of 
inferiority of the disease-free interval for both 1/3D and 1yr could not be rejected. 1/3D-1 yr 
is suboptimal compared to FD-3 yr (HR = 0.75, 95%CI: 0.59-0.94, p = 0.01). Intermediate risk 
patients treated with FD do not benefit from an additional two years of BCG. In high risk 
patients, 3yrs is associated with a reduction in recurrence (HR = 1.61, 95%CI: 1.13-2.30, p = 
0.009), but only when given at FD. There were no differences in progression or survival. 
Conclusions: There were no differences in toxicity between 1/3D and FD. Intermediate risk 
patients should be treated with FD-1 yr. In high-risk patients, FD-3 yr reduces recurrences as 
compared to FD-1yr, but not progressions or deaths. The benefit of the two additional years 
of maintenance should be weighed against its additional costs and inconveniences.  
  
 
INTRODUCTION AND OBJECTIVES 
After initial transurethral resection (TUR), non-muscle invasive bladder cancer (NMIBC) is 
characterized by a high risk of recurrence and, to a lesser extent, progression to muscle 
invasive disease. These risks can be quantified based on a patient’s tumor characteristics using 
EORTC risk tables or with a simplified risk group classification [1,2]. To decrease the risk of 
recurrence and progression, adjuvant instillations of chemotherapy or bacillus Calmette-
Guérin (BCG) are given in accordance with European Association of Urology (EAU) Guidelines 
[3]. In intermediate and high risk patients, the protective effects of maintenance BCG are more 
pronounced as compared to chemotherapy [4, 5]. 
The initial report by Morales et al described six weekly BCG induction instillations [6]. 
Afterwards, it was found that additional instillations of BCG reduced recurrences, however the 
optimal duration of maintenance instillations remains controversial [7-9]. Based on several 
meta-analyses, the EAU guidelines recommend at least 1 year of maintenance. 
A major disadvantage of BCG is its toxicity, leading to interruptions and premature 
discontinuation of maintenance. In EORTC trial 30911, isoniazid (INH) did not reduce toxicity 
for patients on three years of maintenance [10]. However, toxicity was reduced when two 
doses of ofloxacin were given shortly after each of nine BCG instillations [11]. 
The Club Urológico Español de Tratamiento Oncológico (CUETO) compared the effect of a 
reduced dose of BCG to standard dose in intermediate and in high risk patients [12-14]. These 
studies, where a short schedule of < 6 mo BCG was used, suggested that one third dose (1/3D) 
is the minimum effective dose. 
The current randomized phase 3 study (30962) was designed to investigate two strategies to 
decrease the toxicity of maintenance BCG without compromising its efficacy. The purpose is 
to show that 1/3D BCG is not inferior to full dose (FD) BCG and that 1 yr of maintenance is not 
inferior to 3 yr of maintenance with respect to efficacy and that 1/3D and 1 yr of maintenance 
are associated with less toxicity. 
 
MATERIAL AND METHODS 
Inclusion and exclusion criteria 
Patients with biopsy-proven, completely resected, solitary pT1G3 or multiple pTa-T1, grade 1–
3 (1973 World Health Organization [WHO] classification) urothelial carcinoma of the bladder 
were included. Excluded were patients with solitary tumors except T1G3, more than 10 
tumors, carcinoma in situ (CIS), tumors stage T2 or higher, age > 85 yr, WHO performance 
status 3 or 4, previous treatment with BCG and intravesical chemotherapy during the previous 
3 mo. An intravenous pyelography was performed to rule out upper tract tumors. Informed 
consent was obtained in accordance with the Declaration of Helsinki and/or existing national 
and local regulations. 
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ABSTRACT 
Background: The optimal dose and duration of intravesical bacillus Calmette-Guérin (BCG) in 
the treatment of non muscle invasive bladder cancer (NMIBC) are controversial. 
Objectives: To determine if one third dose (1/3D) is not inferior to full dose (FD), if 1 year (1yr) 
maintenance is not inferior to 3 years (3yrs) maintenance and if 1/3D and 1yr maintenance 
are associated with less toxicity. 
Design, Setting, Participants and Intervention:  After transurethral resection, intermediate and 
high risk NMIBC patients were randomized to one of four BCG groups: 1/3D-1 yr, 1/3D-3 yr, 
FD-1 yr, FD-3 yr. 
Outcome Measurements and Statistical Analysis: The trial was designed as a noninferiority 
study with the null hypothesis of a 10% decrease in the disease-free rate at 5 yr.  Times to 
events were estimated using cumulative incidence functions and compared using the Cox 
proportional hazards regression model. 
Results: In an intent-to-treat analysis of 1355 patients with median follow up 7.1 yr, there 
were no significant differences in toxicity between 1/3D and FD. The null hypotheses of 
inferiority of the disease-free interval for both 1/3D and 1yr could not be rejected. 1/3D-1 yr 
is suboptimal compared to FD-3 yr (HR = 0.75, 95%CI: 0.59-0.94, p = 0.01). Intermediate risk 
patients treated with FD do not benefit from an additional two years of BCG. In high risk 
patients, 3yrs is associated with a reduction in recurrence (HR = 1.61, 95%CI: 1.13-2.30, p = 
0.009), but only when given at FD. There were no differences in progression or survival. 
Conclusions: There were no differences in toxicity between 1/3D and FD. Intermediate risk 
patients should be treated with FD-1 yr. In high-risk patients, FD-3 yr reduces recurrences as 
compared to FD-1yr, but not progressions or deaths. The benefit of the two additional years 
of maintenance should be weighed against its additional costs and inconveniences.  
  
 
INTRODUCTION AND OBJECTIVES 
After initial transurethral resection (TUR), non-muscle invasive bladder cancer (NMIBC) is 
characterized by a high risk of recurrence and, to a lesser extent, progression to muscle 
invasive disease. These risks can be quantified based on a patient’s tumor characteristics using 
EORTC risk tables or with a simplified risk group classification [1,2]. To decrease the risk of 
recurrence and progression, adjuvant instillations of chemotherapy or bacillus Calmette-
Guérin (BCG) are given in accordance with European Association of Urology (EAU) Guidelines 
[3]. In intermediate and high risk patients, the protective effects of maintenance BCG are more 
pronounced as compared to chemotherapy [4, 5]. 
The initial report by Morales et al described six weekly BCG induction instillations [6]. 
Afterwards, it was found that additional instillations of BCG reduced recurrences, however the 
optimal duration of maintenance instillations remains controversial [7-9]. Based on several 
meta-analyses, the EAU guidelines recommend at least 1 year of maintenance. 
A major disadvantage of BCG is its toxicity, leading to interruptions and premature 
discontinuation of maintenance. In EORTC trial 30911, isoniazid (INH) did not reduce toxicity 
for patients on three years of maintenance [10]. However, toxicity was reduced when two 
doses of ofloxacin were given shortly after each of nine BCG instillations [11]. 
The Club Urológico Español de Tratamiento Oncológico (CUETO) compared the effect of a 
reduced dose of BCG to standard dose in intermediate and in high risk patients [12-14]. These 
studies, where a short schedule of < 6 mo BCG was used, suggested that one third dose (1/3D) 
is the minimum effective dose. 
The current randomized phase 3 study (30962) was designed to investigate two strategies to 
decrease the toxicity of maintenance BCG without compromising its efficacy. The purpose is 
to show that 1/3D BCG is not inferior to full dose (FD) BCG and that 1 yr of maintenance is not 
inferior to 3 yr of maintenance with respect to efficacy and that 1/3D and 1 yr of maintenance 
are associated with less toxicity. 
 
MATERIAL AND METHODS 
Inclusion and exclusion criteria 
Patients with biopsy-proven, completely resected, solitary pT1G3 or multiple pTa-T1, grade 1–
3 (1973 World Health Organization [WHO] classification) urothelial carcinoma of the bladder 
were included. Excluded were patients with solitary tumors except T1G3, more than 10 
tumors, carcinoma in situ (CIS), tumors stage T2 or higher, age > 85 yr, WHO performance 
status 3 or 4, previous treatment with BCG and intravesical chemotherapy during the previous 
3 mo. An intravenous pyelography was performed to rule out upper tract tumors. Informed 
consent was obtained in accordance with the Declaration of Helsinki and/or existing national 
and local regulations. 
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Randomization and study interventions 
Within 14 d after TUR, patients were randomized to one of four treatment groups: 
1. One third dose BCG with 1 yr of maintenance (1/3D-1 yr): BCG was instilled once a 
week for 6 wk, followed by three weekly instillations at months 3, 6, and 12. 
2. Full dose BCG with 1 yr of maintenance (FD-1 yr). 
3. One third dose BCG with 3 yr of maintenance (1/3D-3 yr): BCG was instilled once a 
week for 6 wk, followed by three weekly instillations at months 3, 6, 12, 18, 24, 30 and 
36, for a total of 27 instillations. 
4. Full dose BCG with 3 yr of maintenance (FD-3 yr). 
 
The OncoTICE® strain containing 5 x 108 CFU was used. Preparation of 1/3 dose was done 
either by dissolving 1 vial with 150ml of saline and taking 50 ml or by dissolving with 50 ml, 
taking 17 ml, and diluting this to 50 ml. 
Patients stopped protocol treatment at the second Ta/T1 recurrence after randomization and 
at progression to muscle-invasive disease, appearance of CIS, carcinoma in the upper urinary 
tract or prostatic urethra, or distant metastases. Further treatment was at the discretion of 
the local investigator. Cystoscopy and urine cytology were repeated every 3 mo during the 
first 3 yr and every 6 mo thereafter. Recurrence of disease was established by histology. 
Local (bacterial cystitis, chemical cystitis, frequency, hematuria) and systemic (fever, general 
malaise, lung infection, skin rash, sepsis) side effects were collected during induction and 
maintenance instillations according to a standardized format. 
 
Endpoints 
The primary endpoint was the duration of the disease-free interval (DFI): the time until first 
recurrence including progression to muscle invasive disease, distant metastases and death 
due to bladder cancer. Secondary endpoints included time to progression (muscle-invasive 
disease, distant metastases, death due to bladder cancer), duration of survival and toxicity. 
 
Statistical considerations 
The trial was designed as a non-inferiority study. Two comparisons were foreseen for each of 
the two null hypotheses:  
(1)  The efficacy of one third dose is inferior to full dose:  
- One third versus FD BCG with 1 yr of maintenance  
- One third versus FD BCG with 3 yr of maintenance  
(2)  The efficacy of one year maintenance is inferior to three years maintenance:  
- One year versus 3 yr of maintenance with 1/3 D BCG 
- One year versus 3 yr of maintenance with FD BCG 
One sided non-inferiority tests at α = 0.025 and β = 0.20 were planned for each comparison. 
Times to events were compared using the Wald test from a Cox proportional hazards 
regression model. The disease free interval and time to progression curves were estimated 
using cumulative incidence functions to take into account patients who died of other causes 
 
prior to the event of interest (competing risks). Duration of survival curves were estimated 
using the Kaplan-Meier technique. 
To reject the null hypothesis of a decrease of 10% in the 5-yr disease-free rate from 50% on 
the control arms (FD BCG, 3 yr of maintenance) to 40% on the experimental arms (1/3 D BCG, 
1 yr of maintenance) with hazard ratio (HR) = 1.32, 414 events and 644 patients were required 
for each of the four comparisons. As patients were analyzed twice, a total of 1288 patients 
and 828 events were required, leading to 322 patients in each treatment group.  
The study was reviewed in September 2011 by the EORTC Independent Data Monitoring 
Committee which recommended the release of the results. Since there was no interaction 
between the dose and duration of maintenance, the study was analyzed as a 2 x 2 factorial 
design, retrospectively stratifying the dose comparison by the duration of maintenance and 
vice versa, with a power of 92% to reject the null hypothesis of inferiority for each comparison 
at one sided α = 0.025 (Table 1). 
 
Table 1. Stratified comparison of the study arms   
Study arms 1/3 dose Full dose 
Dose stratified 
comparison of 
duration 
1 year I II I vs III 
+ 
II vs IV 3 years III IV 
Duration 
stratified 
comparison of 
dose 
I vs II 
+ 
III vs IV 
 
 
Quality assurance 
In accordance with EORTC Quality Assurance policies, central EORTC data management and 
quality control were supplemented by on site audits.  
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Randomization and study interventions 
Within 14 d after TUR, patients were randomized to one of four treatment groups: 
1. One third dose BCG with 1 yr of maintenance (1/3D-1 yr): BCG was instilled once a 
week for 6 wk, followed by three weekly instillations at months 3, 6, and 12. 
2. Full dose BCG with 1 yr of maintenance (FD-1 yr). 
3. One third dose BCG with 3 yr of maintenance (1/3D-3 yr): BCG was instilled once a 
week for 6 wk, followed by three weekly instillations at months 3, 6, 12, 18, 24, 30 and 
36, for a total of 27 instillations. 
4. Full dose BCG with 3 yr of maintenance (FD-3 yr). 
 
The OncoTICE® strain containing 5 x 108 CFU was used. Preparation of 1/3 dose was done 
either by dissolving 1 vial with 150ml of saline and taking 50 ml or by dissolving with 50 ml, 
taking 17 ml, and diluting this to 50 ml. 
Patients stopped protocol treatment at the second Ta/T1 recurrence after randomization and 
at progression to muscle-invasive disease, appearance of CIS, carcinoma in the upper urinary 
tract or prostatic urethra, or distant metastases. Further treatment was at the discretion of 
the local investigator. Cystoscopy and urine cytology were repeated every 3 mo during the 
first 3 yr and every 6 mo thereafter. Recurrence of disease was established by histology. 
Local (bacterial cystitis, chemical cystitis, frequency, hematuria) and systemic (fever, general 
malaise, lung infection, skin rash, sepsis) side effects were collected during induction and 
maintenance instillations according to a standardized format. 
 
Endpoints 
The primary endpoint was the duration of the disease-free interval (DFI): the time until first 
recurrence including progression to muscle invasive disease, distant metastases and death 
due to bladder cancer. Secondary endpoints included time to progression (muscle-invasive 
disease, distant metastases, death due to bladder cancer), duration of survival and toxicity. 
 
Statistical considerations 
The trial was designed as a non-inferiority study. Two comparisons were foreseen for each of 
the two null hypotheses:  
(1)  The efficacy of one third dose is inferior to full dose:  
- One third versus FD BCG with 1 yr of maintenance  
- One third versus FD BCG with 3 yr of maintenance  
(2)  The efficacy of one year maintenance is inferior to three years maintenance:  
- One year versus 3 yr of maintenance with 1/3 D BCG 
- One year versus 3 yr of maintenance with FD BCG 
One sided non-inferiority tests at α = 0.025 and β = 0.20 were planned for each comparison. 
Times to events were compared using the Wald test from a Cox proportional hazards 
regression model. The disease free interval and time to progression curves were estimated 
using cumulative incidence functions to take into account patients who died of other causes 
 
prior to the event of interest (competing risks). Duration of survival curves were estimated 
using the Kaplan-Meier technique. 
To reject the null hypothesis of a decrease of 10% in the 5-yr disease-free rate from 50% on 
the control arms (FD BCG, 3 yr of maintenance) to 40% on the experimental arms (1/3 D BCG, 
1 yr of maintenance) with hazard ratio (HR) = 1.32, 414 events and 644 patients were required 
for each of the four comparisons. As patients were analyzed twice, a total of 1288 patients 
and 828 events were required, leading to 322 patients in each treatment group.  
The study was reviewed in September 2011 by the EORTC Independent Data Monitoring 
Committee which recommended the release of the results. Since there was no interaction 
between the dose and duration of maintenance, the study was analyzed as a 2 x 2 factorial 
design, retrospectively stratifying the dose comparison by the duration of maintenance and 
vice versa, with a power of 92% to reject the null hypothesis of inferiority for each comparison 
at one sided α = 0.025 (Table 1). 
 
Table 1. Stratified comparison of the study arms   
Study arms 1/3 dose Full dose 
Dose stratified 
comparison of 
duration 
1 year I II I vs III 
+ 
II vs IV 3 years III IV 
Duration 
stratified 
comparison of 
dose 
I vs II 
+ 
III vs IV 
 
 
Quality assurance 
In accordance with EORTC Quality Assurance policies, central EORTC data management and 
quality control were supplemented by on site audits.  
  
24
Chapter 2 | Final results of EORTC-GU group trial 30962
 
RESULTS  
From March 1997 to April 2005, 1805 patients were centrally randomized at the EORTC HQ by 
57 centers from 13 countries with stratification by site. During patient entry and prior to 
analysis of endpoint data, study coordinator central review (J.O. and M.B) and on site audits 
led to the exclusion of all data from 6 sites for non-compliance. After quality control exclusion 
of these 450 patients, patient entry continued until 1355 patients had been randomized: 341 
to 1/3D–1 yr, 339 to FD–1 yr, 337 to 1/3D–3 yr, 338 to FD–3 yr.  
A total of 75 of 1355 patients (5.5%) were ineligible, the main reasons being too long a delay 
between TUR and randomization and an incorrect tumor type at entry (Figure 1). 
 
Figure 1. CONSORT Diagram
 
 
Baseline patient and tumor characteristics were generally well balanced between the 4 
treatment groups (Table 2): 59% were primary tumors, 13% had a single tumor, 63% were Ta 
and 27% were G3. Using the simplified classification, 41% were high risk (T1 or G3) and 58% 
were intermediate risk, with somewhat fewer high risk patients in the 1/3D-3 yr arm. 
  
 
Table 2. Patient and tumor characteristics by treatment arm 
 
 
 
 
BCG treatment arm 
1/3 dose - 1yr 
(n=341)  
Full dose - 1yr 
(n=339)  
1/3 dose - 3yrs 
(n=337)  
Full dose - 
3yrs (n=338) 
Total 
(n=1355) 
n (%) n (%)  n (%)  n (%)  n (%)  
Eligible      
No 23 (6.7) 21 (6.2) 18 (5.3) 13 (3.8) 75 (5.5) 
Yes 318 (93.3) 318 (93.8) 319 (94.7) 324 (95.9) 1279 (94.4) 
Unknown 0 0 0 1 (0.3) 1 (0.1) 
Age (years)      
Median  68.0 67.0 69.0 67.0 68.0 
Range  29.0 - 84.0 30.0 - 84.0 39.0 - 85.0 30.0 - 84.0 29.0 - 85.0 
Gender      
Male  275 (80.6) 282 (83.2) 272 (80.7) 270 (79.9) 1099 (81.1) 
Female  64 (18.8) 54 (15.9) 64 (19.0) 65 (19.2) 247 (18.2) 
Unknown  2 (0.6) 3 (0.9) 1 (0.3) 3 (0.9) 9 (0.7) 
WHO  performance 
status 
     
0  281 (82.4) 278 (82.0) 273 (81.0) 287 (84.9) 1119 (82.6) 
1  52 (15.2) 56 (16.5) 59 (17.5) 45 (13.3) 212 (15.6) 
2  8 (2.3) 5 (1.5) 5 (1.5) 6 (1.8) 24 (1.8) 
Type of bladder 
cancer 
     
Primary 208 (61.0) 212 (62.5) 195 (57.9) 178 (52.7) 793 (58.5) 
Recurrent 131 (38.4) 124 (36.6) 141 (41.8) 157 (46.4) 553 (40.8) 
Unknown 2 (0.6) 3 (0.9) 1 (0.3) 3 (0.9) 9 (0.7) 
Number of Tumors      
Single 51 (15.0) 46 (13.6) 44 (13.1) 38 (11.2) 179 (13.2) 
Multiple  286 (83.9) 291 (85.8) 291 (86.4) 295 (87.3) 1163 (85.8) 
Unknown  4 (1.2) 2 (0.6) 2 (0.6) 5 (1.5) 13 (1.0) 
Largest tumor 
diameter (mm) 
     
Median  15.0 15.0 15.0 12.0 15.0 
Range  1.0 - 80.0 2.0 - 98.0 2.0 - 80.0 1.0 - 98.0 1.0 - 98.0 
N obs  318 322 321 315 1276 
T category      
pT0 0 (0.0) 0 (0.0) 1 (0.3) 2 (0.6) 3 (0.2) 
pTa  202 (59.2) 207 (61.1) 229 (68.0) 214 (63.3) 852 (62.9) 
pT1  137 (40.2) 130 (38.3) 107 (31.8) 119 (35.2) 493 (36.4) 
pT2  2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.1) 
Unknown  0 (0.0) 2 (0.6) 0 (0.0) 3 (0.9) 5 (0.4) 
WHO 1973 grade      
G0  0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.1) 
G1  84 (24.6) 94 (27.7) 110 (32.6) 99 (29.3) 387 (28.6) 
G2  162 (47.5) 151 (44.5) 147 (43.6) 138 (40.8) 598 (44.1) 
G3  95 (27.9) 91 (26.8) 78 (23.1) 97 (28.7) 361 (26.6) 
Unknown 0 (0.0) 3 (0.9) 1 (0.3) 4 (1.2) 8 (0.6) 
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RESULTS  
From March 1997 to April 2005, 1805 patients were centrally randomized at the EORTC HQ by 
57 centers from 13 countries with stratification by site. During patient entry and prior to 
analysis of endpoint data, study coordinator central review (J.O. and M.B) and on site audits 
led to the exclusion of all data from 6 sites for non-compliance. After quality control exclusion 
of these 450 patients, patient entry continued until 1355 patients had been randomized: 341 
to 1/3D–1 yr, 339 to FD–1 yr, 337 to 1/3D–3 yr, 338 to FD–3 yr.  
A total of 75 of 1355 patients (5.5%) were ineligible, the main reasons being too long a delay 
between TUR and randomization and an incorrect tumor type at entry (Figure 1). 
 
Figure 1. CONSORT Diagram
 
 
Baseline patient and tumor characteristics were generally well balanced between the 4 
treatment groups (Table 2): 59% were primary tumors, 13% had a single tumor, 63% were Ta 
and 27% were G3. Using the simplified classification, 41% were high risk (T1 or G3) and 58% 
were intermediate risk, with somewhat fewer high risk patients in the 1/3D-3 yr arm. 
  
 
Table 2. Patient and tumor characteristics by treatment arm 
 
 
 
 
BCG treatment arm 
1/3 dose - 1yr 
(n=341)  
Full dose - 1yr 
(n=339)  
1/3 dose - 3yrs 
(n=337)  
Full dose - 
3yrs (n=338) 
Total 
(n=1355) 
n (%) n (%)  n (%)  n (%)  n (%)  
Eligible      
No 23 (6.7) 21 (6.2) 18 (5.3) 13 (3.8) 75 (5.5) 
Yes 318 (93.3) 318 (93.8) 319 (94.7) 324 (95.9) 1279 (94.4) 
Unknown 0 0 0 1 (0.3) 1 (0.1) 
Age (years)      
Median  68.0 67.0 69.0 67.0 68.0 
Range  29.0 - 84.0 30.0 - 84.0 39.0 - 85.0 30.0 - 84.0 29.0 - 85.0 
Gender      
Male  275 (80.6) 282 (83.2) 272 (80.7) 270 (79.9) 1099 (81.1) 
Female  64 (18.8) 54 (15.9) 64 (19.0) 65 (19.2) 247 (18.2) 
Unknown  2 (0.6) 3 (0.9) 1 (0.3) 3 (0.9) 9 (0.7) 
WHO  performance 
status 
     
0  281 (82.4) 278 (82.0) 273 (81.0) 287 (84.9) 1119 (82.6) 
1  52 (15.2) 56 (16.5) 59 (17.5) 45 (13.3) 212 (15.6) 
2  8 (2.3) 5 (1.5) 5 (1.5) 6 (1.8) 24 (1.8) 
Type of bladder 
cancer 
     
Primary 208 (61.0) 212 (62.5) 195 (57.9) 178 (52.7) 793 (58.5) 
Recurrent 131 (38.4) 124 (36.6) 141 (41.8) 157 (46.4) 553 (40.8) 
Unknown 2 (0.6) 3 (0.9) 1 (0.3) 3 (0.9) 9 (0.7) 
Number of Tumors      
Single 51 (15.0) 46 (13.6) 44 (13.1) 38 (11.2) 179 (13.2) 
Multiple  286 (83.9) 291 (85.8) 291 (86.4) 295 (87.3) 1163 (85.8) 
Unknown  4 (1.2) 2 (0.6) 2 (0.6) 5 (1.5) 13 (1.0) 
Largest tumor 
diameter (mm) 
     
Median  15.0 15.0 15.0 12.0 15.0 
Range  1.0 - 80.0 2.0 - 98.0 2.0 - 80.0 1.0 - 98.0 1.0 - 98.0 
N obs  318 322 321 315 1276 
T category      
pT0 0 (0.0) 0 (0.0) 1 (0.3) 2 (0.6) 3 (0.2) 
pTa  202 (59.2) 207 (61.1) 229 (68.0) 214 (63.3) 852 (62.9) 
pT1  137 (40.2) 130 (38.3) 107 (31.8) 119 (35.2) 493 (36.4) 
pT2  2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.1) 
Unknown  0 (0.0) 2 (0.6) 0 (0.0) 3 (0.9) 5 (0.4) 
WHO 1973 grade      
G0  0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.1) 
G1  84 (24.6) 94 (27.7) 110 (32.6) 99 (29.3) 387 (28.6) 
G2  162 (47.5) 151 (44.5) 147 (43.6) 138 (40.8) 598 (44.1) 
G3  95 (27.9) 91 (26.8) 78 (23.1) 97 (28.7) 361 (26.6) 
Unknown 0 (0.0) 3 (0.9) 1 (0.3) 4 (1.2) 8 (0.6) 
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 1/3 dose - 1yr 
(n=341)  
Full dose - 1yr 
(n=339)  
1/3 dose - 3yrs 
(n=337)  
Full dose - 
3yrs (n=338)  
Total 
(n=1355) 
n (%) n (%) n (%) n (%) n (%)  
EORTC Recurrence 
Score 
     
< 9 (Intermediate 
Risk) 
234 (68.6) 242 (71.4) 226 (67.1) 215 (63.6) 917 (67.7) 
10 - 17 (High 
Risk) 
76 (22.3) 74 (21.8) 90 (26.7) 96 (28.4) 336 (24.8) 
Missing 31 (9.1) 23 (6.8) 21 (6.2) 27 (8.0) 102 (7.5) 
EORTC Progression 
Score 
     
< 6 (Intermediate 
Risk) 
92 (27.0) 100 (29.5) 106 (31.5) 71 (21.0) 369 (27.2) 
7 – 13 (High Risk) 174 (51.0) 177 (52.2) 180 (53.4) 202 (59.8) 733 (54.1) 
14 – 23 (High 
Risk) 
44 (12.9) 39 (11.5) 30 (8.9) 38 (11.2) 151 (11.1) 
Missing 31 (9.1) 23 (6.8) 21 (6.2) 27 (8.0) 102 (7.5) 
Simplified Risk 
Group 
     
Intermediate risk 192 (56.3) 191 (56.3) 218 (64.7) 188 (55.6) 789 (58.2)                                                                                          
High risk* 149 (43.7) 146 (43.1) 119 (35.3) 146 (43.2) 560 (41.3)                                                                                          
Unknown 0 (0.0) 2 (0.6) 0 (0.0) 4 (1.2) 6 (0.4)                                                                                           
*High risk = T1 and/or G3 
 
A total of 39 patients (3%) did not start treatment, 11 of whom were ineligible. In the 
remaining 1316 patients, the amount of treatment received is shown in Table 3.  
Table 3. Amount of treatment received 
 BCG treatment arm 
1/3 dose - 1yr 
(n=341) 
Full dose - 1yr 
(n=339) 
1/3 dose - 
3yrs (n=337) 
Full dose - 3yrs 
(n=338) 
n (%) n (%) n (%) n (%) 
No treatment 7 (2.1) 10 (2.9) 14 (4.2) 8 (2.4) 
Started treatment 334 (97.9) 329 (97.1) 323 (95.9) 330 (97.6) 
Amount of treatment     
6 wk  48 (14.1) 36 (10.6) 33 (9.8) 37 (10.9) 
3 mo  35 (10.3) 37 (10.9) 33 (9.8) 37 (10.9) 
6 mo  44 (12.9) 43 (12.7) 46 (13.6) 37 (10.9) 
12 mo 198 (58.1) 210 (61.9) 29 (8.6) 37 (10.9) 
18 mo  8 (2.3) 2 (0.6) 16 (4.7) 18 (5.3) 
24 mo  0 0 18 (5.3) 23 (6.8) 
30 mo 1 (0.3) 1 (0.3) 24 (7.1) 19 (5.6) 
36 mo 0 0 115 (34.1) 119 (35.2) 
> 36 mo 0 0 9 (2.7) 3 (0.9) 
 
 
Median time between TUR and first instillation was 15 d. A total of 420 of 680 patients (61.8%) 
randomized to 1 yr of maintenance completed 12 mo of treatment while 246 of 675 patients 
(36.4%) randomized to 3 yr of maintenance completed all 36 mo. A total of 103 patients (7.8%) 
stopped treatment due to local or systemic side effects (Table 4a, 4b): in 47 patients (7.1%) 
randomized to 1 yr of maintenance and 56 patients (8.6%) randomized to 3 yr of maintenance. 
35 of these 56 patients (5.4%) stopped already during the first year while 21 (3.2%) stopped 
in the second or third year. The most frequent local side effects were bacterial and/or 
chemical cystitis (56.2%), hematuria (46.0%) and frequency (45.1%) whereas the most 
frequent systemic side effects were general malaise (15.5%) and fever (8.1%). There were no 
medically significant differences in toxicity between the treatment groups. Neither reducing 
the dose nor shortening the duration of maintenance decreased the percentage of patients 
who discontinued treatment due to side effects. Toxicity will be reported in more detail in a 
separate paper. 
Tables 4a, b. Definitive stop of instillations due to side effects in patients who started 
treatment (per treatment group) 
(a)   BCG treatment arm  
Systemic or local 
side effects   
1/3 dose - 1yr 
(n=334)  
Full dose - 1yr 
(n=329)  
1/3 dose - 3yrs 
(n=323)  
Full dose - 3yrs 
(n=330)  
Total 
(n=1316) 
 n (%) n (%)  n (%)  n (%)  n (%) 
Within 1st year 24 (7.2) 23 (7.0) 7 (5.3) 18 (5.5) 82 (6.2) 
After the 1st year 0 (0.0) 0 (0.0) 9 (2.8) 12 (3.6) 21 (1.6) 
Total  24 (7.2) 23 (7.0) 26 (8.1) 30 (9.1) 103 (7.8) 
 
(b) BCG intervention 
Systemic or local 
side effects   
1/3 dose 
(1yr + 3yrs) 
(n=657) 
Full dose 
(1yr + 3yrs) 
(n=659) 
1 yr 
(1/3D + FD) 
(n=663) 
3 yrs 
(1/3D + FD) 
(n=653) 
 n (%) n (%) n (%) n (%) 
Within the 1st year  41 (6.2) 41 (6.2) 47 (7.1) 35 (5.4) 
After the 1st year  9 (1.4) 12 (1.8) 0 (0.0) 21 (3.2) 
Total 50 (7,6) 53 (8,0) 47 (7,1) 56 (8,6) 
 
A total of 650 (49%) of 1316 patients started but did not complete their treatment. The 
reasons across the four treatment groups were inefficacy or recurrence in 338 (26%), toxicity 
in 91 (7%) and other reasons in 221 (17%). 
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 1/3 dose - 1yr 
(n=341)  
Full dose - 1yr 
(n=339)  
1/3 dose - 3yrs 
(n=337)  
Full dose - 
3yrs (n=338)  
Total 
(n=1355) 
n (%) n (%) n (%) n (%) n (%)  
EORTC Recurrence 
Score 
     
< 9 (Intermediate 
Risk) 
234 (68.6) 242 (71.4) 226 (67.1) 215 (63.6) 917 (67.7) 
10 - 17 (High 
Risk) 
76 (22.3) 74 (21.8) 90 (26.7) 96 (28.4) 336 (24.8) 
Missing 31 (9.1) 23 (6.8) 21 (6.2) 27 (8.0) 102 (7.5) 
EORTC Progression 
Score 
     
< 6 (Intermediate 
Risk) 
92 (27.0) 100 (29.5) 106 (31.5) 71 (21.0) 369 (27.2) 
7 – 13 (High Risk) 174 (51.0) 177 (52.2) 180 (53.4) 202 (59.8) 733 (54.1) 
14 – 23 (High 
Risk) 
44 (12.9) 39 (11.5) 30 (8.9) 38 (11.2) 151 (11.1) 
Missing 31 (9.1) 23 (6.8) 21 (6.2) 27 (8.0) 102 (7.5) 
Simplified Risk 
Group 
     
Intermediate risk 192 (56.3) 191 (56.3) 218 (64.7) 188 (55.6) 789 (58.2)                                                                                          
High risk* 149 (43.7) 146 (43.1) 119 (35.3) 146 (43.2) 560 (41.3)                                                                                          
Unknown 0 (0.0) 2 (0.6) 0 (0.0) 4 (1.2) 6 (0.4)                                                                                           
*High risk = T1 and/or G3 
 
A total of 39 patients (3%) did not start treatment, 11 of whom were ineligible. In the 
remaining 1316 patients, the amount of treatment received is shown in Table 3.  
Table 3. Amount of treatment received 
 BCG treatment arm 
1/3 dose - 1yr 
(n=341) 
Full dose - 1yr 
(n=339) 
1/3 dose - 
3yrs (n=337) 
Full dose - 3yrs 
(n=338) 
n (%) n (%) n (%) n (%) 
No treatment 7 (2.1) 10 (2.9) 14 (4.2) 8 (2.4) 
Started treatment 334 (97.9) 329 (97.1) 323 (95.9) 330 (97.6) 
Amount of treatment     
6 wk  48 (14.1) 36 (10.6) 33 (9.8) 37 (10.9) 
3 mo  35 (10.3) 37 (10.9) 33 (9.8) 37 (10.9) 
6 mo  44 (12.9) 43 (12.7) 46 (13.6) 37 (10.9) 
12 mo 198 (58.1) 210 (61.9) 29 (8.6) 37 (10.9) 
18 mo  8 (2.3) 2 (0.6) 16 (4.7) 18 (5.3) 
24 mo  0 0 18 (5.3) 23 (6.8) 
30 mo 1 (0.3) 1 (0.3) 24 (7.1) 19 (5.6) 
36 mo 0 0 115 (34.1) 119 (35.2) 
> 36 mo 0 0 9 (2.7) 3 (0.9) 
 
 
Median time between TUR and first instillation was 15 d. A total of 420 of 680 patients (61.8%) 
randomized to 1 yr of maintenance completed 12 mo of treatment while 246 of 675 patients 
(36.4%) randomized to 3 yr of maintenance completed all 36 mo. A total of 103 patients (7.8%) 
stopped treatment due to local or systemic side effects (Table 4a, 4b): in 47 patients (7.1%) 
randomized to 1 yr of maintenance and 56 patients (8.6%) randomized to 3 yr of maintenance. 
35 of these 56 patients (5.4%) stopped already during the first year while 21 (3.2%) stopped 
in the second or third year. The most frequent local side effects were bacterial and/or 
chemical cystitis (56.2%), hematuria (46.0%) and frequency (45.1%) whereas the most 
frequent systemic side effects were general malaise (15.5%) and fever (8.1%). There were no 
medically significant differences in toxicity between the treatment groups. Neither reducing 
the dose nor shortening the duration of maintenance decreased the percentage of patients 
who discontinued treatment due to side effects. Toxicity will be reported in more detail in a 
separate paper. 
Tables 4a, b. Definitive stop of instillations due to side effects in patients who started 
treatment (per treatment group) 
(a)   BCG treatment arm  
Systemic or local 
side effects   
1/3 dose - 1yr 
(n=334)  
Full dose - 1yr 
(n=329)  
1/3 dose - 3yrs 
(n=323)  
Full dose - 3yrs 
(n=330)  
Total 
(n=1316) 
 n (%) n (%)  n (%)  n (%)  n (%) 
Within 1st year 24 (7.2) 23 (7.0) 7 (5.3) 18 (5.5) 82 (6.2) 
After the 1st year 0 (0.0) 0 (0.0) 9 (2.8) 12 (3.6) 21 (1.6) 
Total  24 (7.2) 23 (7.0) 26 (8.1) 30 (9.1) 103 (7.8) 
 
(b) BCG intervention 
Systemic or local 
side effects   
1/3 dose 
(1yr + 3yrs) 
(n=657) 
Full dose 
(1yr + 3yrs) 
(n=659) 
1 yr 
(1/3D + FD) 
(n=663) 
3 yrs 
(1/3D + FD) 
(n=653) 
 n (%) n (%) n (%) n (%) 
Within the 1st year  41 (6.2) 41 (6.2) 47 (7.1) 35 (5.4) 
After the 1st year  9 (1.4) 12 (1.8) 0 (0.0) 21 (3.2) 
Total 50 (7,6) 53 (8,0) 47 (7,1) 56 (8,6) 
 
A total of 650 (49%) of 1316 patients started but did not complete their treatment. The 
reasons across the four treatment groups were inefficacy or recurrence in 338 (26%), toxicity 
in 91 (7%) and other reasons in 221 (17%). 
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Median follow up was 7.1 yr with a maximum of 13.5 yr. In an intent to treat analysis, 587 of 
1355 patients (43.3%) recurred, including 507 (37.4%) with a Ta/T1 recurrence, 91 (6.7%) who 
developed CIS, 109 (8.0%) who progressed to ≥ pT2 and 67 (4.9%) who developed distant 
metastases.  369 patients (27.2%) died, 68 (5.0%) due to bladder cancer (Table 5). 
Table 5. Patient Outcome by Treatment Group 
 BCG treatment arm 
1/3 dose - 1yr 
(n=341) 
Full dose - 1yr 
(n=339) 
1/3 dose - 3yrs 
(n=337) 
Full dose - 3yrs 
(n=338) 
Total 
(n=1355) 
n (%) n (%) n (%) n (%) n (%) 
Disease Recurrence      
No  175 (51.3) 194 (57.2) 192 (57.0) 207 (61.2) 768 (56.7) 
Yes  166 (48.7) 145 (42.8) 145 (43.0) 131 (38.8) 587 (43.3) 
5 Year Disease Free 
Rate 
54.5% 58.8% 62.6% 64.2%  
Progression to ≥pT2       
No  315 (92.4) 308 (90.9) 307 (91.1) 316 (93.5) 1246 (92.0) 
Yes  26 (7.6) 31 (9.1) 30 (8.9) 22 (6.5) 109 (8.0) 
Presence of CIS      
No  318 (93.3) 315 (92.9) 309 (91.7) 322 (95.3) 1264 (93.3) 
Yes  23 (6.7) 24 (7.1) 28 (8.3) 16 (4.7) 91 (6.7) 
Distant metastases      
No  326 (95.6) 323 (95.3) 319 (94.7) 320 (94.7) 1288 (95.1) 
Yes  15 (4.4) 16 (4.7) 18 (5.3) 18 (5.3) 67 (4.9) 
Second primary tumor      
No  302 (88.6) 308 (90.9) 290 (86.1) 289 (85.5) 1189 (87.7) 
Yes  39 (11.4) 31 (9.1) 47 (13.9) 49 (14.5) 166 (12.3) 
Survival status      
Alive  258 (75.7) 251 (74.0) 236 (70.0) 241 (71.3) 986 (72.8) 
Dead  83 (24.3) 88 (26.0) 101 (30.0) 97 (28.7) 369 (27.2) 
Bladder cancer  13 (3.8) 20 (5.9) 17 (5.0) 18 (5.3) 68 (5.0) 
Cardiovascular  29 (8.5) 34 (10.0) 39 (11.6) 32 (9.5) 134 (9.9) 
Other   
malignancy 
8 (2.3) 13 (3.8) 19 (5.6) 22 (6.5) 62 (4.6) 
Other cause 18 (5,3) 13 (3,8) 18 (5,3) 13 (3,8) 62 (4,6) 
Cause unknown  15 (4.4) 8 (2.4) 8 (2.4) 12 (3.6) 43 (3.2) 
 
A total of 5 yr disease free (DF) rates were 54.5%, 58.8%, 62.6% and 64.2% on 1/3D-1 yr, FD-1 
yr, 1/3D-3 yr and FD-3 yr, respectively (Figure 2). The pre-specified decrease of 10% in the 5yr 
DF rate was only observed between the patients receiving 1/3D-1yr and FD-3yrs, (HR = 0.75, 
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The null hypotheses of inferiority for duration of the DFI of 1/3D BCG (HR = 1.15, 95%CI: 0.98-
1.35, p = 0.045, Figure 3) and 1 yr of BCG maintenance (HR = 1.17, 95%CI: 0.99-1.38, p = 0.069, 
Figure 4) could not be rejected at the one sided 0.025 level. Tests for the superiority of FD 
versus 1/3D (p = 0.092) and 3 yr versus 1 yr of maintenance (p = 0.059) were also not significant 
at the two sided 0.05 level. In patients who were still disease free at 18 mo, i.e. those patients 
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Median follow up was 7.1 yr with a maximum of 13.5 yr. In an intent to treat analysis, 587 of 
1355 patients (43.3%) recurred, including 507 (37.4%) with a Ta/T1 recurrence, 91 (6.7%) who 
developed CIS, 109 (8.0%) who progressed to ≥ pT2 and 67 (4.9%) who developed distant 
metastases.  369 patients (27.2%) died, 68 (5.0%) due to bladder cancer (Table 5). 
Table 5. Patient Outcome by Treatment Group 
 BCG treatment arm 
1/3 dose - 1yr 
(n=341) 
Full dose - 1yr 
(n=339) 
1/3 dose - 3yrs 
(n=337) 
Full dose - 3yrs 
(n=338) 
Total 
(n=1355) 
n (%) n (%) n (%) n (%) n (%) 
Disease Recurrence      
No  175 (51.3) 194 (57.2) 192 (57.0) 207 (61.2) 768 (56.7) 
Yes  166 (48.7) 145 (42.8) 145 (43.0) 131 (38.8) 587 (43.3) 
5 Year Disease Free 
Rate 
54.5% 58.8% 62.6% 64.2%  
Progression to ≥pT2       
No  315 (92.4) 308 (90.9) 307 (91.1) 316 (93.5) 1246 (92.0) 
Yes  26 (7.6) 31 (9.1) 30 (8.9) 22 (6.5) 109 (8.0) 
Presence of CIS      
No  318 (93.3) 315 (92.9) 309 (91.7) 322 (95.3) 1264 (93.3) 
Yes  23 (6.7) 24 (7.1) 28 (8.3) 16 (4.7) 91 (6.7) 
Distant metastases      
No  326 (95.6) 323 (95.3) 319 (94.7) 320 (94.7) 1288 (95.1) 
Yes  15 (4.4) 16 (4.7) 18 (5.3) 18 (5.3) 67 (4.9) 
Second primary tumor      
No  302 (88.6) 308 (90.9) 290 (86.1) 289 (85.5) 1189 (87.7) 
Yes  39 (11.4) 31 (9.1) 47 (13.9) 49 (14.5) 166 (12.3) 
Survival status      
Alive  258 (75.7) 251 (74.0) 236 (70.0) 241 (71.3) 986 (72.8) 
Dead  83 (24.3) 88 (26.0) 101 (30.0) 97 (28.7) 369 (27.2) 
Bladder cancer  13 (3.8) 20 (5.9) 17 (5.0) 18 (5.3) 68 (5.0) 
Cardiovascular  29 (8.5) 34 (10.0) 39 (11.6) 32 (9.5) 134 (9.9) 
Other   
malignancy 
8 (2.3) 13 (3.8) 19 (5.6) 22 (6.5) 62 (4.6) 
Other cause 18 (5,3) 13 (3,8) 18 (5,3) 13 (3,8) 62 (4,6) 
Cause unknown  15 (4.4) 8 (2.4) 8 (2.4) 12 (3.6) 43 (3.2) 
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Table 6. Patient Outcome by Treatment Type 
 BCG treatment  
1/3 dose 
(n=678) 
Full dose 
(n=677) 
1 yr 
(n=680) 
3 yrs 
(n=675) 
n (%) n (%) n (%) n (%) 
Recurrence     
No  367 (54.1) 401 (59.2) 369 (54.3) 399 (59.1) 
Yes  311 (45.9) 276 (40.8) 311 (45.7) 276 (40.9) 
5 Year Disease Free Rate 58.5% 61.7% 56.6% 63.4% 
Progression to ≥pT2      
No  622 (91.7) 624 (92.2) 623 (91.6) 623 (92.3) 
Yes  56 (8.3) 53 (7.8) 57 (8.4) 52 (7.7) 
Presence of CIS     
No  627 (92.5) 637 (94.1) 633 (93.1) 631 (93.5) 
Yes  51 (7.5) 40 (5.9) 47 (6.9) 44 (6.5) 
Distant metastases     
No  645 (95.1) 643 (95.0) 649 (95.4) 639 (94.7) 
Yes  33 (4.9) 34 (5.0) 31 (4.6) 36 (5.3) 
Second primary tumor     
No  592 (87.3) 597 (88.2) 610 (89.7) 579 (85.8) 
Yes  86 (12.7) 80 (11.8) 70 (10.3) 96 (14.2) 
Survival status     
Alive  494 (72.9) 492 (72.7) 509 (74.9) 477 (70.7) 
Dead  184 (27.1) 185 (27.3) 171 (25.1) 198 (29.3) 
Bladder cancer  30 (4.4) 38 (5.6) 33 (4.9) 35 (5.2) 
Cardiovascular  68 (10.0) 66 (9.7) 63 (9.3) 71 (10.5) 
Other malignancy 27 (4.0) 35 (5.2) 21 (3.1) 41 (6.1) 
Other cause 36 (5,2) 26 (3,9) 31 (4,5) 31 (4,5) 
Cause unknown  23 (3.4) 20 (3.0) 23 (3.4) 20 (3.0) 
 
 
 
Figure 3. Disease Free Interval: One Third Dose versus Full Dose 
 
 
Figure 4. Disease Free Interval: One Year Maintenance versus Three Years Maintenance 
 
To take into account the imbalance in risk group distribution in the treatment groups, the two 
main treatment comparisons were also stratified by the simplified risk groups. Comparing 
1/3D to FD BCG, the conclusions did not change. For the comparison of 1 yr to 3 yr of 
maintenance, the difference was significant at p = 0.0384 in favor of 3 yr, however the 
treatment effect was not homogeneous in the 4 risk by dose subgroups, p = 0.05 (Figure 5). In 
intermediate risk patients, 3 yr of maintenance was more effective than 1 yr in patients 
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To take into account the imbalance in risk group distribution in the treatment groups, the two 
main treatment comparisons were also stratified by the simplified risk groups. Comparing 
1/3D to FD BCG, the conclusions did not change. For the comparison of 1 yr to 3 yr of 
maintenance, the difference was significant at p = 0.0384 in favor of 3 yr, however the 
treatment effect was not homogeneous in the 4 risk by dose subgroups, p = 0.05 (Figure 5). In 
intermediate risk patients, 3 yr of maintenance was more effective than 1 yr in patients 
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receiving 1/3D (HR = 1.35, 95%CI: 1.03-1.79, p = 0.0318) but not in patients receiving FD BCG 
(HR = 0.88, 95%CI: 0.64-1.21, p = 0.4380). In high risk patients, 3 yr of maintenance was more 
effective than 1 yr in patients receiving FD (HR = 1.61, 95%CI: 1.13-2.30, p = 0.0087) but not in 
patients receiving 1/3D BCG (HR = 1.01, 95%CI: 0.69-1.47, p = 0.9716). Analyses carried out in 
patients who were still disease free at 18 mo yielded similar results. Comparable conclusions 
were obtained when stratifying by the EORTC recurrence and progression risk scores. 
 
Figure 5.  Disease Free Interval: One Year Maintenance versus Three Years Maintenance 
According to Dose and Risk Group 
 
There were no significant differences between the treatment groups for the time to 
progression (Figure 6) or overall duration of survival (Figure 7).  
Figure 6. Time to Progression by Treatment Group 
 
 
Figure 7. Duration of Survival by Treatment Group 
 
 
DISCUSSION  
The aim of this study was to prove that decreasing the dose of BCG from FD to 1/3 D and/or 
shortening maintenance from 3 yr to 1yr to reduce toxicity would not compromise treatment 
efficacy. 
CUETO published several studies with a reduction of BCG to 1/3 D and one-sixth dose (1/6 D). 
In one report, CUETO claimed the efficacy of 1/3 D was comparable to FD [13], however their 
trial was not designed as a non-inferiority study [15]. In another study, intermediate risk 
patients were randomized between 1/3 D and 1/6 D BCG and 30 mg of mitomycin-C (MMC) 
[14]. They concluded that 1/6 D is suboptimal as compared to 1/3 D and more toxic as 
compared to MMC. Their maximum treatment duration was 5 months whereas in the current 
study, where there were no significant differences in toxicity between 1/3D and FD BCG, the 
minimum treatment duration was 1 yr. 
In our study, the null hypotheses of a decrease of 10% in the disease free rate at 5 yr could 
not be rejected for either one third dose or 1 yr maintenance. Testing for superiority, the 
differences in the disease free rate were likewise not significant for either the dose or duration 
of maintenance. The observed difference at 5 yr reached 10% only between 1 yr-1/3D and 3 
yr-FD, p = 0.01. One third dose during 1 y is insufficient treatment. 
In intermediate risk patients, 3 yr of maintenance is not more effective than 1 yr when full 
dose is given. In high risk patients, 3 yr of maintenance reduces recurrences when FD is given 
(p = 0.009), but not when 1/3D is applied (p = 0.97). 
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In one report, CUETO claimed the efficacy of 1/3 D was comparable to FD [13], however their 
trial was not designed as a non-inferiority study [15]. In another study, intermediate risk 
patients were randomized between 1/3 D and 1/6 D BCG and 30 mg of mitomycin-C (MMC) 
[14]. They concluded that 1/6 D is suboptimal as compared to 1/3 D and more toxic as 
compared to MMC. Their maximum treatment duration was 5 months whereas in the current 
study, where there were no significant differences in toxicity between 1/3D and FD BCG, the 
minimum treatment duration was 1 yr. 
In our study, the null hypotheses of a decrease of 10% in the disease free rate at 5 yr could 
not be rejected for either one third dose or 1 yr maintenance. Testing for superiority, the 
differences in the disease free rate were likewise not significant for either the dose or duration 
of maintenance. The observed difference at 5 yr reached 10% only between 1 yr-1/3D and 3 
yr-FD, p = 0.01. One third dose during 1 y is insufficient treatment. 
In intermediate risk patients, 3 yr of maintenance is not more effective than 1 yr when full 
dose is given. In high risk patients, 3 yr of maintenance reduces recurrences when FD is given 
(p = 0.009), but not when 1/3D is applied (p = 0.97). 
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Although the median follow-up is 7.1 yr, the recurrence rate was lower than expected. 
Nevertheless, analysis of the study based on a 2 x 2 factorial design provided a power of 92% 
to reject the null hypothesis of treatment inferiority. The lower than expected recurrence rate 
might be explained by improvements in TUR technique. The TUR procedure was not described 
in the protocol, but the introduction of better endoscopes and more meticulous TUR 
techniques during the 8 years of patient entry may have led to a reduced recurrence rate [16]. 
After the start of patient entry, the important role of a restaging TUR also emerged [17,18], 
but it is unknown how many patients had a re-TUR. The value of an immediate post-operative 
instillation was not known yet. 
The current risk group definitions and 1999/2004 grading systems did not exist when the study 
was designed. However, because intermediate risk patients might not need as aggressive 
treatment as high risk patients [3], separate analyses were carried out in intermediate and 
high risk (T1 and/or G3) patients showing that two additional years of maintenance with FD 
BCG reduced recurrences in high risk patients but not in intermediate risk patients. 
 
 
CONCLUSION 
This is the largest study on the toxicity and efficacy of BCG dose reduction and duration of 
maintenance. There were no significant differences in toxicity between 1/3D and FD BCG. 
Based on the primary endpoint of disease free interval, 1/3D with 1 yr of maintenance is 
suboptimal compared to standard full dose during 3 yr. It is recommended to treat 
intermediate risk patients with FD for 1 yr as there is no further improvement in outcome by 
continuing treatment to 3 yr. 
In high risk patients, FD-3 yr BCG reduces recurrences as compared to FD-1 yr, however there 
were no long term differences in progression or survival. The benefit of the two additional 
years of maintenance should thus be weighed against its additional costs, side effects and 
inconveniences. 
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Although the median follow-up is 7.1 yr, the recurrence rate was lower than expected. 
Nevertheless, analysis of the study based on a 2 x 2 factorial design provided a power of 92% 
to reject the null hypothesis of treatment inferiority. The lower than expected recurrence rate 
might be explained by improvements in TUR technique. The TUR procedure was not described 
in the protocol, but the introduction of better endoscopes and more meticulous TUR 
techniques during the 8 years of patient entry may have led to a reduced recurrence rate [16]. 
After the start of patient entry, the important role of a restaging TUR also emerged [17,18], 
but it is unknown how many patients had a re-TUR. The value of an immediate post-operative 
instillation was not known yet. 
The current risk group definitions and 1999/2004 grading systems did not exist when the study 
was designed. However, because intermediate risk patients might not need as aggressive 
treatment as high risk patients [3], separate analyses were carried out in intermediate and 
high risk (T1 and/or G3) patients showing that two additional years of maintenance with FD 
BCG reduced recurrences in high risk patients but not in intermediate risk patients. 
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continuing treatment to 3 yr. 
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were no long term differences in progression or survival. The benefit of the two additional 
years of maintenance should thus be weighed against its additional costs, side effects and 
inconveniences. 
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ABSTRACT 
Background: Although maintenance Bacillus-Calmette-Guérin (BCG) is the recommended 
treatment in high-risk non-muscle-invasive bladder cancer (BC), its efficacy in older patients 
is controversial. 
Objectives: To determine the effect of age on prognosis and treatment outcome in patients 
with stage Ta-T1 BC treated with maintenance BCG. 
Design, Setting, Participants, Intervention:  957 patients with intermediate or high risk Ta-
T1 (without CIS) BC were randomized in EORTC trial 30911 comparing 6 weekly instillations 
of epirubicin, BCG and BCG plus isoniazid followed by 3 weekly maintenance instillations 
during 3 years.  
Outcome Measurements, Statistical Analysis: Cox multivariate proportional hazards 
regression models were used to assess the relative importance of age for recurrence, 
progression, overall and BC specific survival with adjustment for EORTC risk scores. 
Results: 822 eligible patients were included: 546 patients in the BCG +/- INH arms and 276 
in the epirubicin arm. In patients treated with BCG +/- INH, 34.1% were older than 70 years 
and 3.7% were older than 80. With a median follow up of 9.2 years, patients older than 70 
had a shorter time to progression (p = 0.028), overall (p < 0.001) and BC specific survival (p 
= 0.049) after adjustment for EORTC risk scores in the multivariate analysis. The time to 
recurrence was similar compared to the younger patients. BCG was more effective than 
epirubicin for all four endpoints considered and there was no evidence that BCG was any 
less effective as compared to epirubicin in patients older than 70 years. 
Conclusions: In intermediate and high risk Ta T1 urothelial bladder cancer patients treated 
with BCG, patients older than 70 years have a worse long term prognosis, however BCG is 
more effective than epirubicin independent of patient age. 
  
 
INTRODUCTION 
The challenge in the treatment of non-muscle invasive bladder cancer (NMIBC) is to retain the 
bladder and its function for as long as possible, accepting to a certain extent the risk of 
recurrence while minimizing the probability of progression to muscle invasive disease. To 
quantify these risks, the EORTC risk tables can be used [1,2].  After TURBT, preferably followed 
by an immediate postoperative instillation and pathological confirmation of the stage and 
grade of the disease, adjuvant intravesical instillations are recommended in the intermediate 
and high risk groups, with BCG being the treatment of choice in high risk patients [2]. 
BCG with maintenance is more effective than chemotherapeutic agents such as mitomycin C 
and epirubicin in preventing recurrences, however its superiority over mitomycin C in 
preventing progression could not be proven in an individual patient data meta-analysis [3-7]. 
In spite of the superiority of maintenance BCG with regard to the reduction of the recurrence 
rate, the increased incidence and potential severity of BCG toxicity compared to 
chemotherapeutic agents prevents it from being recommended in all patients with NMIBC [2, 
8, 9]. Therefore, in daily practice, it is only in high and possibly in intermediate risk patients 
that the benefit of BCG therapy is considered to outweigh the risk of toxicity. 
The working mechanism of BCG in the treatment of bladder cancer is still not completely 
clarified. Influx of immune cells into the bladder wall, such as polymorphonuclear neutrophil 
granulocytes (PMN), T-helper cells, T-cells and Natural Killer (NK) cells is seen. These 
immunological responses also lead to an elevation of cytokines in urine [10]. 
The part of the massive immunogenic cascade triggered by BCG which is responsible for its 
anti-tumor effect has not been unraveled completely. What we do know is that the 
effectiveness of the treatment is related to a quantitative response of the immune system. In 
patients treated with BCG, the clinical response depends, for example, on the increase of IL-2 
measured in urine samples during the induction course [11,12]. 
It is therefore likely that individual differences in immunological response contribute to 
differences in a patient’s response to BCG. In line with this assumption, it can be hypothesized 
that factors contributing to a deterioration of one’s immune system may negatively influence 
treatment outcome. The most obvious factor in this regard is patient age.  
The capacity to generate an adequate immune response decreases with age. This 
phenomenon is called immunosenescence. Already in the 1970’s it was shown that immune 
responses, especially T-cell mediated responses, were significantly depressed in healthy 
people above 60 years of age compared to a control group younger than 25 years of age [13]. 
In more recent studies focusing on the beneficial effects of vaccination programs, age is a 
challenging problem: older patients have a higher risk of dying of infectious disease but also 
have a worse immunological response to the vaccine resulting in a lower protection against 
the infection [14]. This raises the question of what influence age has in the response of NMIBC 
patients treated with BCG, in a disease that is predominantly present in older people. 
Approximately 65% of bladder cancer patients in the SEER-database were over 65 years of age 
[15]. 
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ABSTRACT 
Background: Although maintenance Bacillus-Calmette-Guérin (BCG) is the recommended 
treatment in high-risk non-muscle-invasive bladder cancer (BC), its efficacy in older patients 
is controversial. 
Objectives: To determine the effect of age on prognosis and treatment outcome in patients 
with stage Ta-T1 BC treated with maintenance BCG. 
Design, Setting, Participants, Intervention:  957 patients with intermediate or high risk Ta-
T1 (without CIS) BC were randomized in EORTC trial 30911 comparing 6 weekly instillations 
of epirubicin, BCG and BCG plus isoniazid followed by 3 weekly maintenance instillations 
during 3 years.  
Outcome Measurements, Statistical Analysis: Cox multivariate proportional hazards 
regression models were used to assess the relative importance of age for recurrence, 
progression, overall and BC specific survival with adjustment for EORTC risk scores. 
Results: 822 eligible patients were included: 546 patients in the BCG +/- INH arms and 276 
in the epirubicin arm. In patients treated with BCG +/- INH, 34.1% were older than 70 years 
and 3.7% were older than 80. With a median follow up of 9.2 years, patients older than 70 
had a shorter time to progression (p = 0.028), overall (p < 0.001) and BC specific survival (p 
= 0.049) after adjustment for EORTC risk scores in the multivariate analysis. The time to 
recurrence was similar compared to the younger patients. BCG was more effective than 
epirubicin for all four endpoints considered and there was no evidence that BCG was any 
less effective as compared to epirubicin in patients older than 70 years. 
Conclusions: In intermediate and high risk Ta T1 urothelial bladder cancer patients treated 
with BCG, patients older than 70 years have a worse long term prognosis, however BCG is 
more effective than epirubicin independent of patient age. 
  
 
INTRODUCTION 
The challenge in the treatment of non-muscle invasive bladder cancer (NMIBC) is to retain the 
bladder and its function for as long as possible, accepting to a certain extent the risk of 
recurrence while minimizing the probability of progression to muscle invasive disease. To 
quantify these risks, the EORTC risk tables can be used [1,2].  After TURBT, preferably followed 
by an immediate postoperative instillation and pathological confirmation of the stage and 
grade of the disease, adjuvant intravesical instillations are recommended in the intermediate 
and high risk groups, with BCG being the treatment of choice in high risk patients [2]. 
BCG with maintenance is more effective than chemotherapeutic agents such as mitomycin C 
and epirubicin in preventing recurrences, however its superiority over mitomycin C in 
preventing progression could not be proven in an individual patient data meta-analysis [3-7]. 
In spite of the superiority of maintenance BCG with regard to the reduction of the recurrence 
rate, the increased incidence and potential severity of BCG toxicity compared to 
chemotherapeutic agents prevents it from being recommended in all patients with NMIBC [2, 
8, 9]. Therefore, in daily practice, it is only in high and possibly in intermediate risk patients 
that the benefit of BCG therapy is considered to outweigh the risk of toxicity. 
The working mechanism of BCG in the treatment of bladder cancer is still not completely 
clarified. Influx of immune cells into the bladder wall, such as polymorphonuclear neutrophil 
granulocytes (PMN), T-helper cells, T-cells and Natural Killer (NK) cells is seen. These 
immunological responses also lead to an elevation of cytokines in urine [10]. 
The part of the massive immunogenic cascade triggered by BCG which is responsible for its 
anti-tumor effect has not been unraveled completely. What we do know is that the 
effectiveness of the treatment is related to a quantitative response of the immune system. In 
patients treated with BCG, the clinical response depends, for example, on the increase of IL-2 
measured in urine samples during the induction course [11,12]. 
It is therefore likely that individual differences in immunological response contribute to 
differences in a patient’s response to BCG. In line with this assumption, it can be hypothesized 
that factors contributing to a deterioration of one’s immune system may negatively influence 
treatment outcome. The most obvious factor in this regard is patient age.  
The capacity to generate an adequate immune response decreases with age. This 
phenomenon is called immunosenescence. Already in the 1970’s it was shown that immune 
responses, especially T-cell mediated responses, were significantly depressed in healthy 
people above 60 years of age compared to a control group younger than 25 years of age [13]. 
In more recent studies focusing on the beneficial effects of vaccination programs, age is a 
challenging problem: older patients have a higher risk of dying of infectious disease but also 
have a worse immunological response to the vaccine resulting in a lower protection against 
the infection [14]. This raises the question of what influence age has in the response of NMIBC 
patients treated with BCG, in a disease that is predominantly present in older people. 
Approximately 65% of bladder cancer patients in the SEER-database were over 65 years of age 
[15]. 
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In order to study the effect of age on the prognosis and treatment outcome in patients with 
stage Ta T1 urothelial bladder cancer treated with maintenance BCG, we used the database 
of EORTC trial 30911 which compared 6 weekly instillations of epirubicin, BCG and BCG plus 
isoniazid (INH) followed by maintenance instillations during 36 months [7,8]. This allowed us 
not only to determine the variability in outcome related to age in BCG-treated patients but 
also to compare the outcome with BCG to the results obtained with epirubicin in both the 
younger and older patients. 
 
MATERIAL & METHODS 
From January 1992 to February 1997, 957 patients with intermediate or high risk stage Ta T1 
urothelial bladder cancer were randomized in EORTC GU Group trial 30911. In this European 
multicenter study, patients with single or multiple, primary or recurrent, completely 
resectable stages Ta to T1, grades 1 to 3, histological proven urothelial bladder cancer were 
included. Exclusion criteria were a primary solitary tumor, muscle invasive tumor or carcinoma 
in situ, patient age older than 85 years, a WHO performance status 3 or 4, previous treatment 
with doxorubicin, epirubicin or BCG and intravesical treatment during the previous 3 months. 
Tumors were classified according to the 1992 TNM classification of the International Union 
against Cancer [16].  
Within 24 hours after TUR, before receiving the definitive histology report, patients were 
randomized to one of 3 adjuvant treatment arms: epirubicin weekly for 6 consecutive weeks 
starting within 24 hours after transurethral resection or BCG +/- INH weekly for 6 consecutive 
weeks starting 7 to 15 days after transurethral resection. In all groups, the initial 6 instillations 
were followed by 3 weekly instillations at months 3, 6, 12, 18, 24, 30 and 36. Cytology and 
cystoscopy were performed every 3 months during the first 3 years and every 6 months 
thereafter. In case of a suspected recurrence, pathological confirmation by a TUR was 
mandatory. The primary endpoint was the time to first bladder recurrence with secondary 
endpoints of time to muscle-invasive disease, time to distant metastases, time to progression 
(muscle invasion or distant metastases), overall duration of survival, and time to death due to 
bladder cancer. The efficacy results have been previously published [7,8]. 
In order to determine the prognostic importance of age in patients treated with BCG and to 
compare the outcome with BCG to the results obtained with epirubicin in both the younger 
and older patients, Cox univariate and multivariate proportional hazards regression models 
were fit with endpoints time to recurrence, time to progression (muscle invasive or metastatic 
disease), and overall and disease specific mortality. Based on the literature [17,18], two age 
groups were defined: younger than or equal to 70 years and older than 70 years of age. The 
effect of age as a continuous variable was also assessed. In the multivariate analyses, the 
effect of age was adjusted for the EORTC recurrence (0-17) and recoded progression (0-6, 7-
13, 14-23) scores [1].  Recoded progression scores were used due to the smaller number of 
patients with progression and death due to bladder cancer. Times to event were estimated 
using cumulative incidence curves in order to take into account patients who may have died 
 
before the event of interest (competing risk) except for overall survival which was estimated 
using Kaplan-Meier curves. 
 
RESULTS 
Because randomization took place before histology was known, 120 of the 957 randomized 
patients were ineligible. In the 837 eligible patients, data on age were lacking in 15 patients, 
resulting in 822 patients who are included in the current analysis: 546 patients in the BCG +/- 
INH arms and 276 patients in the epirubicin arm which was used as a reference group. 
The distribution of age along with other patient characteristics is provided in Table 1. In the 
546 patients treated with maintenance BCG +/- INH, 360 (65.9%) were less than or equal to 
70 years of age, while 34.1% were older than 70 years. Only 20 patients (3.7%) were older 
than 80 years. Table 2 reflects the distribution of age according to the EORTC recurrence and 
progression scores in BCG patients and Appendix-table 1 provides patient outcome according 
to treatment group for the various endpoints.  
Table 3 provides the results of the univariate and the EORTC recurrence and progression score 
adjusted analyses of age (both dichotomized and as a continuous variable) in BCG patients. 
Based on a median duration of follow up of 9.2 years, there wasn’t a significant effect of age 
on time to recurrence in patients receiving BCG (Table 3 and Figure 1). However, in both the 
univariate and multivariate analyses, BCG patients older than 70 years had a significantly 
shorter time to progression (Table 3 and Figure 2), overall survival (Table 3 and Appendix-
Figure 1) and bladder cancer specific survival (Table 3 and Figure 3) than BCG patients less 
than or equal to 70 years. When analyzed as a continuous variable, older patients also had a 
shorter time to progression and overall survival in both the univariate and adjusted analyses. 
For the four endpoints considered above, forest plots in Figures 4a – 4d show the benefit of 
BCG as compared to epirubicin in the two age groups, with similar reductions in the event rate 
on BCG in both age groups for all 4 endpoints.  
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In order to study the effect of age on the prognosis and treatment outcome in patients with 
stage Ta T1 urothelial bladder cancer treated with maintenance BCG, we used the database 
of EORTC trial 30911 which compared 6 weekly instillations of epirubicin, BCG and BCG plus 
isoniazid (INH) followed by maintenance instillations during 36 months [7,8]. This allowed us 
not only to determine the variability in outcome related to age in BCG-treated patients but 
also to compare the outcome with BCG to the results obtained with epirubicin in both the 
younger and older patients. 
 
MATERIAL & METHODS 
From January 1992 to February 1997, 957 patients with intermediate or high risk stage Ta T1 
urothelial bladder cancer were randomized in EORTC GU Group trial 30911. In this European 
multicenter study, patients with single or multiple, primary or recurrent, completely 
resectable stages Ta to T1, grades 1 to 3, histological proven urothelial bladder cancer were 
included. Exclusion criteria were a primary solitary tumor, muscle invasive tumor or carcinoma 
in situ, patient age older than 85 years, a WHO performance status 3 or 4, previous treatment 
with doxorubicin, epirubicin or BCG and intravesical treatment during the previous 3 months. 
Tumors were classified according to the 1992 TNM classification of the International Union 
against Cancer [16].  
Within 24 hours after TUR, before receiving the definitive histology report, patients were 
randomized to one of 3 adjuvant treatment arms: epirubicin weekly for 6 consecutive weeks 
starting within 24 hours after transurethral resection or BCG +/- INH weekly for 6 consecutive 
weeks starting 7 to 15 days after transurethral resection. In all groups, the initial 6 instillations 
were followed by 3 weekly instillations at months 3, 6, 12, 18, 24, 30 and 36. Cytology and 
cystoscopy were performed every 3 months during the first 3 years and every 6 months 
thereafter. In case of a suspected recurrence, pathological confirmation by a TUR was 
mandatory. The primary endpoint was the time to first bladder recurrence with secondary 
endpoints of time to muscle-invasive disease, time to distant metastases, time to progression 
(muscle invasion or distant metastases), overall duration of survival, and time to death due to 
bladder cancer. The efficacy results have been previously published [7,8]. 
In order to determine the prognostic importance of age in patients treated with BCG and to 
compare the outcome with BCG to the results obtained with epirubicin in both the younger 
and older patients, Cox univariate and multivariate proportional hazards regression models 
were fit with endpoints time to recurrence, time to progression (muscle invasive or metastatic 
disease), and overall and disease specific mortality. Based on the literature [17,18], two age 
groups were defined: younger than or equal to 70 years and older than 70 years of age. The 
effect of age as a continuous variable was also assessed. In the multivariate analyses, the 
effect of age was adjusted for the EORTC recurrence (0-17) and recoded progression (0-6, 7-
13, 14-23) scores [1].  Recoded progression scores were used due to the smaller number of 
patients with progression and death due to bladder cancer. Times to event were estimated 
using cumulative incidence curves in order to take into account patients who may have died 
 
before the event of interest (competing risk) except for overall survival which was estimated 
using Kaplan-Meier curves. 
 
RESULTS 
Because randomization took place before histology was known, 120 of the 957 randomized 
patients were ineligible. In the 837 eligible patients, data on age were lacking in 15 patients, 
resulting in 822 patients who are included in the current analysis: 546 patients in the BCG +/- 
INH arms and 276 patients in the epirubicin arm which was used as a reference group. 
The distribution of age along with other patient characteristics is provided in Table 1. In the 
546 patients treated with maintenance BCG +/- INH, 360 (65.9%) were less than or equal to 
70 years of age, while 34.1% were older than 70 years. Only 20 patients (3.7%) were older 
than 80 years. Table 2 reflects the distribution of age according to the EORTC recurrence and 
progression scores in BCG patients and Appendix-table 1 provides patient outcome according 
to treatment group for the various endpoints.  
Table 3 provides the results of the univariate and the EORTC recurrence and progression score 
adjusted analyses of age (both dichotomized and as a continuous variable) in BCG patients. 
Based on a median duration of follow up of 9.2 years, there wasn’t a significant effect of age 
on time to recurrence in patients receiving BCG (Table 3 and Figure 1). However, in both the 
univariate and multivariate analyses, BCG patients older than 70 years had a significantly 
shorter time to progression (Table 3 and Figure 2), overall survival (Table 3 and Appendix-
Figure 1) and bladder cancer specific survival (Table 3 and Figure 3) than BCG patients less 
than or equal to 70 years. When analyzed as a continuous variable, older patients also had a 
shorter time to progression and overall survival in both the univariate and adjusted analyses. 
For the four endpoints considered above, forest plots in Figures 4a – 4d show the benefit of 
BCG as compared to epirubicin in the two age groups, with similar reductions in the event rate 
on BCG in both age groups for all 4 endpoints.  
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Table 1. Distribution of Patient Characteristics according to Treatment 
 Treatment Total 
 
(n=822) 
BCG +/- INH 
(n=546) 
Epirubicin 
(n=276) 
n (%) n (%) n (%) 
Age     
 < 60 Years  146 (26.7) 74 (26.8) 220 (26.8) 
 61-70 Years  214 (39.2) 100 (36.2) 314 (38.2) 
 71-80 Years  166 (30.4) 90 (32.6) 256 (31.1) 
 > 80 Years  20 (3.7) 12 (4.3) 32 (3.9) 
Sex     
 Male  429 (78.6) 223 (80.8) 652 (79.3) 
 Female  117 (21.4) 53 (19.2) 170 (20.7) 
Prior Recurrence Rate     
 Primary   238 (43.6) 127 (46.0) 365 (44.4) 
 Recurrent, < 1 rec/yr  145 (26.6) 61 (22.1) 206 (25.1) 
 Recurrent, > 1 rec/yr  149 (27.3) 85 (30.8) 234 (28.5) 
 Unknown   14 (2.6) 3 (1.1) 17 (2.1) 
Largest Tumor Diameter     
 < 1 cm  265 (48.5) 132 (47.8) 397 (48.3) 
 < 3 cm  210 (38.5) 110 (39.9) 320 (38.9) 
 > 3 cm  49 (9.0) 19 (6.9) 68 (8.3) 
 Unknown   22 (4.0) 15 (5.4) 37 (4.5) 
Number of Tumors     
 1  86 (15.8) 35 (12.7) 121 (14.7) 
 2-7  395 (72.3) 212 (76.8) 607 (73.8) 
 > 8  59 (10.8) 22 (8.0) 81 (9.9) 
 Unknown  6 (1.1) 7 (2.5) 13 (1.6) 
T Category     
 Ta   342 (62.6) 179 (64.9) 521 (63.4) 
 T1  203 (37.2) 95 (34.4) 298 (36.3) 
 Unknown   1 (0.2) 2 (0.7) 3 (0.4) 
Grade (1973 WHO)     
 G1  204 (37.4) 108 (39.1) 312 (38.0) 
 G2  268 (49.1) 133 (48.2) 401 (48.8) 
 G3  71 (13.0) 31 (11.2) 102 (12.4) 
 Unknown  3 (0.5) 4 (1.4) 7 (0.9) 
Recurrence Score     
 0-4  150 (27.5) 74 (26.8) 224 (27.3) 
 5-9  309 (56.6) 158 (57.2) 467 (56.8) 
 10-17  42 (7.7) 20 (7.2) 62 (7.5) 
 Unknown  45 (8.2) 24 (8.7) 69 (8.4) 
Progression Score     
 0-6  314 (57.5) 164 (59.4) 478 (58.2) 
 7-13  180 (33.0) 83 (30.1) 263 (32.0) 
 14-23  20 (3.7) 8 (2.9) 28 (3.4) 
 Unknown  32 (5.9) 21 (7.6) 53 (6.4) 
 
 
Table 2.  Distribution of Age according to EORTC Recurrence and Progression Scores in BCG 
Patients 
 Age Total 
 
(n=546) 
< 60 yr 
(n=146) 
61-70 yr 
(n=214) 
71-80 yr 
(n=166) 
> 80 yr 
(n=20) 
n (%) n (%) n (%) n (%) n (%) 
Recurrence Score      
 0-4 42 (28.8) 72 (33.6) 31 (18.7) 5 (25.0) 150 (27.5) 
 5-9 82 (56.2) 107 (50.0) 106 (63.9) 14 (70.0) 309 (56.6) 
 10-17 8 (5.5) 19 (8.9) 14 (8.4) 1 (5.0) 42 (7.7) 
 Unknown 14 (9.6) 16 (7.5) 15 (9.0) 0 (0.0) 45 (8.2) 
Progression Score      
 0-6  87 (59.6) 130 (60.7) 86 (51.8) 11 (55.0) 314 (57.5) 
 7-13  44 (30.1) 67 (31.3) 61 (36.7) 8 (40.0) 180 (33.0) 
 14-23  4 (2.7) 8 (3.7) 7 (4.2) 1 (5.0) 20 (3.7) 
 Unknown  11 (7.5) 9 (4.2) 12 (7.2) 0 (0.0) 32 (5.9) 
 
Table 3.  Univariate and EORTC Risk Score Adjusted Effect of Age in BCG Patients 
  
Recurrence 
 
Progression 
 
Overall Survival 
Death Bladder 
Cancer 
Univariate HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value 
Age (years) 
≤70 
 >70  
 
1 
1.26 
[0.95-1.66] 
 
0.11 
 
1 
1.92 
[1.10-3.34] 
 
0.019 
 
1 
2.57 
[1.90-3.48] 
 
< 0.001 
 
1 
2.40 
[0.97-5.91] 
 
0.050 
Age 
(Continuous) 
1.00 
[0.99-1.02] 
0.88 1.03 
[1.00-1.07] 
0.033 1.08 
[1.06-1.10] 
< 0.001 1.03 
[0.98-1.08] 
0.302 
  
Recurrence* 
 
Progression** 
 
Overall Survival** 
Death Bladder 
Cancer** 
Multivariate HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value 
Age (years) 
≤70 
 >70  
 
1 
1.17 
[0.88-1.57] 
 
0.29 
 
1 
1.89 
[1.07-3.34] 
 
0.028 
 
1 
2.55 
[1.86-3.48] 
 
< 0.001 
 
1 
2.55 
[1.00-6.49] 
 
0.049 
Age 
(Continuous) 
1.00 
[0.98-1.01] 
0.64 1.03 
[1.00-1.06] 
0.047 1.08 
[1.06-1.10] 
< 0.001 1.03 
[0.98-1.08] 
0.312 
* Adjusted for EORTC recurrence score (0 – 17)   
**Adjusted for recoded EORTC progression score (0-6, 7-13, 14-23) 
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Table 1. Distribution of Patient Characteristics according to Treatment 
 Treatment Total 
 
(n=822) 
BCG +/- INH 
(n=546) 
Epirubicin 
(n=276) 
n (%) n (%) n (%) 
Age     
 < 60 Years  146 (26.7) 74 (26.8) 220 (26.8) 
 61-70 Years  214 (39.2) 100 (36.2) 314 (38.2) 
 71-80 Years  166 (30.4) 90 (32.6) 256 (31.1) 
 > 80 Years  20 (3.7) 12 (4.3) 32 (3.9) 
Sex     
 Male  429 (78.6) 223 (80.8) 652 (79.3) 
 Female  117 (21.4) 53 (19.2) 170 (20.7) 
Prior Recurrence Rate     
 Primary   238 (43.6) 127 (46.0) 365 (44.4) 
 Recurrent, < 1 rec/yr  145 (26.6) 61 (22.1) 206 (25.1) 
 Recurrent, > 1 rec/yr  149 (27.3) 85 (30.8) 234 (28.5) 
 Unknown   14 (2.6) 3 (1.1) 17 (2.1) 
Largest Tumor Diameter     
 < 1 cm  265 (48.5) 132 (47.8) 397 (48.3) 
 < 3 cm  210 (38.5) 110 (39.9) 320 (38.9) 
 > 3 cm  49 (9.0) 19 (6.9) 68 (8.3) 
 Unknown   22 (4.0) 15 (5.4) 37 (4.5) 
Number of Tumors     
 1  86 (15.8) 35 (12.7) 121 (14.7) 
 2-7  395 (72.3) 212 (76.8) 607 (73.8) 
 > 8  59 (10.8) 22 (8.0) 81 (9.9) 
 Unknown  6 (1.1) 7 (2.5) 13 (1.6) 
T Category     
 Ta   342 (62.6) 179 (64.9) 521 (63.4) 
 T1  203 (37.2) 95 (34.4) 298 (36.3) 
 Unknown   1 (0.2) 2 (0.7) 3 (0.4) 
Grade (1973 WHO)     
 G1  204 (37.4) 108 (39.1) 312 (38.0) 
 G2  268 (49.1) 133 (48.2) 401 (48.8) 
 G3  71 (13.0) 31 (11.2) 102 (12.4) 
 Unknown  3 (0.5) 4 (1.4) 7 (0.9) 
Recurrence Score     
 0-4  150 (27.5) 74 (26.8) 224 (27.3) 
 5-9  309 (56.6) 158 (57.2) 467 (56.8) 
 10-17  42 (7.7) 20 (7.2) 62 (7.5) 
 Unknown  45 (8.2) 24 (8.7) 69 (8.4) 
Progression Score     
 0-6  314 (57.5) 164 (59.4) 478 (58.2) 
 7-13  180 (33.0) 83 (30.1) 263 (32.0) 
 14-23  20 (3.7) 8 (2.9) 28 (3.4) 
 Unknown  32 (5.9) 21 (7.6) 53 (6.4) 
 
 
Table 2.  Distribution of Age according to EORTC Recurrence and Progression Scores in BCG 
Patients 
 Age Total 
 
(n=546) 
< 60 yr 
(n=146) 
61-70 yr 
(n=214) 
71-80 yr 
(n=166) 
> 80 yr 
(n=20) 
n (%) n (%) n (%) n (%) n (%) 
Recurrence Score      
 0-4 42 (28.8) 72 (33.6) 31 (18.7) 5 (25.0) 150 (27.5) 
 5-9 82 (56.2) 107 (50.0) 106 (63.9) 14 (70.0) 309 (56.6) 
 10-17 8 (5.5) 19 (8.9) 14 (8.4) 1 (5.0) 42 (7.7) 
 Unknown 14 (9.6) 16 (7.5) 15 (9.0) 0 (0.0) 45 (8.2) 
Progression Score      
 0-6  87 (59.6) 130 (60.7) 86 (51.8) 11 (55.0) 314 (57.5) 
 7-13  44 (30.1) 67 (31.3) 61 (36.7) 8 (40.0) 180 (33.0) 
 14-23  4 (2.7) 8 (3.7) 7 (4.2) 1 (5.0) 20 (3.7) 
 Unknown  11 (7.5) 9 (4.2) 12 (7.2) 0 (0.0) 32 (5.9) 
 
Table 3.  Univariate and EORTC Risk Score Adjusted Effect of Age in BCG Patients 
  
Recurrence 
 
Progression 
 
Overall Survival 
Death Bladder 
Cancer 
Univariate HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value 
Age (years) 
≤70 
 >70  
 
1 
1.26 
[0.95-1.66] 
 
0.11 
 
1 
1.92 
[1.10-3.34] 
 
0.019 
 
1 
2.57 
[1.90-3.48] 
 
< 0.001 
 
1 
2.40 
[0.97-5.91] 
 
0.050 
Age 
(Continuous) 
1.00 
[0.99-1.02] 
0.88 1.03 
[1.00-1.07] 
0.033 1.08 
[1.06-1.10] 
< 0.001 1.03 
[0.98-1.08] 
0.302 
  
Recurrence* 
 
Progression** 
 
Overall Survival** 
Death Bladder 
Cancer** 
Multivariate HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value HR 
[95% CI] 
p-value 
Age (years) 
≤70 
 >70  
 
1 
1.17 
[0.88-1.57] 
 
0.29 
 
1 
1.89 
[1.07-3.34] 
 
0.028 
 
1 
2.55 
[1.86-3.48] 
 
< 0.001 
 
1 
2.55 
[1.00-6.49] 
 
0.049 
Age 
(Continuous) 
1.00 
[0.98-1.01] 
0.64 1.03 
[1.00-1.06] 
0.047 1.08 
[1.06-1.10] 
< 0.001 1.03 
[0.98-1.08] 
0.312 
* Adjusted for EORTC recurrence score (0 – 17)   
**Adjusted for recoded EORTC progression score (0-6, 7-13, 14-23) 
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Figure 1.  Distribution of Patient Characteristics according to treatment. 
 
  
 
Figure 2.  Time to progression in BCG patients by age group (LE= equal or younger than 70,  
GT= older than 70). 
 
  
 
Figure 3. Bladder cancer specific mortality of BCG patients by age group (LE= equal or 
younger than 70,  GT= older than 70). 
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Figure 1.  Distribution of Patient Characteristics according to treatment. 
 
  
 
Figure 2.  Time to progression in BCG patients by age group (LE= equal or younger than 70,  
GT= older than 70). 
 
  
 
Figure 3. Bladder cancer specific mortality of BCG patients by age group (LE= equal or 
younger than 70,  GT= older than 70). 
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Figure 4a.  Time to First Recurrence. (LE= equal or younger than 70,  GT= older than 70). 
 
 
 
 
 
Figure 4b.  Time to Progression. (LE= equal or younger than 70,  GT= older than 70). 
 
  
Events / Patients
BCG +/- INH Epirubicin
Statistics
  (O-E) Var.
HR & CI*
:(BCG +/- INH Epirubicin) HR (95% CI)
Time to first recurrence
*95% CI everywhere
Treatment effect: p<0.0001
better betterChi-square=0.01, df=1: p>0.1
BCG +/- INH EpirubicinTest for heterogeneity
0.25 0.5 1.0 2.0 4.0
GT 70 Years           77/ 186           58/ 102        -14.2         29.3 0.61 (0.43;0.88)
Total          213 / 546          147 /276       -37.9        75.4 0.60 (0.48;0.76)
(39 %) (53.3 %)
Age (years)
LE 70 Years          136/ 360           89/ 174        -23.7         46.1 0.60 (0.45;0.80)
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Statistics
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*95% CI everywhere
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BCG +/- INH EpirubicinTest for heterogeneity
0.25 0.5 1.0 2.0 4.0
GT 70 Years           23/ 186           19/ 102         -4.8          9.4 0.60 (0.31;1.13)
Total           51 / 546           39 /276        -9.4        19.8 0.62 (0.40;0.96)
(9.3 %) (14.1 %)
Age (years)
LE 70 Years           28/ 360           20/ 174         -4.6         10.4 0.64 (0.35;1.18)
 
Figure 4c.  Duration of Survival. (LE= equal or younger than 70,  GT= older than 70). 
 
 
 
 
 
 
Figure 4d.  Bladder cancer specific mortality. (LE= equal or younger than 70,  GT= older than 
70). 
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Total          172 / 546          106 /276       -16.9        60.4 0.76 (0.59;0.97)
(31.5 %) (38.4 %)
Age (years)
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BCG +/- INH EpirubicinTest for heterogeneity
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Total           19 /546           19 /276        -6.8         8.3 0.44 (0.22;0.87)
(3.5 %) (6.9 %)
Age (years)
LE 70 Years            9/ 360           10/ 174         -3.9          4.1 0.39 (0.15;1.02)
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Figure 4a.  Time to First Recurrence. (LE= equal or younger than 70,  GT= older than 70). 
 
 
 
 
 
Figure 4b.  Time to Progression. (LE= equal or younger than 70,  GT= older than 70). 
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Figure 4c.  Duration of Survival. (LE= equal or younger than 70,  GT= older than 70). 
 
 
 
 
 
 
Figure 4d.  Bladder cancer specific mortality. (LE= equal or younger than 70,  GT= older than 
70). 
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DISCUSSION 
The most effective adjuvant treatment for decreasing the recurrence rate in intermediate 
and high risk NMIBC patients is immunotherapy by BCG instillations in a maintenance 
scheme.  
On the basis of cytokine studies on IL-2 and IL-10 in urine samples that showed individual 
differences in immune responses related to different treatment outcome, one could 
hypothesize that, when the immune system is less active, the outcome of BCG treatment 
might be worse [11,19]. The immune system deteriorates as one grows older, a 
phenomenon known as immunosenescence [13,14]. Hence, one could expect that the 
response to BCG will in general decline with age.  
In the evaluation of a phase II trial in which 1106 patients were treated with BCG combined 
with IFN alpha in a maintenance scheme of 1 year, age above 80 years compared to patients 
61 - 70 years was indeed an independent negative predictor of cancer-free survival with an 
adjusted HR of 1.564 (1.065–2.296), p = 0.02 [17].  
Two reports on age and BCG induction only in high risk patients also showed that age was 
a prognostic factor for treatment outcome. In one of these, age above 70 years was a 
prognostic factor with regards to recurrence [18]. In the second report, advanced age (≥75 
years) was associated with a higher progression rate [20].  
In the current study, age greater than 70 years was also found to be a negative factor for 
the prognosis of patients treated with maintenance BCG with respect to time to 
progression, overall and bladder cancer specific survival but not for time to recurrence. 
When coded as a continuous variable, older patients also had a worse prognosis for both 
time to progression and overall survival. A limitation of our study, however, is the upper 
age limit of 85 years which has reduced the number of patients in the older age group. 
CUETO, which used a scheme of 12 BCG instillations during 5 months, as compared to the 
current report involving a true maintenance scheme of 36 instillations during 3 years, found 
age above 60 years to be an independent prognostic factor for progression, p = 0.052 [21].  
One of the main findings in the current report is that despite a worse outcome in patients 
more than 70 years of age, BCG is still more effective than epirubicin even in this older age 
group.  
Despite the negative prognostic effect of age, why is BCG still more effective than epirubicin 
even in the older patients? It is possible that the immunological response to full dose BCG 
may be much stronger than necessary for an adequate anti-tumor response, allowing some 
older patients to retain a less intense but still therapeutic response. This may explain why 
a reduced dose of BCG can still be effective, although recent data suggest that full dose 
BCG is more effective than one third or one quarter dose BCG [22, 23]. But if 
immunosenescenese is the reason for the decreased efficacy of BCG, it could be that older 
patients may also have a poorer response to epirubicin or chemotherapeutics in general, 
so that BCG still maintains its advantage in efficacy compared to epirubicin. To our 
knowledge, no studies assessing the efficacy of chemotherapeutic instillations according to 
age have been published [24]. 
 
Besides the upper age limit of 85 years, there are several other limitations to this study. 
Patients were entered from 1992 until 1997 so not all patients were treated in accordance 
with current guidelines. High risk patients did not have a re-TURB and 32% of the high risk 
patients received epirubicin. No patients had a fluorescence cystoscopy. However, BCG 
maintained its superiority to epirubicin even in the intermediate risk patients [7] whose 
treatment matches the recommendations in current guidelines. The results of this study 
are thus expected to be valid in current day practice. 
 
CONCLUSIONS 
In intermediate and high risk stage Ta T1 urothelial bladder cancer patients who receive 
BCG, BCG is less effective in patients older than 70 years of age in terms of time to 
progression, overall and bladder cancer specific survival. The time to recurrence did not 
depend on age. However, BCG is still more effective than epirubicin even in this older age 
group for the endpoints considered. 
  
49
Ch
ap
te
r 3
 |
 E
ff
ec
t 
of
 a
ge
 o
n 
effi
ca
cy
 o
f B
CG
 r
el
ati
ve
 t
o 
ep
ir
ub
ic
in
3
 
DISCUSSION 
The most effective adjuvant treatment for decreasing the recurrence rate in intermediate 
and high risk NMIBC patients is immunotherapy by BCG instillations in a maintenance 
scheme.  
On the basis of cytokine studies on IL-2 and IL-10 in urine samples that showed individual 
differences in immune responses related to different treatment outcome, one could 
hypothesize that, when the immune system is less active, the outcome of BCG treatment 
might be worse [11,19]. The immune system deteriorates as one grows older, a 
phenomenon known as immunosenescence [13,14]. Hence, one could expect that the 
response to BCG will in general decline with age.  
In the evaluation of a phase II trial in which 1106 patients were treated with BCG combined 
with IFN alpha in a maintenance scheme of 1 year, age above 80 years compared to patients 
61 - 70 years was indeed an independent negative predictor of cancer-free survival with an 
adjusted HR of 1.564 (1.065–2.296), p = 0.02 [17].  
Two reports on age and BCG induction only in high risk patients also showed that age was 
a prognostic factor for treatment outcome. In one of these, age above 70 years was a 
prognostic factor with regards to recurrence [18]. In the second report, advanced age (≥75 
years) was associated with a higher progression rate [20].  
In the current study, age greater than 70 years was also found to be a negative factor for 
the prognosis of patients treated with maintenance BCG with respect to time to 
progression, overall and bladder cancer specific survival but not for time to recurrence. 
When coded as a continuous variable, older patients also had a worse prognosis for both 
time to progression and overall survival. A limitation of our study, however, is the upper 
age limit of 85 years which has reduced the number of patients in the older age group. 
CUETO, which used a scheme of 12 BCG instillations during 5 months, as compared to the 
current report involving a true maintenance scheme of 36 instillations during 3 years, found 
age above 60 years to be an independent prognostic factor for progression, p = 0.052 [21].  
One of the main findings in the current report is that despite a worse outcome in patients 
more than 70 years of age, BCG is still more effective than epirubicin even in this older age 
group.  
Despite the negative prognostic effect of age, why is BCG still more effective than epirubicin 
even in the older patients? It is possible that the immunological response to full dose BCG 
may be much stronger than necessary for an adequate anti-tumor response, allowing some 
older patients to retain a less intense but still therapeutic response. This may explain why 
a reduced dose of BCG can still be effective, although recent data suggest that full dose 
BCG is more effective than one third or one quarter dose BCG [22, 23]. But if 
immunosenescenese is the reason for the decreased efficacy of BCG, it could be that older 
patients may also have a poorer response to epirubicin or chemotherapeutics in general, 
so that BCG still maintains its advantage in efficacy compared to epirubicin. To our 
knowledge, no studies assessing the efficacy of chemotherapeutic instillations according to 
age have been published [24]. 
 
Besides the upper age limit of 85 years, there are several other limitations to this study. 
Patients were entered from 1992 until 1997 so not all patients were treated in accordance 
with current guidelines. High risk patients did not have a re-TURB and 32% of the high risk 
patients received epirubicin. No patients had a fluorescence cystoscopy. However, BCG 
maintained its superiority to epirubicin even in the intermediate risk patients [7] whose 
treatment matches the recommendations in current guidelines. The results of this study 
are thus expected to be valid in current day practice. 
 
CONCLUSIONS 
In intermediate and high risk stage Ta T1 urothelial bladder cancer patients who receive 
BCG, BCG is less effective in patients older than 70 years of age in terms of time to 
progression, overall and bladder cancer specific survival. The time to recurrence did not 
depend on age. However, BCG is still more effective than epirubicin even in this older age 
group for the endpoints considered. 
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APPENDIX 
Appendix-table 1.  Treatment Outcome. 
 
 Treatment  
Total 
 
(n=822) 
BCG +/- INH 
 
(n=546) 
Epirubicin 
 
(n=276) 
n (%) n (%) n (%) 
Recurrence                                     
 No                                         333 (61.0) 129 (46.7) 462 (56.2) 
 Yes                                        213 (39.0) 147 (53.3) 360 (43.8) 
Muscle Invasion                                
 No                                         504 (92.3) 252 (91.3) 756 (92.0) 
 Yes                                        42 (7.7) 24 (8.7) 66 (8.0) 
Distant Metastases                             
 No                                         518 (94.9) 252 (91.3) 770 (93.7) 
 Yes                                        28 (5.1) 24 (8.7) 52 (6.3) 
Progression (Muscle Invasion or 
Metastases) 
   
 No                                         495 (90.7) 237 (85.9) 732 (89.1) 
 Yes                                        51 (9.3) 39 (14.1) 90 (10.9) 
Cause of Death                                 
 Alive                                      374 (68.5) 170 (61.6) 544 (66.2) 
 Bladder Cancer                             19 (3.5) 19 (6.9) 38 (4.6) 
 Other/Unknown                                  153 (28.0) 87 (31.5) 240 (29.2) 
 
 
Appendix-figure 1.  Overall survival in BCG patients by age group (LE= equal or younger 
than 70,  GT= older than 70). 
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APPENDIX 
Appendix-table 1.  Treatment Outcome. 
 
 Treatment  
Total 
 
(n=822) 
BCG +/- INH 
 
(n=546) 
Epirubicin 
 
(n=276) 
n (%) n (%) n (%) 
Recurrence                                     
 No                                         333 (61.0) 129 (46.7) 462 (56.2) 
 Yes                                        213 (39.0) 147 (53.3) 360 (43.8) 
Muscle Invasion                                
 No                                         504 (92.3) 252 (91.3) 756 (92.0) 
 Yes                                        42 (7.7) 24 (8.7) 66 (8.0) 
Distant Metastases                             
 No                                         518 (94.9) 252 (91.3) 770 (93.7) 
 Yes                                        28 (5.1) 24 (8.7) 52 (6.3) 
Progression (Muscle Invasion or 
Metastases) 
   
 No                                         495 (90.7) 237 (85.9) 732 (89.1) 
 Yes                                        51 (9.3) 39 (14.1) 90 (10.9) 
Cause of Death                                 
 Alive                                      374 (68.5) 170 (61.6) 544 (66.2) 
 Bladder Cancer                             19 (3.5) 19 (6.9) 38 (4.6) 
 Other/Unknown                                  153 (28.0) 87 (31.5) 240 (29.2) 
 
 
Appendix-figure 1.  Overall survival in BCG patients by age group (LE= equal or younger 
than 70,  GT= older than 70). 
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ABSTRACT 
Background: There are no prognostic factor publications in stage Ta-T1 non-muscle invasive 
bladder cancer (NMIBC) treated with 1 to 3 years of maintenance Bacillus Calmette-Guérin 
(BCG). 
Objectives: To determine prognostic factors in NMIBC patients treated with 1 to 3 years of 
BCG after transurethral resection of the bladder (TURB), to derive nomograms and risk groups 
and to identify high risk patients who should be considered for early cystectomy. 
Design, Setting and Participants: Data for 1812 patients were merged from two European 
Organization for Research and Treatment of Cancer randomized phase 3 trials in intermediate 
and high risk NMIBC. 
Interventions: Patients received 1-3 years of maintenance BCG after TURB and induction BCG. 
Outcome measurements and statistical analysis: Prognostic factors for risk of early recurrence 
and times to late recurrence, progression and death were identified in a training data set using 
multivariable models and applied to a validation dataset. 
Results and Limitations: With a median follow up of 7.4 years, 762 patients recurred, 173 
progressed and 520 died, 83 due to bladder cancer (BCa). Statistically significant prognostic 
factors identified by multivariable analyses were prior recurrence rate and number of tumors 
for recurrence, and tumor stage and grade for progression and death due to BCa. T1G3 
patients do poorly, with 1 and 5 year disease progression rates of 11.4% and 19.8%, 
respectively, and 1 and 5 year disease specific death rates of 4.8% and 11.3%. Limitations 
include lack of repeat transurethral resection in high-risk patients and exclusion of patients 
with carcinoma in situ. 
Conclusions: NMIBC patients treated with 1 to 3 years of maintenance BCG have a 
heterogeneous prognosis. Patients at high risk of recurrence and/or progression do poorly on 
currently recommended maintenance schedules. Alternative treatments are urgently 
required. 
 
INTRODUCTION 
European Association of Urology (EAU) recommendations for adjuvant treatment of non-
muscle invasive bladder cancer (NMIBC) are based on risk groups: low, intermediate or high 
risk [1,2]. They are derived from European Organization for Research and Treatment of Cancer 
(EORTC) risk tables which provide probabilities of recurrence and progression after 
transurethral resection of the bladder (TURB) [3], but these patients didn’t received 
maintenance bacilli Calmette-Guérin (BCG), which is now recommended for high risk patients.  
In 1062 patients treated with a maintenance schedule of six two-weekly BCG instillations for 
5–6 months, the Club Urológico Español de Tratamiento Oncológico (CUETO) found that 
EORTC risk tables overestimated the overall risk of recurrence and the probability of 
progression in high risk patients [4]. Using these data, CUETO developed a model to stratify 
patients according to their risk of recurrence and progression [5,6] which also successfully 
stratified a patient’s risk of recurrence after BCG plus interferon-alpha therapy [7]. 
The CUETO maintenance schedule is considerably shorter than the 1 to 3 years of maintenance 
BCG currently recommended by the EAU [1,2]. Prognostic factors for this longer maintenance 
schedule are unknown.  
Our aim was to determine prognostic factors and the probabilities of recurrence, progression, 
disease specific survival (DSS) and overall survival (OS) in stage Ta-T1 NMIBC patients treated 
with 1 to 3 years of maintenance BCG and identify high-risk patients who may need early 
cystectomy. We also assess the performance of the CUETO models on EORTC data. 
 
MATERIALS AND METHODS 
Individual patient data were merged from two EORTC phase 3 trials (30911, 30962) in Ta-T1 
NMIBC (without carcinoma in situ (CIS)) where patients were randomized to receive 1 or 3 
years of maintenance Tice BCG [8,9] (See Appendix Supplement for study details). Treatment 
duration had no impact on determination of the prognostic factors. Its possible impact was 
diluted because 40-50% of patients randomized to 3 years of maintenance BCG in the two 
studies received ≤ 1 year, mainly due to inefficacy. 
Patient and tumor characteristics previously investigated by the EORTC or CUETO were 
retrospectively analyzed: age, gender, prior recurrence rate, number of tumors, largest tumor 
diameter, tumor stage, and 1973 World Health Organization (WHO) grade.   
The following endpoints were assessed: 
Time to first recurrence (Disease Free Interval), defined as (1) early recurrence within the first 
4.5 months after randomization (the time between randomization and first follow-up 
cystoscopy, normally at 3 months, which was delayed in some patients) or (2) time to late 
recurrence (the first recurrence in patients without an early recurrence who have follow-up 
after 4.5 months (Landmark analysis)). Patients still alive without recurrence were censored 
at the last follow-up. The time was censored at death and/or cystectomy in absence of 
recurrence (competing risk). 
Time to progression was defined as the time from randomization to first increase to stage T2 
or higher or development of metastases. Patients still alive without progression were 
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ABSTRACT 
Background: There are no prognostic factor publications in stage Ta-T1 non-muscle invasive 
bladder cancer (NMIBC) treated with 1 to 3 years of maintenance Bacillus Calmette-Guérin 
(BCG). 
Objectives: To determine prognostic factors in NMIBC patients treated with 1 to 3 years of 
BCG after transurethral resection of the bladder (TURB), to derive nomograms and risk groups 
and to identify high risk patients who should be considered for early cystectomy. 
Design, Setting and Participants: Data for 1812 patients were merged from two European 
Organization for Research and Treatment of Cancer randomized phase 3 trials in intermediate 
and high risk NMIBC. 
Interventions: Patients received 1-3 years of maintenance BCG after TURB and induction BCG. 
Outcome measurements and statistical analysis: Prognostic factors for risk of early recurrence 
and times to late recurrence, progression and death were identified in a training data set using 
multivariable models and applied to a validation dataset. 
Results and Limitations: With a median follow up of 7.4 years, 762 patients recurred, 173 
progressed and 520 died, 83 due to bladder cancer (BCa). Statistically significant prognostic 
factors identified by multivariable analyses were prior recurrence rate and number of tumors 
for recurrence, and tumor stage and grade for progression and death due to BCa. T1G3 
patients do poorly, with 1 and 5 year disease progression rates of 11.4% and 19.8%, 
respectively, and 1 and 5 year disease specific death rates of 4.8% and 11.3%. Limitations 
include lack of repeat transurethral resection in high-risk patients and exclusion of patients 
with carcinoma in situ. 
Conclusions: NMIBC patients treated with 1 to 3 years of maintenance BCG have a 
heterogeneous prognosis. Patients at high risk of recurrence and/or progression do poorly on 
currently recommended maintenance schedules. Alternative treatments are urgently 
required. 
 
INTRODUCTION 
European Association of Urology (EAU) recommendations for adjuvant treatment of non-
muscle invasive bladder cancer (NMIBC) are based on risk groups: low, intermediate or high 
risk [1,2]. They are derived from European Organization for Research and Treatment of Cancer 
(EORTC) risk tables which provide probabilities of recurrence and progression after 
transurethral resection of the bladder (TURB) [3], but these patients didn’t received 
maintenance bacilli Calmette-Guérin (BCG), which is now recommended for high risk patients.  
In 1062 patients treated with a maintenance schedule of six two-weekly BCG instillations for 
5–6 months, the Club Urológico Español de Tratamiento Oncológico (CUETO) found that 
EORTC risk tables overestimated the overall risk of recurrence and the probability of 
progression in high risk patients [4]. Using these data, CUETO developed a model to stratify 
patients according to their risk of recurrence and progression [5,6] which also successfully 
stratified a patient’s risk of recurrence after BCG plus interferon-alpha therapy [7]. 
The CUETO maintenance schedule is considerably shorter than the 1 to 3 years of maintenance 
BCG currently recommended by the EAU [1,2]. Prognostic factors for this longer maintenance 
schedule are unknown.  
Our aim was to determine prognostic factors and the probabilities of recurrence, progression, 
disease specific survival (DSS) and overall survival (OS) in stage Ta-T1 NMIBC patients treated 
with 1 to 3 years of maintenance BCG and identify high-risk patients who may need early 
cystectomy. We also assess the performance of the CUETO models on EORTC data. 
 
MATERIALS AND METHODS 
Individual patient data were merged from two EORTC phase 3 trials (30911, 30962) in Ta-T1 
NMIBC (without carcinoma in situ (CIS)) where patients were randomized to receive 1 or 3 
years of maintenance Tice BCG [8,9] (See Appendix Supplement for study details). Treatment 
duration had no impact on determination of the prognostic factors. Its possible impact was 
diluted because 40-50% of patients randomized to 3 years of maintenance BCG in the two 
studies received ≤ 1 year, mainly due to inefficacy. 
Patient and tumor characteristics previously investigated by the EORTC or CUETO were 
retrospectively analyzed: age, gender, prior recurrence rate, number of tumors, largest tumor 
diameter, tumor stage, and 1973 World Health Organization (WHO) grade.   
The following endpoints were assessed: 
Time to first recurrence (Disease Free Interval), defined as (1) early recurrence within the first 
4.5 months after randomization (the time between randomization and first follow-up 
cystoscopy, normally at 3 months, which was delayed in some patients) or (2) time to late 
recurrence (the first recurrence in patients without an early recurrence who have follow-up 
after 4.5 months (Landmark analysis)). Patients still alive without recurrence were censored 
at the last follow-up. The time was censored at death and/or cystectomy in absence of 
recurrence (competing risk). 
Time to progression was defined as the time from randomization to first increase to stage T2 
or higher or development of metastases. Patients still alive without progression were 
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censored at the last follow-up. The time was censored upon death and/or cystectomy before 
progression (competing risks).  
Duration of survival was defined as the time from randomization to death from any cause or 
last follow-up. For DSS deaths not due to bladder cancer (BCa) are competing risks. For both 
endpoints, patients still alive were censored at the last follow-up. 
Median follow-up in all patients was estimated using the Kaplan-Meier technique and OS time 
but with status indicator reversed: Patients still alive were considered to have died at last 
follow-up, and patients who died were censored at date of death [10]. 
The dataset was split into two sets based on country: a training set from the largest 
participating countries for model development and a validation set (Appendix Table 1). Using 
previous publications as a guide [3,5,6], variables were coded based on training set univariate 
analyses.  
In multivariate regression models for recurrence, variables were: age (continuous), gender, 
prior recurrence rate (primary versus ≤ 1 per year versus >1 per year), tumor size (< 3 cm 
versus ≥ 3 cm), number of tumors (< 4 versus > 4 [6]), stage (Ta versus T1), and 1973 WHO 
grade (G1 versus G2-G3).  For progression, time to death due to BCa and OS, the same 
variables and coding were used except for tumor size (continuous), number of tumors (< 8 
versus ≥ 8) and grade (G1, G2 or G3).   
For early recurrence, multivariable logistic regression models were fit using Bayesian 
Information Criterion (BIC) variable selection to allow covariates to leave the model [11].  
For endpoints affected by competing risks, Fine and Gray regression models were fit using 
Bayesian Information Criterion for Competing Risks (BICcr) variable selection [12]. For overall 
survival, Cox regression models were fit based on BIC variable selection.  Final models were 
based on the frequency of variables retained using BIC/BICcr selection procedures with 
bootstrap re-sampling. 
Kaplan-Meier OS curves were estimated. Based on the multivariable model, a nomogram was 
constructed to predict 1 and 5 year survival. The nomogram provides a graphic representation 
linking an individual patient’s multivariable prognostic factors to his or her survival probability. 
Goodness of fit was assessed with calibration plots. For other endpoints, time to event 
distributions were estimated using cumulative incidence curves. 
Based on multivariable analyses in the training set, prognostic factors were identified and 
prognostic categories formed. Categories with similar prognoses were grouped together, with 
emphasis placed on identifying the best prognosis and the worst prognosis patients. These 
categories and survival regression coefficients were applied to the validation set.  
The Area under the Curve (AUC) and Harrell’s bias corrected concordance index (C index) were 
used to assess model accuracy (discrimination) in the training and validation datasets [13-14]. 
The C index is the probability that for two randomly chosen patients, the patient who had the 
event first has a higher probability of having the event according to the model. Consequently, 
C = 0.50 represents agreement by chance; c = 1.0 represents perfect discrimination. 
For all endpoints, sensitivity analyses were done stratified by study.  Sensitivity analyses also 
compared the results of Cox and the Fine and Gray models.   
 
Statistical analyses were done in SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 
3.0.1 (R Foundation, Vienna, Austria) with crrstep package v.2014-07.16, cmprsk package v. 
2.2-7, and rms package v. 4.2-1 for constructing nomograms.  
 
RESULTS 
A total of 1812 Ta-T1 patients from EORTC studies 30962 (n=1272 patients) and 30911 (n=540) 
were included, 1180 (65%) of whom were allocated to 3 years of maintenance BCG and 632 
(35%) to 1 year. They were divided into a training dataset with 1178 patients and a validation 
dataset with 634 patients.  
 
Table 1. Patient characteristics  
 Training 
(n=1178) 
Validation 
(n=634) 
Total 
(n=1812) 
n (%) n (%) n (%) 
Age                       
 ≤60                      333 (28) 162 (26) 495 (27) 
 61-70                     397 (34) 233 (37) 630 (35) 
 71-80                     393 (33) 201 (32) 594 (33) 
 >80                      55 (4.7) 38 (6.0) 93 (5.1) 
Gender                        
 Female                    199 (17) 101 (16) 300 (17) 
 Male                      979 (83) 530 (84) 1509 (83) 
 Unknown                   0 (0.0) 3 (0.5) 3 (0.2) 
Prior recurrence rate                      
 Primary                        635 (54) 358 (56) 993 (55) 
 Recurrent, ≤1/Year                         220 (19) 121 (19) 341 (19) 
 Recurrent, >1/Year                         297 (25) 137 (22) 434 (24) 
 Unknown                  26 (2.2) 18 (2.8) 44 (2.4) 
Largest tumor size                          
 ≤1cm                     517 (44) 306 (48) 823 (45) 
 >1cm - <3cm                     354 (30) 196 (31) 550 (30) 
 ≥3cm                      247 (21) 112 (18) 359 (20) 
 Unknown                   60 (5.1) 20 (3.2) 80 (4.4) 
Number of tumors              
1 175 (15) 69 (11) 244 (13) 
2-3 700 (59) 372 (59) 1072 (59) 
4-7 253 (21) 138 (22) 391 (22) 
≥8 50 (4.2) 55 (8.7) 105 (5.8) 
T category                    
 Ta                         807 (69) 345 (54) 1152 (64) 
 T1                         370 (31) 289 (46) 659 (36) 
 Unknown                         1 (0.1) 0 (0.0) 1 (0.1) 
1973 WHO grade                     
 G1                         389 (33) 191 (30) 580 (32) 
 G2                         506 (43) 309 (49) 815 (45) 
 G3                         280 (24) 132 (21) 412 (23) 
 Unknown                3 (0.3) 2 (0.3) 5 (0.3) 
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censored at the last follow-up. The time was censored upon death and/or cystectomy before 
progression (competing risks).  
Duration of survival was defined as the time from randomization to death from any cause or 
last follow-up. For DSS deaths not due to bladder cancer (BCa) are competing risks. For both 
endpoints, patients still alive were censored at the last follow-up. 
Median follow-up in all patients was estimated using the Kaplan-Meier technique and OS time 
but with status indicator reversed: Patients still alive were considered to have died at last 
follow-up, and patients who died were censored at date of death [10]. 
The dataset was split into two sets based on country: a training set from the largest 
participating countries for model development and a validation set (Appendix Table 1). Using 
previous publications as a guide [3,5,6], variables were coded based on training set univariate 
analyses.  
In multivariate regression models for recurrence, variables were: age (continuous), gender, 
prior recurrence rate (primary versus ≤ 1 per year versus >1 per year), tumor size (< 3 cm 
versus ≥ 3 cm), number of tumors (< 4 versus > 4 [6]), stage (Ta versus T1), and 1973 WHO 
grade (G1 versus G2-G3).  For progression, time to death due to BCa and OS, the same 
variables and coding were used except for tumor size (continuous), number of tumors (< 8 
versus ≥ 8) and grade (G1, G2 or G3).   
For early recurrence, multivariable logistic regression models were fit using Bayesian 
Information Criterion (BIC) variable selection to allow covariates to leave the model [11].  
For endpoints affected by competing risks, Fine and Gray regression models were fit using 
Bayesian Information Criterion for Competing Risks (BICcr) variable selection [12]. For overall 
survival, Cox regression models were fit based on BIC variable selection.  Final models were 
based on the frequency of variables retained using BIC/BICcr selection procedures with 
bootstrap re-sampling. 
Kaplan-Meier OS curves were estimated. Based on the multivariable model, a nomogram was 
constructed to predict 1 and 5 year survival. The nomogram provides a graphic representation 
linking an individual patient’s multivariable prognostic factors to his or her survival probability. 
Goodness of fit was assessed with calibration plots. For other endpoints, time to event 
distributions were estimated using cumulative incidence curves. 
Based on multivariable analyses in the training set, prognostic factors were identified and 
prognostic categories formed. Categories with similar prognoses were grouped together, with 
emphasis placed on identifying the best prognosis and the worst prognosis patients. These 
categories and survival regression coefficients were applied to the validation set.  
The Area under the Curve (AUC) and Harrell’s bias corrected concordance index (C index) were 
used to assess model accuracy (discrimination) in the training and validation datasets [13-14]. 
The C index is the probability that for two randomly chosen patients, the patient who had the 
event first has a higher probability of having the event according to the model. Consequently, 
C = 0.50 represents agreement by chance; c = 1.0 represents perfect discrimination. 
For all endpoints, sensitivity analyses were done stratified by study.  Sensitivity analyses also 
compared the results of Cox and the Fine and Gray models.   
 
Statistical analyses were done in SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 
3.0.1 (R Foundation, Vienna, Austria) with crrstep package v.2014-07.16, cmprsk package v. 
2.2-7, and rms package v. 4.2-1 for constructing nomograms.  
 
RESULTS 
A total of 1812 Ta-T1 patients from EORTC studies 30962 (n=1272 patients) and 30911 (n=540) 
were included, 1180 (65%) of whom were allocated to 3 years of maintenance BCG and 632 
(35%) to 1 year. They were divided into a training dataset with 1178 patients and a validation 
dataset with 634 patients.  
 
Table 1. Patient characteristics  
 Training 
(n=1178) 
Validation 
(n=634) 
Total 
(n=1812) 
n (%) n (%) n (%) 
Age                       
 ≤60                      333 (28) 162 (26) 495 (27) 
 61-70                     397 (34) 233 (37) 630 (35) 
 71-80                     393 (33) 201 (32) 594 (33) 
 >80                      55 (4.7) 38 (6.0) 93 (5.1) 
Gender                        
 Female                    199 (17) 101 (16) 300 (17) 
 Male                      979 (83) 530 (84) 1509 (83) 
 Unknown                   0 (0.0) 3 (0.5) 3 (0.2) 
Prior recurrence rate                      
 Primary                        635 (54) 358 (56) 993 (55) 
 Recurrent, ≤1/Year                         220 (19) 121 (19) 341 (19) 
 Recurrent, >1/Year                         297 (25) 137 (22) 434 (24) 
 Unknown                  26 (2.2) 18 (2.8) 44 (2.4) 
Largest tumor size                          
 ≤1cm                     517 (44) 306 (48) 823 (45) 
 >1cm - <3cm                     354 (30) 196 (31) 550 (30) 
 ≥3cm                      247 (21) 112 (18) 359 (20) 
 Unknown                   60 (5.1) 20 (3.2) 80 (4.4) 
Number of tumors              
1 175 (15) 69 (11) 244 (13) 
2-3 700 (59) 372 (59) 1072 (59) 
4-7 253 (21) 138 (22) 391 (22) 
≥8 50 (4.2) 55 (8.7) 105 (5.8) 
T category                    
 Ta                         807 (69) 345 (54) 1152 (64) 
 T1                         370 (31) 289 (46) 659 (36) 
 Unknown                         1 (0.1) 0 (0.0) 1 (0.1) 
1973 WHO grade                     
 G1                         389 (33) 191 (30) 580 (32) 
 G2                         506 (43) 309 (49) 815 (45) 
 G3                         280 (24) 132 (21) 412 (23) 
 Unknown                3 (0.3) 2 (0.3) 5 (0.3) 
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Median age was 67 years, 43% were recurrent, 24% had a prior recurrence rate > 1 per year, 
87% had multiple tumors, 20% tumors ≥ 3 cm in diameter, 36% were T1 and 23% had grade 3 
tumors (Table 1). Patient characteristics in the training and validation datasets were similar, 
except for a higher percentage of T1 patients in the validation dataset (46% versus 31%).  
 After a median follow-up of 7.4 years, 6.7 years in patients still alive, 762 patients recurred, 
173 progressed and 520 died, 83 due to BCa (Table 2). 
Table 2. Number of events 
 Training 
(n=1178) 
Validation 
(n=634) 
Total 
(n=1812) 
n (%) n (%) n (%) 
Recurrence 509 253 762 
   Early recurrence  202 (17.1) 83 (13.1) 285 (15.7) 
   Late recurrence  307 170 477 
Progression 116 57 173 
Dead 318 202 520 
   Bladder cancer 59 24 83 
   Dead other cause 259 178 437 
 
The 1 and 5 year recurrence rates were 25.9% (95% CI: 23.8%-27.9%) and 41.3% (95% CI: 
39.0%-43.7%), respectively. (Appendix Figure 1). 
Overall, 285 (15.7%) patients had an early recurrence (Table 2). Using the training data set, 
the final logistic model for early recurrence included prior recurrence, number of tumors, and 
grade.  Table 3 shows the probabilities of early recurrence in the training and validation data 
sets in six prognostic groups.  The best prognosis patients, G1 patients with less than 4 tumors 
and a prior recurrence rate < 1 per year, had an 8% probability of early recurrence in the 
validation set.  The worst prognosis group, 4 or more G2 or G3 tumors and > 1 recurrence per 
year, had a 29% probability of early recurrence in the validation set.  For these six groups, the 
Area under the curves (AUC) were 0.67 and 0.65 in the training and validation datasets, 
respectively. 
  
 
Table 3. Probabilities of early recurrence and 95% confidence intervals in the training and 
validation datasets according to prognostic group 
 Six prognostic groups for early recurrence Training dataset: 
AUC 0.67 
% (95% CI) 
Validation dataset: 
AUC 0.65 
% (95% CI) 
1 Grade 1 
Prior recurrence ≤1/y 
<4 tumors 
 11/204 
 
5 (0.03-0.09) 
8/102 
 
8 (0.04-0.15) 
2 Grade 1 
Prior recurrence >1/y 
<4 tumors 
 13/65 
 
20 (0.12-0.31) 
6/33 
 
18 (0.08-0.35) 
3 Grade 1 
Prior recurrence ≤1/y 
≥4 tumors 
Grade 2 or 3 
Prior recurrence ≤1/y 
<4 tumors  
75/540 
 
14 (0.11-0.17) 
26/290 
 
9 (0.06-0.13) 
4 Grade 1 
Prior recurrence >1/y 
≥4 tumors 
Grade 2 or 3 
Prior recurrence >1/y 
<4 tumors 
46/154 
 
30 (0.23-0.37) 
8/56 
 
14 (0.07-0.26) 
5 Grade 2 or 3 
Prior recurrence ≤1/y 
≥4 tumors 
 24/109 
 
22 (0.15-0.31) 
21/87 
 
24 (0.16-0.34) 
6 Grade 2 or 3 
Prior recurrence >1/y 
≥4 tumors 
 31/77 
 
40 (0.30-0.51) 
14/48 
 
29 (0.18-0.43) 
 Missing  2/29 0/18 
 Total  202/1178 83/616 
 
Late recurrence was observed in 477 patients (Table 2).  A total of 375 patients were excluded 
from the analysis, 285 patients due to early recurrence and 90 patients due to absence of 
follow up after the landmark. Prognostic variables in the final model were prior recurrence 
rate and number of tumors. With these variables, 4 prognostic groups were created (Table 4). 
The best prognosis group (<4 tumors and ≤ 1 recurrence per year) has recurrence probabilities 
of 14.0% and 28.3% at 1 year and 5 years, respectively, in the validation set.  The worst 
prognosis group, (≥ 4 tumors and > 1 recurrence per year) recurrence probabilities of 33.0% 
and 51.7%, respectively.  The C-indexes in the training and validation data sets were 0,59 and 
0,56, respectively. Cumulative incidence curves are provided in Figures 1a/b. 
 
  
59
Ch
ap
te
r 4
 |
 E
O
RT
C 
no
m
og
ra
m
s 
an
d 
ri
sk
gr
ou
ps
 in
 B
CG
 t
re
at
ed
 p
ati
en
ts
4
 
Median age was 67 years, 43% were recurrent, 24% had a prior recurrence rate > 1 per year, 
87% had multiple tumors, 20% tumors ≥ 3 cm in diameter, 36% were T1 and 23% had grade 3 
tumors (Table 1). Patient characteristics in the training and validation datasets were similar, 
except for a higher percentage of T1 patients in the validation dataset (46% versus 31%).  
 After a median follow-up of 7.4 years, 6.7 years in patients still alive, 762 patients recurred, 
173 progressed and 520 died, 83 due to BCa (Table 2). 
Table 2. Number of events 
 Training 
(n=1178) 
Validation 
(n=634) 
Total 
(n=1812) 
n (%) n (%) n (%) 
Recurrence 509 253 762 
   Early recurrence  202 (17.1) 83 (13.1) 285 (15.7) 
   Late recurrence  307 170 477 
Progression 116 57 173 
Dead 318 202 520 
   Bladder cancer 59 24 83 
   Dead other cause 259 178 437 
 
The 1 and 5 year recurrence rates were 25.9% (95% CI: 23.8%-27.9%) and 41.3% (95% CI: 
39.0%-43.7%), respectively. (Appendix Figure 1). 
Overall, 285 (15.7%) patients had an early recurrence (Table 2). Using the training data set, 
the final logistic model for early recurrence included prior recurrence, number of tumors, and 
grade.  Table 3 shows the probabilities of early recurrence in the training and validation data 
sets in six prognostic groups.  The best prognosis patients, G1 patients with less than 4 tumors 
and a prior recurrence rate < 1 per year, had an 8% probability of early recurrence in the 
validation set.  The worst prognosis group, 4 or more G2 or G3 tumors and > 1 recurrence per 
year, had a 29% probability of early recurrence in the validation set.  For these six groups, the 
Area under the curves (AUC) were 0.67 and 0.65 in the training and validation datasets, 
respectively. 
  
 
Table 3. Probabilities of early recurrence and 95% confidence intervals in the training and 
validation datasets according to prognostic group 
 Six prognostic groups for early recurrence Training dataset: 
AUC 0.67 
% (95% CI) 
Validation dataset: 
AUC 0.65 
% (95% CI) 
1 Grade 1 
Prior recurrence ≤1/y 
<4 tumors 
 11/204 
 
5 (0.03-0.09) 
8/102 
 
8 (0.04-0.15) 
2 Grade 1 
Prior recurrence >1/y 
<4 tumors 
 13/65 
 
20 (0.12-0.31) 
6/33 
 
18 (0.08-0.35) 
3 Grade 1 
Prior recurrence ≤1/y 
≥4 tumors 
Grade 2 or 3 
Prior recurrence ≤1/y 
<4 tumors  
75/540 
 
14 (0.11-0.17) 
26/290 
 
9 (0.06-0.13) 
4 Grade 1 
Prior recurrence >1/y 
≥4 tumors 
Grade 2 or 3 
Prior recurrence >1/y 
<4 tumors 
46/154 
 
30 (0.23-0.37) 
8/56 
 
14 (0.07-0.26) 
5 Grade 2 or 3 
Prior recurrence ≤1/y 
≥4 tumors 
 24/109 
 
22 (0.15-0.31) 
21/87 
 
24 (0.16-0.34) 
6 Grade 2 or 3 
Prior recurrence >1/y 
≥4 tumors 
 31/77 
 
40 (0.30-0.51) 
14/48 
 
29 (0.18-0.43) 
 Missing  2/29 0/18 
 Total  202/1178 83/616 
 
Late recurrence was observed in 477 patients (Table 2).  A total of 375 patients were excluded 
from the analysis, 285 patients due to early recurrence and 90 patients due to absence of 
follow up after the landmark. Prognostic variables in the final model were prior recurrence 
rate and number of tumors. With these variables, 4 prognostic groups were created (Table 4). 
The best prognosis group (<4 tumors and ≤ 1 recurrence per year) has recurrence probabilities 
of 14.0% and 28.3% at 1 year and 5 years, respectively, in the validation set.  The worst 
prognosis group, (≥ 4 tumors and > 1 recurrence per year) recurrence probabilities of 33.0% 
and 51.7%, respectively.  The C-indexes in the training and validation data sets were 0,59 and 
0,56, respectively. Cumulative incidence curves are provided in Figures 1a/b. 
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Table 4. Probabilities of late recurrence and 95% confidence intervals in the training and 
validation datasets according to prognostic group 
 Training dataset (C-index 0.59)* Validation dataset (C-index 0.56)* 
1 year % (95% CI) 5 years % (95% CI) 1 year % (95% CI) 5 years % (95% CI) 
Prior recurrence ≤1/y 
and < 4 tumors 
11.0 
(8.4-13.5) 
25.9 
(22.1-29.6) 
14.0 
(10.2-17.9) 
28.3 
(23.1-33.6) 
Prior recurrence ≤1/y 
and ≥ 4 tumors 
20.6 
(13.9-27.3) 
31.6 
(23.7-39.5) 
16.3 
(8.5-24.1) 
31.0 
(20.8-41.3) 
Prior recurrence >1/y 
and < 4 tumors 
23.8 
(16.5-31.2) 
39.6 
(30.9-48.2) 
21.8 
(11.3-32.3) 
42.4 
(29.3-55.5) 
Prior recurrence >1/y 
and ≥ 4 tumors 
31.2 
(20.1-42.3) 
55.4 
(43.1-67.6) 
33.0 
(19.3-46.7) 
51.7 
(36.9-66.6) 
*Maximum achievable C-index in both groups: 0.90 [13] 
 
The multivariable model for disease progression identified two variables:  grade and T 
category, with four prognostic groups (Table 5). The best prognostic group, TaG1 patients, had 
a progression probability of 1.9% at 1 year and 7.1% at 5 years in the validation data set.  The 
group, T1G3 patients, had a progression probability of 11.4% at 1 year and 19.8% at 5 years 
(Table 5, Figures 2a and 2b). The C-indexes in the training and validation data sets were 0,72 
and 0,64, respectively. 
 
Table 5. Probabilities of progression and 95% confidence intervals in the training and 
validation datasets according to stage and grade 
 Training data set (C-index 0.72) Validation data set (C-index 0.64) 
1 year % (95% CI) 5 years % (95% CI) 1 year % (95% CI) 5 years % (95% CI) 
TaG1 0.28 (0-0.82) 2.4 (0.76-4.1) 1.9 (0-4.1) 7.1 (2.8-11.4) 
TaG2 or T1G1 2.5 (0.97-4.0) 7.0 (4.4-9.6) 1.6 (0-3.4) 4.6 (1.5-7.7) 
TaG3 or T1G2 3.5 (0.75-6.3) 15.2 (9.6-20.8) 1.8 (0-3.8) 5.9 (2.1-9.6) 
T1G3 10.6 (6.5-14.7) 18.9 (13.6-24.4) 11.4 (5.3-17.5) 19.8 (12.0-27.6) 
 
A total of 83 of 520 deaths were due to BCa. The same variables as for progression were of 
prognostic importance, grade and T category, and the same prognostic groups were formed 
(Table 6). TaG1, the best prognosis group, had a probability of death due to BCa of 1.5% at 5 
years in the validation data set.  The worst prognosis group, T1G3, has the highest probability 
of death due to BCa, 4.8% at 1 year and 11.3% at 5 years (Table 6). The C-indexes in the training 
and validation data sets were 0,72 and 0,71, respectively. The cumulative incidence curves are 
given in Figures 3a/b. 
 
 
Figure 1.  Time to late recurrence according to prognostic groups: (a) training set; (b) 
validation set. 
(a) 
 
(b) 
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Table 4. Probabilities of late recurrence and 95% confidence intervals in the training and 
validation datasets according to prognostic group 
 Training dataset (C-index 0.59)* Validation dataset (C-index 0.56)* 
1 year % (95% CI) 5 years % (95% CI) 1 year % (95% CI) 5 years % (95% CI) 
Prior recurrence ≤1/y 
and < 4 tumors 
11.0 
(8.4-13.5) 
25.9 
(22.1-29.6) 
14.0 
(10.2-17.9) 
28.3 
(23.1-33.6) 
Prior recurrence ≤1/y 
and ≥ 4 tumors 
20.6 
(13.9-27.3) 
31.6 
(23.7-39.5) 
16.3 
(8.5-24.1) 
31.0 
(20.8-41.3) 
Prior recurrence >1/y 
and < 4 tumors 
23.8 
(16.5-31.2) 
39.6 
(30.9-48.2) 
21.8 
(11.3-32.3) 
42.4 
(29.3-55.5) 
Prior recurrence >1/y 
and ≥ 4 tumors 
31.2 
(20.1-42.3) 
55.4 
(43.1-67.6) 
33.0 
(19.3-46.7) 
51.7 
(36.9-66.6) 
*Maximum achievable C-index in both groups: 0.90 [13] 
 
The multivariable model for disease progression identified two variables:  grade and T 
category, with four prognostic groups (Table 5). The best prognostic group, TaG1 patients, had 
a progression probability of 1.9% at 1 year and 7.1% at 5 years in the validation data set.  The 
group, T1G3 patients, had a progression probability of 11.4% at 1 year and 19.8% at 5 years 
(Table 5, Figures 2a and 2b). The C-indexes in the training and validation data sets were 0,72 
and 0,64, respectively. 
 
Table 5. Probabilities of progression and 95% confidence intervals in the training and 
validation datasets according to stage and grade 
 Training data set (C-index 0.72) Validation data set (C-index 0.64) 
1 year % (95% CI) 5 years % (95% CI) 1 year % (95% CI) 5 years % (95% CI) 
TaG1 0.28 (0-0.82) 2.4 (0.76-4.1) 1.9 (0-4.1) 7.1 (2.8-11.4) 
TaG2 or T1G1 2.5 (0.97-4.0) 7.0 (4.4-9.6) 1.6 (0-3.4) 4.6 (1.5-7.7) 
TaG3 or T1G2 3.5 (0.75-6.3) 15.2 (9.6-20.8) 1.8 (0-3.8) 5.9 (2.1-9.6) 
T1G3 10.6 (6.5-14.7) 18.9 (13.6-24.4) 11.4 (5.3-17.5) 19.8 (12.0-27.6) 
 
A total of 83 of 520 deaths were due to BCa. The same variables as for progression were of 
prognostic importance, grade and T category, and the same prognostic groups were formed 
(Table 6). TaG1, the best prognosis group, had a probability of death due to BCa of 1.5% at 5 
years in the validation data set.  The worst prognosis group, T1G3, has the highest probability 
of death due to BCa, 4.8% at 1 year and 11.3% at 5 years (Table 6). The C-indexes in the training 
and validation data sets were 0,72 and 0,71, respectively. The cumulative incidence curves are 
given in Figures 3a/b. 
 
 
Figure 1.  Time to late recurrence according to prognostic groups: (a) training set; (b) 
validation set. 
(a) 
 
(b) 
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Table 6. Probabilities of death due to bladder cancer and 95% confidence intervals in the 
training and validation datasets according to stage and grade  
 Training data set (C-index 0.72) Validation data set (C index 0.71) 
1 year % (95% CI) 5 years % (95% CI) 1 year % (95% CI) 5 years % (95% CI) 
TaG1 0 (no events) 0.87 (0-1.9) 0 (no events) 1.5 (0-3.6) 
TaG2 or T1G1 0.75 (0-1.6) 3.6 (1.7-5.6) 0 (no events) 1.7 (0-3.6) 
TaG3 or T1G2 0 (no events) 7.1 (3.1-11.2) 0 (no events) 1.4 (0-3.3) 
T1G3 1.9 (0.05-3.7) 11.5 (6.9-16.0) 4.8 (0.70-8.9) 11.3 (5.0-17.6) 
 
The final multivariable survival model included age and grade. The C indexes in the training 
and validation datasets were both 0.68. Model calibration of the selected model was checked 
with calibration plots (Appendix Figures 2a/b). Appendix Figures 3a, 3b and 4a present the 
Kaplan-Meier curves according to age and grade, respectively, in both datasets. Figure 4 
provides a nomogram for survival based on age and grade. Points associated with the 
nomogram are given in Appendix Table 2. For example, a 65-year-old patient with a G3 tumor 
has 79 points (67 + 12), which results in survival probabilities of 97% at 1 year and 78% at 5 
years.  The sensitivity analyses gave the same conclusions for all end points.  
CUETO recurrence and progression scores were calculated using the EORTC data [6]. Time to 
recurrence and time to progression cumulative incidence curves were estimated and are 
presented in Appendix Figures 5a and 5b. The CUETO model did not perform as well when 
applied to EORTC data. The C-indexes for recurrence and progression decreased from 0.64 to 
0.48 and from 0.69 to 0.53, respectively. Applied to the EORTC data, the CUETO model 
underestimated the risk of recurrence in the good risk patients and overestimated the risk of 
progression at 5 years in the poorer risk patients. 
 
 
  
 
Figure 2. Time to progression according to prognostic groups: (a) training set; (b) validation 
set. 
(a) 
 
(b) 
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Table 6. Probabilities of death due to bladder cancer and 95% confidence intervals in the 
training and validation datasets according to stage and grade  
 Training data set (C-index 0.72) Validation data set (C index 0.71) 
1 year % (95% CI) 5 years % (95% CI) 1 year % (95% CI) 5 years % (95% CI) 
TaG1 0 (no events) 0.87 (0-1.9) 0 (no events) 1.5 (0-3.6) 
TaG2 or T1G1 0.75 (0-1.6) 3.6 (1.7-5.6) 0 (no events) 1.7 (0-3.6) 
TaG3 or T1G2 0 (no events) 7.1 (3.1-11.2) 0 (no events) 1.4 (0-3.3) 
T1G3 1.9 (0.05-3.7) 11.5 (6.9-16.0) 4.8 (0.70-8.9) 11.3 (5.0-17.6) 
 
The final multivariable survival model included age and grade. The C indexes in the training 
and validation datasets were both 0.68. Model calibration of the selected model was checked 
with calibration plots (Appendix Figures 2a/b). Appendix Figures 3a, 3b and 4a present the 
Kaplan-Meier curves according to age and grade, respectively, in both datasets. Figure 4 
provides a nomogram for survival based on age and grade. Points associated with the 
nomogram are given in Appendix Table 2. For example, a 65-year-old patient with a G3 tumor 
has 79 points (67 + 12), which results in survival probabilities of 97% at 1 year and 78% at 5 
years.  The sensitivity analyses gave the same conclusions for all end points.  
CUETO recurrence and progression scores were calculated using the EORTC data [6]. Time to 
recurrence and time to progression cumulative incidence curves were estimated and are 
presented in Appendix Figures 5a and 5b. The CUETO model did not perform as well when 
applied to EORTC data. The C-indexes for recurrence and progression decreased from 0.64 to 
0.48 and from 0.69 to 0.53, respectively. Applied to the EORTC data, the CUETO model 
underestimated the risk of recurrence in the good risk patients and overestimated the risk of 
progression at 5 years in the poorer risk patients. 
 
 
  
 
Figure 2. Time to progression according to prognostic groups: (a) training set; (b) validation 
set. 
(a) 
 
(b) 
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Figure 3. Disease-specific survival according to prognostic groups: (a) training set; (b) 
validation set. 
(a) 
 
(b) 
 
 
  
 
Figure 4. Nomogram for overall survival according to age and grade. 
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Figure 3. Disease-specific survival according to prognostic groups: (a) training set; (b) 
validation set. 
(a) 
 
(b) 
 
 
  
 
Figure 4. Nomogram for overall survival according to age and grade. 
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DISCUSSION 
This paper presents the first prognostic factor analysis in NMIBC patients receiving the 
currently recommended 1 to 3 years of maintenance BCG and identified prognostic factors for 
recurrence, progression, DSS and OS. 
The analysis made a distinction between early recurrence which may be influenced by 
unintended incomplete resection [15] and late recurrence in patients who are disease free at 
the first follow-up cystoscopy.  
The most important prognostic factor for early recurrence were prior recurrence rat, number 
of tumors and grade. The prior recurrence rate and number of tumors were also the most 
important factors for time to recurrence in patients without an early recurrence. These results 
correspond with those from the EORTC [3] and CUETO [5-6]. However, CUETO also identified 
the prognostic importance of grade along with age and gender.  
For progression, the most important factors were stage and grade which were also previously 
identified by the EORTC and CUETO. As expected, T1G3 patients had the worst prognosis with 
1 and 5 yr progression rates of 11.4% and 19.8%, respectively. 
CUETO models for recurrence and progression are “optimized” for their dataset and do not 
perform as well when applied to EORTC data. The longer duration of BCG in EORTC studies 
may have also had an impact on the results. 
For the first time, prognostic factor analyses for both DSS and OS are provided. For DSS, the 
most important factors were the same as for progression: stage and grade. T1G3 patients had 
the worst prognosis with 1 and 5 yr disease specific death rates of 4.8% and 11.3%, 
respectively. Although grade remained statistically significant for OS, age was the dominant 
factor (Figure 4). The clinical utility of this nomogram in daily practice still needs to be proven. 
Patients previously identified as being at the highest risk of recurrence [3,5-6] still remain at 
the highest risk even when treated with 1 to 3 years of maintenance BCG. Patients with > 4 
tumors and a prior recurrence rate > 1 per year still have a probability of recurrence at 1 and 
5 years of 33.0% and 51.7%, respectively, even if no tumor was detected at the first follow-up 
cystoscopy. With recurrences after more than 10 years, our study along with studies from 
CUETO, SWOG and FinnBladder have shown the need for long term follow-up in NMIBC 
patients [5,6,16,17]. 
Many patients do well on maintenance, with a 5 yr recurrence free rate of 58.7%.  Although 
we can accurately identify the patients who do not progress or die due to their disease 
(approximately 95% of TaG1 patients do not progress, 98% do not die due to their disease), 
we cannot reliably identify the important subgroup of patients who do progress and die of 
their disease. Patients with T1G3 tumors, even without CIS, do relatively poorly, with 5 yr 
progression and disease specific death rates of 19.8% and 11.3%, respectively, but we need 
improved methods to identify the really high risk patients and develop effective treatments 
for them.  
Because the number of tumors and the prior recurrence rate have also been shown to 
contribute to a worse prognosis, T1G3 patients with recurrent and/or multiple lesions should 
be considered for early cystectomy instead of BCG, especially if they have concomitant CIS, as 
 
was concluded by Gontero et al [18]. However, we need better markers of immune response 
and molecular profiling to optimize patient selection and treatment strategy [19,20]. 
This dataset has a number of limitations. No patients with CIS were included. Both studies 
were carried out in an era when routine repeat transurethral resection was not performed in 
high risk patients. This could have contributed to under-staging that may have led to higher 
progression rates, especially in T1G3 patients. There was no central pathology review. No 
information was collected on the status of the upper urinary tract upon recurrence or 
progression, or on potential biomarkers. It was not possible to make a meaningful distinction 
between 1 year and 3 years of maintenance in the analysis. Nevertheless, this study provides 
the best available information about the prognosis of patients treated with the currently 
recommended 1 to 3 years of maintenance BCG. 
 
CONCLUSIONS 
NMIBC patients treated with 1 to 3 years of maintenance BCG have a heterogeneous prognosis 
for both the time to first recurrence (according to the prior recurrence rate and number of 
tumors) and the time to progression and death due to bladder cancer (based on tumor stage 
and grade). 
Patients at high risk of recurrence and/or progression still do poorly on current maintenance 
schedules and alternative treatments are urgently required. 
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APPENDIX CHAPTER 4 
 
Supplement: Study-specific details 
 
1. Treatment  
Treatment details are given in the respective publications [8,9]. No patients received an early 
post-operative instillation of chemotherapy. Treatment with BCG was to be started 15 days 
after TUR. 
 
2. Follow Up 
Three monthly cystoscopies and urinary cytology during at least the first two years was the 
recommended follow up schedule used in clinical practice at the time the studies were started. 
The same follow up schedule was used in both protocols: 
Cystoscopy and urine cytology were repeated every 3 months during the first 3 years and 
every 6 months thereafter. All visible lesions had to be resected with recurrence established 
only by histological confirmation. If cytology was positive and no lesions were visible on 
cystoscopy, random biopsies had to be taken. 
 
3. Treatment Completion 
The main reason for stopping treatment was treatment inefficacy: disease recurrence or 
progression. 
In trial 30911 [8], 149 patients (27%) completed all 3 years of treatment. 99 patients (18%) 
prematurely stopped treatment for toxicity. 
In trial 30962 [9], 420 patients (66%) randomized to 1 year completed all 12 months of 
treatment and 246 patients (38%) randomized to 3 years completed all 36 months of 
treatment.  103 patients (8%) prematurely stopped treatment for toxicity. 
 
4. Treatment Outcome 
In trial 30962 [9], a statistically significant difference in time to recurrence between 1 and 3 
years of treatment could not be detected, p = 0.069. There was no suggestion of a treatment 
difference for progression or survival. The possible impact of 3 years of maintenance on the 
determination of the prognostic factors is diluted by the events occurring already during the 
first year of treatment. 
 
5. Further treatment after recurrence or progression  
After stopping protocol treatment for any reason in trial 30911, 59 patients received further 
BCG, 57 patients received intravesical chemotherapy, and 25 patients had a cystectomy. In 
trial 30962, the data on further treatment are incomplete so further treatment was not 
analyzed, however 76 patients had a cystectomy. 
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Appendix Figure 2a. Overall survival: calibration training set
 
 
 
Appendix Figure 2b. Overall survival: calibration validation set 
  
 
Appendix Figure 3a. Overall survival by age groups: training set 
 
 
 
Appendix Figure 3b. Overall survival by age groups: validation set 
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Appendix Figure 2b. Overall survival: calibration validation set 
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Appendix Figure 4a. Overall survival by grade: training set 
 
 
 
Appendix Figure 4b. Overall survival by grade: validation set 
 
  
 
Appendix Figure 5a. Validation of CUETO model, time to first recurrence 
 
 
 
Appendix Figure 5b. Validation of CUETO model, time to progression 
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ABSTRACT 
Background: Although BCG has been proven to be highly effective in NMIBC it can cause 
severe local and systemic side effects (SE). 
Objectives: The objective was to determine if reducing the dose or duration of BCG was 
associated with less SE. Efficacy comparisons of 1/3 dose (1/3D) versus full dose (FD) BCG 
given for 1 versus 3 years were previously published. 
Design, Setting, Participants and Intervention:  After TUR, patients with intermediate and high 
risk NMIBC without CIS were randomized to either 1/3D or FD BCG and 1 or 3 years of 
maintenance.  
Outcome Measurements and Statistical Analysis: local and systemic SE were recorded at every 
instillation and were divided into 3 time periods: during induction, during the first year after 
induction, and during the 2nd and 3rd years of maintenance. 
Results: In the 1316 patients who started BCG, 826 (62.8%) reported local SE, 403 (30.6%) 
systemic SE and 914 (69.5%) local or systemic SE. The percent of patients with at least one SE 
was similar in the 4 treatment arms (p = 0.41), both overall and in the different time periods. 
The most frequent local and systemic SE were chemical cystitis in 460 (35.0%) patients and 
general malaise in 204 patients (15.5%). 
103 patients (7.8%) stopped treatment due to SE. No significant difference was seen between 
treatment groups (p = 0.74). In the 653 patients randomized to 3 years BCG, 35 (5.4%) stopped 
during the first year and 21 (3.2%) stopped in the 2nd or 3rd year.  
Conclusions: No significant differences in SE were detected according to dose or duration of 
BCG treatment in the 4 arms. SE requiring treatment stop were seen more frequently in the 
1st year, so not all patients are able to receive the one to three years of treatment 
recommended in current guidelines. 
  
 
INTRODUCTION. 
After transurethral resection (TUR), intravesical immunotherapy with Bacillus Calmette Guerin 
(BCG) is considered to be the most effective prophylactic treatment for patients with 
intermediate and high risk urothelial non muscle invasive bladder cancer (NMIBC) [1,2]. BCG 
induction instillations are classically given according to the empirical 6-weekly schedule that 
Morales introduced more than 35 years ago [3]. A number of randomized trials and meta-
analyses published thereafter suggested that maintenance BCG instillations during 1 to 3 years 
is superior to both chemotherapy and induction BCG alone in reducing recurrences and even 
progression to muscle invasive disease [4-8]. As a result, current clinical practice guidelines 
recommend BCG with 1 to 3 years of maintenance as the intravesical therapy of choice for 
high-risk disease [1, 2]. 
Although BCG has been proven to be effective in Ta-T1 high grade tumors and CIS, it can 
produce moderate to severe local and systemic side effects. In Lamm’s report on maintenance 
BCG, only 16% of patients were able to receive all instillations of the 3 yr treatment, mainly 
due to side effects [5]. More recently, in the report on EORTC trial 30911 comparing 
maintenance BCG ± isoniazid (INH) to epirubicin, 19% of patients in the BCG group had to stop 
treatment because of side effects, however 29% completed all 3 years of treatment [9]. 
The occurrence of side effects is one of the main reasons why urologists try to avoid the use 
of BCG, particularly in intermediate risk patients, for whom chemotherapeutic agents are 
often prescribed. Reduction in side effects might be achieved in several different ways: for 
example, with the administration of the antituberculosis drug INH [9,10,11] or the antibiotic 
ofloxacin [12] or by reducing the dose [13-15]. 
After EORTC trial 30911 showed that INH did not reduce side effects of BCG, EORTC study 
30962 was designed with the primary objective to determine if 1/3 dose (1/3D) is not inferior 
to full dose (FD), if 1 year (1yr) maintenance is not inferior to 3 years (3yrs) maintenance and 
if 1/3D and 1yr maintenance are associated with less side effects. 
As the efficacy results have already been reported [16], this article will focus on toxicity. 
 
MATERIAL AND METHODS 
Inclusion and exclusion criteria. 
Patients with biopsy-proven, completely resected, solitary pT1G3 or multiple pTa-T1, grade 1–
3 (1973 WHO classification) urothelial carcinoma of the bladder were included. Excluded were 
patients with solitary tumors except T1G3, more than 10 tumors, CIS, tumors stage T2 or 
higher, age > 85 yrs, WHO performance status 3 or 4, previous treatment with BCG and 
intravesical chemotherapy during the previous 3 months. An intravenous pyelography was 
performed to rule out upper tract tumors. Informed consent was obtained in accordance with 
the Declaration of Helsinki and/or existing national and local regulations. 
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ABSTRACT 
Background: Although BCG has been proven to be highly effective in NMIBC it can cause 
severe local and systemic side effects (SE). 
Objectives: The objective was to determine if reducing the dose or duration of BCG was 
associated with less SE. Efficacy comparisons of 1/3 dose (1/3D) versus full dose (FD) BCG 
given for 1 versus 3 years were previously published. 
Design, Setting, Participants and Intervention:  After TUR, patients with intermediate and high 
risk NMIBC without CIS were randomized to either 1/3D or FD BCG and 1 or 3 years of 
maintenance.  
Outcome Measurements and Statistical Analysis: local and systemic SE were recorded at every 
instillation and were divided into 3 time periods: during induction, during the first year after 
induction, and during the 2nd and 3rd years of maintenance. 
Results: In the 1316 patients who started BCG, 826 (62.8%) reported local SE, 403 (30.6%) 
systemic SE and 914 (69.5%) local or systemic SE. The percent of patients with at least one SE 
was similar in the 4 treatment arms (p = 0.41), both overall and in the different time periods. 
The most frequent local and systemic SE were chemical cystitis in 460 (35.0%) patients and 
general malaise in 204 patients (15.5%). 
103 patients (7.8%) stopped treatment due to SE. No significant difference was seen between 
treatment groups (p = 0.74). In the 653 patients randomized to 3 years BCG, 35 (5.4%) stopped 
during the first year and 21 (3.2%) stopped in the 2nd or 3rd year.  
Conclusions: No significant differences in SE were detected according to dose or duration of 
BCG treatment in the 4 arms. SE requiring treatment stop were seen more frequently in the 
1st year, so not all patients are able to receive the one to three years of treatment 
recommended in current guidelines. 
  
 
INTRODUCTION. 
After transurethral resection (TUR), intravesical immunotherapy with Bacillus Calmette Guerin 
(BCG) is considered to be the most effective prophylactic treatment for patients with 
intermediate and high risk urothelial non muscle invasive bladder cancer (NMIBC) [1,2]. BCG 
induction instillations are classically given according to the empirical 6-weekly schedule that 
Morales introduced more than 35 years ago [3]. A number of randomized trials and meta-
analyses published thereafter suggested that maintenance BCG instillations during 1 to 3 years 
is superior to both chemotherapy and induction BCG alone in reducing recurrences and even 
progression to muscle invasive disease [4-8]. As a result, current clinical practice guidelines 
recommend BCG with 1 to 3 years of maintenance as the intravesical therapy of choice for 
high-risk disease [1, 2]. 
Although BCG has been proven to be effective in Ta-T1 high grade tumors and CIS, it can 
produce moderate to severe local and systemic side effects. In Lamm’s report on maintenance 
BCG, only 16% of patients were able to receive all instillations of the 3 yr treatment, mainly 
due to side effects [5]. More recently, in the report on EORTC trial 30911 comparing 
maintenance BCG ± isoniazid (INH) to epirubicin, 19% of patients in the BCG group had to stop 
treatment because of side effects, however 29% completed all 3 years of treatment [9]. 
The occurrence of side effects is one of the main reasons why urologists try to avoid the use 
of BCG, particularly in intermediate risk patients, for whom chemotherapeutic agents are 
often prescribed. Reduction in side effects might be achieved in several different ways: for 
example, with the administration of the antituberculosis drug INH [9,10,11] or the antibiotic 
ofloxacin [12] or by reducing the dose [13-15]. 
After EORTC trial 30911 showed that INH did not reduce side effects of BCG, EORTC study 
30962 was designed with the primary objective to determine if 1/3 dose (1/3D) is not inferior 
to full dose (FD), if 1 year (1yr) maintenance is not inferior to 3 years (3yrs) maintenance and 
if 1/3D and 1yr maintenance are associated with less side effects. 
As the efficacy results have already been reported [16], this article will focus on toxicity. 
 
MATERIAL AND METHODS 
Inclusion and exclusion criteria. 
Patients with biopsy-proven, completely resected, solitary pT1G3 or multiple pTa-T1, grade 1–
3 (1973 WHO classification) urothelial carcinoma of the bladder were included. Excluded were 
patients with solitary tumors except T1G3, more than 10 tumors, CIS, tumors stage T2 or 
higher, age > 85 yrs, WHO performance status 3 or 4, previous treatment with BCG and 
intravesical chemotherapy during the previous 3 months. An intravenous pyelography was 
performed to rule out upper tract tumors. Informed consent was obtained in accordance with 
the Declaration of Helsinki and/or existing national and local regulations. 
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Randomization and study interventions 
Within 14 days after TUR, patients were randomized to one of four treatment groups: 
1. 1/3 dose BCG with 1 yr maintenance (1/3D-1yr): BCG was given once a week for 6 wk, 
followed by 3 weekly instillations at months 3, 6, and 12. (A total of 4 cycles and 15 
instillations.) 
2. Full dose BCG with 1 yr maintenance (FD-1yr). 
3. 1/3 dose BCG with 3 yr maintenance (1/3D-3yrs): BCG was given once a week for 6 wk, 
followed by 3 weekly instillations at months 3, 6, 12, 18, 24, 30 and 36. (A total of 8 
cycles and 27 instillations.) 
4. Full dose BCG with 3 yr maintenance (FD-3yrs). 
 
For this study OncoTICE® (Organon-Teknika), containing 5 x 108 CFU, was used. 1/3 dose was 
prepared either by dissolving 1 vial with 150ml of saline and taking 50 ml or by dissolving with 
50 ml, taking 17 ml, and diluting this to 50 ml. 
Patients stopped protocol treatment at the second Ta/T1 recurrence after randomization and 
at progression to muscle-invasive disease, appearance of CIS, carcinoma in the upper urinary 
tract or prostatic urethra, or distant metastases. Further treatment was at the discretion of 
the local investigator. 
 
Endpoints 
The primary endpoint, the duration of the disease free interval (DFI), has been previously 
reported [16]. Secondary endpoints included the occurrence of side effects and their 
relationship to reduced dose or shorter duration of maintenance. The time of appearance of 
the side effects will also be addressed.  
 
Side effects 
At each instillation, patient complaints and symptoms were recorded as were urine cultures. 
Information about the presence or absence of local and systemic side effects and their impact 
on further treatment instillations was collected and reported during each cycle of protocol 
treatment according to a pre-defined format used in previous EORTC studies.  
 
Local side effects included bacterial or chemical cystitis, frequency, hematuria, and other.  
Bacterial cystitis was defined as the occurrence of culture proven (not BCG related) cystitis. 
Irritative bladder symptoms with negative urine culture were classified as BCG induced 
(chemical) cystitis. Other local side effects included granulomatous prostatitis, epididymitis, 
ureteral obstruction and contracted bladder.  
Systemic side effects included fever (>39°C), influenza like symptoms including general 
malaise and chills, BCG induced lung infection, liver toxicity and BCG sepsis. Skin rash, 
arthralgia and arthritis were classified as possible allergic reactions. 
 
 
The protocol provided recommendations for the treatment of BCG related complications 
(table 1). Based on the severity of the adverse effects, the treating physician decided whether 
instillations were to be postponed or even definitively stopped. In addition to an overall 
assessment of side effects, the treatment period was divided into 3 time intervals to evaluate 
when the side effects appeared: 
1. The induction period (first 6 weekly instillations) 
2. The first year of therapy after induction (next 9 instillations) 
3. The second and third years of therapy (next 12 instillations, only in the 3 yr 
maintenance arms) 
 
Table 1. Treatment recommendations for BCG-related complications as provided in the 
study-protocol 
Complication Recommended treatment 
Fever < 38,5 °C, BCG cystitis, mild malaise No treatment, hold BCG until symptoms resolve 
Fever > 38,5 °C for 12-24 h Isoniazid 300mg daily for 3 mo, may resume BCG 
when asymptomatic 
Allergic reactions (arthralgia, myalgia, rash) Isoniazid 300mg, further BCG is indicated only if 
benefit exceeds risk 
Acute severe illness, local or systemic pneumonitis, 
hepatitis, prostatitis, ureteral obstruction, renal 
abscess, persisting high fever > 39 °C 
Isoniazid 300mg, rifampin 600mg, ethambutol at 
1200 mg daily for 6 months, no further BCG 
BCG sepsis Isoniazid 300mg, rifampin 600mg, ethambutol 
1200mg cycloserine 500mg twice daily orally; 
confider prednisolone 40 mg immediately 
 
In an analysis of side effects that led to the decision to definitely stop treatment, a distinction 
has been made between the first year of therapy and the 2nd and 3rd years of treatment (in 
the 3 yr maintenance arms) to judge whether continuing with a three-year maintenance 
schedule leads to a higher percentage of patients with severe toxicity. 
The percent of patients experiencing side effects in the treatment groups was compared using 
the Pearson chi square statistic. P-values were not adjusted for multiple testing. 
 
RESULTS 
After the quality control exclusion of 450 patients from 6 institutions, 1355 patients were 
centrally randomized by 51 institutions from 13 European countries from March 1997 to April 
2005. Seventy-five patients (5.5%) were ineligible. Delay between TUR and randomization 
(>21 days) and type of tumor were the most common reasons of ineligibility. 
341 patients were randomized to 1/3 dose BCG for 1 year, 339 to full dose BCG for 1 year, 337 
to 1/3 dose for 3 years and 338 to full dose BCG for 3 years (Figure 1).  
Patient characteristics were generally well balanced between the arms. Patient and disease 
characteristics along with the efficacy results already have been published [16]. 
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Randomization and study interventions 
Within 14 days after TUR, patients were randomized to one of four treatment groups: 
1. 1/3 dose BCG with 1 yr maintenance (1/3D-1yr): BCG was given once a week for 6 wk, 
followed by 3 weekly instillations at months 3, 6, and 12. (A total of 4 cycles and 15 
instillations.) 
2. Full dose BCG with 1 yr maintenance (FD-1yr). 
3. 1/3 dose BCG with 3 yr maintenance (1/3D-3yrs): BCG was given once a week for 6 wk, 
followed by 3 weekly instillations at months 3, 6, 12, 18, 24, 30 and 36. (A total of 8 
cycles and 27 instillations.) 
4. Full dose BCG with 3 yr maintenance (FD-3yrs). 
 
For this study OncoTICE® (Organon-Teknika), containing 5 x 108 CFU, was used. 1/3 dose was 
prepared either by dissolving 1 vial with 150ml of saline and taking 50 ml or by dissolving with 
50 ml, taking 17 ml, and diluting this to 50 ml. 
Patients stopped protocol treatment at the second Ta/T1 recurrence after randomization and 
at progression to muscle-invasive disease, appearance of CIS, carcinoma in the upper urinary 
tract or prostatic urethra, or distant metastases. Further treatment was at the discretion of 
the local investigator. 
 
Endpoints 
The primary endpoint, the duration of the disease free interval (DFI), has been previously 
reported [16]. Secondary endpoints included the occurrence of side effects and their 
relationship to reduced dose or shorter duration of maintenance. The time of appearance of 
the side effects will also be addressed.  
 
Side effects 
At each instillation, patient complaints and symptoms were recorded as were urine cultures. 
Information about the presence or absence of local and systemic side effects and their impact 
on further treatment instillations was collected and reported during each cycle of protocol 
treatment according to a pre-defined format used in previous EORTC studies.  
 
Local side effects included bacterial or chemical cystitis, frequency, hematuria, and other.  
Bacterial cystitis was defined as the occurrence of culture proven (not BCG related) cystitis. 
Irritative bladder symptoms with negative urine culture were classified as BCG induced 
(chemical) cystitis. Other local side effects included granulomatous prostatitis, epididymitis, 
ureteral obstruction and contracted bladder.  
Systemic side effects included fever (>39°C), influenza like symptoms including general 
malaise and chills, BCG induced lung infection, liver toxicity and BCG sepsis. Skin rash, 
arthralgia and arthritis were classified as possible allergic reactions. 
 
 
The protocol provided recommendations for the treatment of BCG related complications 
(table 1). Based on the severity of the adverse effects, the treating physician decided whether 
instillations were to be postponed or even definitively stopped. In addition to an overall 
assessment of side effects, the treatment period was divided into 3 time intervals to evaluate 
when the side effects appeared: 
1. The induction period (first 6 weekly instillations) 
2. The first year of therapy after induction (next 9 instillations) 
3. The second and third years of therapy (next 12 instillations, only in the 3 yr 
maintenance arms) 
 
Table 1. Treatment recommendations for BCG-related complications as provided in the 
study-protocol 
Complication Recommended treatment 
Fever < 38,5 °C, BCG cystitis, mild malaise No treatment, hold BCG until symptoms resolve 
Fever > 38,5 °C for 12-24 h Isoniazid 300mg daily for 3 mo, may resume BCG 
when asymptomatic 
Allergic reactions (arthralgia, myalgia, rash) Isoniazid 300mg, further BCG is indicated only if 
benefit exceeds risk 
Acute severe illness, local or systemic pneumonitis, 
hepatitis, prostatitis, ureteral obstruction, renal 
abscess, persisting high fever > 39 °C 
Isoniazid 300mg, rifampin 600mg, ethambutol at 
1200 mg daily for 6 months, no further BCG 
BCG sepsis Isoniazid 300mg, rifampin 600mg, ethambutol 
1200mg cycloserine 500mg twice daily orally; 
confider prednisolone 40 mg immediately 
 
In an analysis of side effects that led to the decision to definitely stop treatment, a distinction 
has been made between the first year of therapy and the 2nd and 3rd years of treatment (in 
the 3 yr maintenance arms) to judge whether continuing with a three-year maintenance 
schedule leads to a higher percentage of patients with severe toxicity. 
The percent of patients experiencing side effects in the treatment groups was compared using 
the Pearson chi square statistic. P-values were not adjusted for multiple testing. 
 
RESULTS 
After the quality control exclusion of 450 patients from 6 institutions, 1355 patients were 
centrally randomized by 51 institutions from 13 European countries from March 1997 to April 
2005. Seventy-five patients (5.5%) were ineligible. Delay between TUR and randomization 
(>21 days) and type of tumor were the most common reasons of ineligibility. 
341 patients were randomized to 1/3 dose BCG for 1 year, 339 to full dose BCG for 1 year, 337 
to 1/3 dose for 3 years and 338 to full dose BCG for 3 years (Figure 1).  
Patient characteristics were generally well balanced between the arms. Patient and disease 
characteristics along with the efficacy results already have been published [16]. 
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The amount of treatment actually received is listed in Table 2. 39 patients (2.9%) did not 
receive any treatment, 11 of whom were ineligible. 420 (61.8%) patients randomized to 
receive BCG maintenance for 1 year completed the treatment versus 246 (36.4%) patients 
randomized to receive BCG for 3 years. Globally, 650 of 1316 patients (49.4%) started but did 
not complete their treatment, the main reason being treatment inefficacy in 338 (25.7%) 
patients. Side effects as reason for stopping treatment occurred in 103 (7.8%) patients while 
in 221 (16.8%) patients, other reasons for stopping were reported (Figure 2). 
 
 
Figure 1. CONSORT Diagram
 
 
  
 
Table 2. Amount of treatment received 
 BCG treatment arm 
1/3 dose - 1yr 
(n=341) 
Full dose - 1yr 
(n=339) 
1/3 dose - 3yrs 
(n=337) 
Full dose - 3yrs 
(n=338) 
n (%) n (%) n (%) n (%) 
No treatment 7 (2.1) 10 (2.9) 14 (4.2) 8 (2.4) 
Started treatment 334 (97.9) 329 (97.1) 323 (95.9) 330 (97.6) 
Amount of treatment     
6 weeks  48 (14.1) 36 (10.6) 33 (9.8) 37 (10.9) 
3 months  35 (10.3) 37 (10.9) 33 (9.8) 37 (10.9) 
6 months  44 (12.9) 43 (12.7) 46 (13.6) 37 (10.9) 
12 months 198 (58.1) 210 (61.9) 29 (8.6) 37 (10.9) 
18 months  8 (2.3) 2 (0.6) 16 (4.7) 18 (5.3) 
24 months  0 0 18 (5.3) 23 (6.8) 
30 months 1 (0.3) 1 (0.3) 24 (7.1) 19 (5.6) 
36 months 0 0 115 (34.1) 119 (35.2) 
> 36 months 0 0 9 (2.7) 3 (0.9) 
Completed Treatment 207 (60.7%) 213 (62.8%) 124 (36.8) 122 (36.1) 
 
 
Figure 2. Reasons for stopping treatment 
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The amount of treatment actually received is listed in Table 2. 39 patients (2.9%) did not 
receive any treatment, 11 of whom were ineligible. 420 (61.8%) patients randomized to 
receive BCG maintenance for 1 year completed the treatment versus 246 (36.4%) patients 
randomized to receive BCG for 3 years. Globally, 650 of 1316 patients (49.4%) started but did 
not complete their treatment, the main reason being treatment inefficacy in 338 (25.7%) 
patients. Side effects as reason for stopping treatment occurred in 103 (7.8%) patients while 
in 221 (16.8%) patients, other reasons for stopping were reported (Figure 2). 
 
 
Figure 1. CONSORT Diagram
 
 
  
 
Table 2. Amount of treatment received 
 BCG treatment arm 
1/3 dose - 1yr 
(n=341) 
Full dose - 1yr 
(n=339) 
1/3 dose - 3yrs 
(n=337) 
Full dose - 3yrs 
(n=338) 
n (%) n (%) n (%) n (%) 
No treatment 7 (2.1) 10 (2.9) 14 (4.2) 8 (2.4) 
Started treatment 334 (97.9) 329 (97.1) 323 (95.9) 330 (97.6) 
Amount of treatment     
6 weeks  48 (14.1) 36 (10.6) 33 (9.8) 37 (10.9) 
3 months  35 (10.3) 37 (10.9) 33 (9.8) 37 (10.9) 
6 months  44 (12.9) 43 (12.7) 46 (13.6) 37 (10.9) 
12 months 198 (58.1) 210 (61.9) 29 (8.6) 37 (10.9) 
18 months  8 (2.3) 2 (0.6) 16 (4.7) 18 (5.3) 
24 months  0 0 18 (5.3) 23 (6.8) 
30 months 1 (0.3) 1 (0.3) 24 (7.1) 19 (5.6) 
36 months 0 0 115 (34.1) 119 (35.2) 
> 36 months 0 0 9 (2.7) 3 (0.9) 
Completed Treatment 207 (60.7%) 213 (62.8%) 124 (36.8) 122 (36.1) 
 
 
Figure 2. Reasons for stopping treatment 
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Table 3. Local and systemic side effects in all treatment arms (at any time).  
 1 yr  n (%) 3 yr  n (%) Total n (%) 
 1/3 dose Full dose 1/3 dose Full dose  
No of patients 334 329 323 330 1316 
Bacterial cystitis  71 (21,3) 69 (20,9) 89 (27,5) 77 (23,3) 306 (23,3 
Chemical cystitis  94 (28,2) 109 (33,1) 25 (39) 128 (38,7) 457 (34,7) 
Other side effects 76 (22,8) 70 (21,2) 80 (24,5) 82 (24,8) 308 (23,4) 
Frequency (>Once per 
hour) 
63 (18.9) 76 (23.1) 87 (26.9) 84 (25.5) 310 (23.6) 
Macroscopic Hematuria 73 (21.9) 78 (23.7) 77 (23.8) 70 (21.2) 298 (22.6) 
Local side effects 195 (58.4) 205 (62.3) 217 (67.2) 209 (63.3) 826 (62.8) 
Fever 17 (5.1) 29 (8.8) 27 (8.4) 33 (10.0) 106 (8.1) 
Lung infection 2 (0.6) 1 (0.3) 0 (0.0) 2 (0.6) 5 (0.4) 
Sepsis 1 (0.3) 1 (0.3) 0 (0.0) 2 (0.6) 4 (0.3) 
Skin rash 7 (2.1) 7 (2.1) 9 (2.8) 9 (2.7) 32 (2.4) 
General malaise 42 (12.6) 51 (15.5) 49 (15.2) 62 (18.8) 204 (15.5) 
Other systemic side 
effects 
48 (14.4) 52 (15.8) 62 (19.2) 61 (18.5) 223 (16.9) 
Systemic side effects 92 (27.5) 100 (30.4) 100 (31.0) 111 (33.6) 403 (30.6) 
Local or systemic side 
effects 
221 (66.2) 228 (69.3) 227 (70.3) 238 (72.1) 914 (69.5) 
Treatment Comparisons:  
 Local Side Effects: 4 treatment groups: p = 0.14; 1/3D versus FD (adjusted for duration of 
maintenance): p = 0.98; 1 yr versus 3 yr (adjusted for BCG dose): p = 0.07 
 Systemic side effects: 4 treatment groups: p = 0.40; 1/3D versus FD (adjusted for duration of 
maintenance): p = 0.28; 1 yr versus 3 yr (adjusted for BCG dose): p = 0.19 
 Local or systemic side effects: 4 treatment groups: p = 0.41; 1/3D versus FD (adjusted for duration of 
maintenance): p = 0.33; 1 yr versus 3 yr (adjusted for BCG dose): p = 0.17 
 
In the 1316 patients who started BCG, 826 (62.8%) reported local SE, 403 (30.6%) systemic SE 
and 914 (69.5%) local or systemic SE. In Table 3, the various local and systemic side effects are 
listed by treatment. The percent of patients with local SE, systemic SE and local or systemic SE 
was similar in the 4 treatment groups (p = 0.14, 0.40 and 0.41, respectively). Likewise, no 
significant differences in the occurrence of side effects between the 1/3D and FD or 1 year 
and 3 years of maintenance groups were seen. 
The most frequent side effects were local: chemical cystitis in 460 (35.0%) patients, bacterial 
cystitis in 307 patients (23.3%), frequency of more than once/hour in 310 patients (23.6%) and 
macroscopic hematuria in 298 patients (22.6%). Twenty-seven patients (2.1%) complained of 
urinary incontinence. The most frequent systemic SE were general malaise in 204 patients 
(15.5%) and fever in 106 patients (8.1%). Sepsis was observed in 4 patients (0.3%). When 
divided according to the time period of treatment (first 6 instillations, the first year of 
treatment after induction, and after 1 year of treatment (in treatment arms with 3 years of 
maintenance)), the distributions of side effects in the treatment groups were similar (Table 4).  
 
Table 4. Local and systemic side effects in all treatment arms according to time of 
occurrence. 
  
During induction 
 
n (%) 
During the first year of 
maintenance 
(after induction) 
n (%) 
During years 2 
and 3 of 
maintenance 
n (%) 
 1 yr 3 yr 1 yr 3 yr 3 yr 
 1/3 D FD 1/3 D FD 1/3 D FD 1/3 D FD 1/3 D FD 
No of patients 334 329 323 330 286 293 290 293 182 182 
Bacterial cystitis 49 
(14.7) 
55 
(16.7) 
48 
(14.9) 
42 
(12.7) 
33 
(11.5) 
31 
(10.6) 
43 
(14.8) 
43 
(14.7) 
23 
(12.6) 
20 
(11.0) 
Chemical cystitis 60 
(18.0) 
55 
(16.7) 
52 
(16.1) 
54 
(16.4) 
63 
(22.0) 
79 
(27.0) 
84 
(29.0) 
92 
(31.4) 
52 
(28.6) 
56 
(30.8) 
Other local side 
effects 
34 
(10.2) 
38 
(11.6) 
40 
(12.4) 
31 
(9.4) 
53 
(18.5) 
50 
(17.1) 
43 
(14.8) 
43 
(14.7) 
30 
(16.5) 
31 
(17.0) 
Frequency  
(> once per hour) 
25 
(7.5) 
38 
(11.6) 
27 
(8.4) 
20 
(6.1) 
45 
(15.7) 
54 
(18.4) 
44 
(15.2) 
56 
(19.1) 
40 
(22.0) 
35 
(19.2) 
Macroscopic 
hematuria 
32 
(9.6) 
39 
(11.9) 
34 
(10.5) 
29 
(8.8) 
48 
(16.8) 
46 
(15.7) 
46 
(15.9) 
39 
(13.3) 
21 
(11.5) 
18 
(9.9) 
Local side effects 133 
(39.8) 
145 
(44.1) 
133 
(41.2) 
121 
(36.7) 
135 
(47.2) 
147 
(50.2) 
144 
(49.7) 
150 
(51.2) 
93 
(51.1) 
84 
(46.2) 
Fever 12 
(3.6) 
15 
(4.6) 
17 
(5.3) 
13 
(3.9) 
5 
(1.7) 
17 
(5.8) 
9 
(3.1) 
18 
(6.1) 
3 
(1.6) 
6 
(3.3) 
Lung infection 1 
(0.3) 
1 
(0.3) 
0 
(0.0) 
1 
(0.3) 
1 
(0.3) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(0.5) 
Sepsis 0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(0.3) 
1 
(0.3) 
1 
(0.3) 
0 ( 
0.0) 
1 
(0.3) 
0 
(0.0) 
0 
(0.0) 
Skin rash 4 
(1.2) 
4 
(1.2) 
2 
(0.6) 
5 
(1.5) 
3 
(1.0) 
4 
(1.4) 
5 
(1.7) 
4 
(1.4) 
4 
(2.2) 
1 
(0.5) 
General malaise 28 
(8.4) 
26 
(7.9) 
28 
(8.7) 
25 
(7.6) 
23 
(8.0) 
34 
(11.6) 
21 
(7.2) 
32 
(10.9) 
12 
(6.6) 
19 
(10.4) 
Other systemic 
side effects 
24 
(7.2) 
35 
(10.6) 
22 
(6.8) 
28 
(8.5) 
31 
(10.8) 
27 
(9.2) 
36 
(12.4) 
34 
(11.6) 
21 
(11.5) 
20 
(11.0) 
Systemic side 
effects 
57 
(17.1) 
63 
(19.1) 
52 
(16.1) 
53 
(16.1) 
51 
(17.8) 
62 
(21.2) 
60 
(20.7) 
66 
(22.5) 
33 
(18.1) 
33 
(18.1) 
Local or systemic 
side effects 
160 
(47.9) 
172 
(52.3) 
149 
(46.1) 
143 
(43.3) 
153 
(53.5) 
165 
(56.3) 
160 
(55.2) 
175 
(59.7) 
100 
(54.9) 
93 
(51.1) 
 
In 207 (15.7%) patients, instillations were delayed or temporarily stopped due to side effects. 
Most treatment discontinuations due to side effects occurred within the first year: 103 
patients (7.8%) stopped for toxicity, with 82 patients (6.2%) stopping during the first year. 
Among the 653 patients randomized to 3 yrs of BCG, 35 (5.4%) stopped during the first year 
of treatment due to side effects and 21 (3.2%) stopped during the second or third year (Tables 
5 and 6).  
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Table 3. Local and systemic side effects in all treatment arms (at any time).  
 1 yr  n (%) 3 yr  n (%) Total n (%) 
 1/3 dose Full dose 1/3 dose Full dose  
No of patients 334 329 323 330 1316 
Bacterial cystitis  71 (21,3) 69 (20,9) 89 (27,5) 77 (23,3) 306 (23,3 
Chemical cystitis  94 (28,2) 109 (33,1) 25 (39) 128 (38,7) 457 (34,7) 
Other side effects 76 (22,8) 70 (21,2) 80 (24,5) 82 (24,8) 308 (23,4) 
Frequency (>Once per 
hour) 
63 (18.9) 76 (23.1) 87 (26.9) 84 (25.5) 310 (23.6) 
Macroscopic Hematuria 73 (21.9) 78 (23.7) 77 (23.8) 70 (21.2) 298 (22.6) 
Local side effects 195 (58.4) 205 (62.3) 217 (67.2) 209 (63.3) 826 (62.8) 
Fever 17 (5.1) 29 (8.8) 27 (8.4) 33 (10.0) 106 (8.1) 
Lung infection 2 (0.6) 1 (0.3) 0 (0.0) 2 (0.6) 5 (0.4) 
Sepsis 1 (0.3) 1 (0.3) 0 (0.0) 2 (0.6) 4 (0.3) 
Skin rash 7 (2.1) 7 (2.1) 9 (2.8) 9 (2.7) 32 (2.4) 
General malaise 42 (12.6) 51 (15.5) 49 (15.2) 62 (18.8) 204 (15.5) 
Other systemic side 
effects 
48 (14.4) 52 (15.8) 62 (19.2) 61 (18.5) 223 (16.9) 
Systemic side effects 92 (27.5) 100 (30.4) 100 (31.0) 111 (33.6) 403 (30.6) 
Local or systemic side 
effects 
221 (66.2) 228 (69.3) 227 (70.3) 238 (72.1) 914 (69.5) 
Treatment Comparisons:  
 Local Side Effects: 4 treatment groups: p = 0.14; 1/3D versus FD (adjusted for duration of 
maintenance): p = 0.98; 1 yr versus 3 yr (adjusted for BCG dose): p = 0.07 
 Systemic side effects: 4 treatment groups: p = 0.40; 1/3D versus FD (adjusted for duration of 
maintenance): p = 0.28; 1 yr versus 3 yr (adjusted for BCG dose): p = 0.19 
 Local or systemic side effects: 4 treatment groups: p = 0.41; 1/3D versus FD (adjusted for duration of 
maintenance): p = 0.33; 1 yr versus 3 yr (adjusted for BCG dose): p = 0.17 
 
In the 1316 patients who started BCG, 826 (62.8%) reported local SE, 403 (30.6%) systemic SE 
and 914 (69.5%) local or systemic SE. In Table 3, the various local and systemic side effects are 
listed by treatment. The percent of patients with local SE, systemic SE and local or systemic SE 
was similar in the 4 treatment groups (p = 0.14, 0.40 and 0.41, respectively). Likewise, no 
significant differences in the occurrence of side effects between the 1/3D and FD or 1 year 
and 3 years of maintenance groups were seen. 
The most frequent side effects were local: chemical cystitis in 460 (35.0%) patients, bacterial 
cystitis in 307 patients (23.3%), frequency of more than once/hour in 310 patients (23.6%) and 
macroscopic hematuria in 298 patients (22.6%). Twenty-seven patients (2.1%) complained of 
urinary incontinence. The most frequent systemic SE were general malaise in 204 patients 
(15.5%) and fever in 106 patients (8.1%). Sepsis was observed in 4 patients (0.3%). When 
divided according to the time period of treatment (first 6 instillations, the first year of 
treatment after induction, and after 1 year of treatment (in treatment arms with 3 years of 
maintenance)), the distributions of side effects in the treatment groups were similar (Table 4).  
 
Table 4. Local and systemic side effects in all treatment arms according to time of 
occurrence. 
  
During induction 
 
n (%) 
During the first year of 
maintenance 
(after induction) 
n (%) 
During years 2 
and 3 of 
maintenance 
n (%) 
 1 yr 3 yr 1 yr 3 yr 3 yr 
 1/3 D FD 1/3 D FD 1/3 D FD 1/3 D FD 1/3 D FD 
No of patients 334 329 323 330 286 293 290 293 182 182 
Bacterial cystitis 49 
(14.7) 
55 
(16.7) 
48 
(14.9) 
42 
(12.7) 
33 
(11.5) 
31 
(10.6) 
43 
(14.8) 
43 
(14.7) 
23 
(12.6) 
20 
(11.0) 
Chemical cystitis 60 
(18.0) 
55 
(16.7) 
52 
(16.1) 
54 
(16.4) 
63 
(22.0) 
79 
(27.0) 
84 
(29.0) 
92 
(31.4) 
52 
(28.6) 
56 
(30.8) 
Other local side 
effects 
34 
(10.2) 
38 
(11.6) 
40 
(12.4) 
31 
(9.4) 
53 
(18.5) 
50 
(17.1) 
43 
(14.8) 
43 
(14.7) 
30 
(16.5) 
31 
(17.0) 
Frequency  
(> once per hour) 
25 
(7.5) 
38 
(11.6) 
27 
(8.4) 
20 
(6.1) 
45 
(15.7) 
54 
(18.4) 
44 
(15.2) 
56 
(19.1) 
40 
(22.0) 
35 
(19.2) 
Macroscopic 
hematuria 
32 
(9.6) 
39 
(11.9) 
34 
(10.5) 
29 
(8.8) 
48 
(16.8) 
46 
(15.7) 
46 
(15.9) 
39 
(13.3) 
21 
(11.5) 
18 
(9.9) 
Local side effects 133 
(39.8) 
145 
(44.1) 
133 
(41.2) 
121 
(36.7) 
135 
(47.2) 
147 
(50.2) 
144 
(49.7) 
150 
(51.2) 
93 
(51.1) 
84 
(46.2) 
Fever 12 
(3.6) 
15 
(4.6) 
17 
(5.3) 
13 
(3.9) 
5 
(1.7) 
17 
(5.8) 
9 
(3.1) 
18 
(6.1) 
3 
(1.6) 
6 
(3.3) 
Lung infection 1 
(0.3) 
1 
(0.3) 
0 
(0.0) 
1 
(0.3) 
1 
(0.3) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(0.5) 
Sepsis 0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
1 
(0.3) 
1 
(0.3) 
1 
(0.3) 
0 ( 
0.0) 
1 
(0.3) 
0 
(0.0) 
0 
(0.0) 
Skin rash 4 
(1.2) 
4 
(1.2) 
2 
(0.6) 
5 
(1.5) 
3 
(1.0) 
4 
(1.4) 
5 
(1.7) 
4 
(1.4) 
4 
(2.2) 
1 
(0.5) 
General malaise 28 
(8.4) 
26 
(7.9) 
28 
(8.7) 
25 
(7.6) 
23 
(8.0) 
34 
(11.6) 
21 
(7.2) 
32 
(10.9) 
12 
(6.6) 
19 
(10.4) 
Other systemic 
side effects 
24 
(7.2) 
35 
(10.6) 
22 
(6.8) 
28 
(8.5) 
31 
(10.8) 
27 
(9.2) 
36 
(12.4) 
34 
(11.6) 
21 
(11.5) 
20 
(11.0) 
Systemic side 
effects 
57 
(17.1) 
63 
(19.1) 
52 
(16.1) 
53 
(16.1) 
51 
(17.8) 
62 
(21.2) 
60 
(20.7) 
66 
(22.5) 
33 
(18.1) 
33 
(18.1) 
Local or systemic 
side effects 
160 
(47.9) 
172 
(52.3) 
149 
(46.1) 
143 
(43.3) 
153 
(53.5) 
165 
(56.3) 
160 
(55.2) 
175 
(59.7) 
100 
(54.9) 
93 
(51.1) 
 
In 207 (15.7%) patients, instillations were delayed or temporarily stopped due to side effects. 
Most treatment discontinuations due to side effects occurred within the first year: 103 
patients (7.8%) stopped for toxicity, with 82 patients (6.2%) stopping during the first year. 
Among the 653 patients randomized to 3 yrs of BCG, 35 (5.4%) stopped during the first year 
of treatment due to side effects and 21 (3.2%) stopped during the second or third year (Tables 
5 and 6).  
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Table 5. Definitive stop of instillations due to side effects in patients who started treatment 
(per treatment group) 
 BCG treatment arm 
Systemic or local 
side effects   
1/3 D - 1yr 
(n=334) 
FD - 1yr 
(n=329) 
1/3 D - 3yrs 
(n=323) 
FD - 3yrs 
(n=330) 
Total 
(n=1316) 
 n (%) n (%) n (%) n (%) n (%) 
Within 1st year 24 (7.2) 23 (7.0) 17 (5.3) 18 (5.5) 82 (6.2) 
After the 1st year 0 (0.0) 0 (0.0) 9 (2.8) 12 (3.6) 21 (1.6) 
Total  24 (7.2) 23 (7.0) 26 (8.1) 30 (9.1) 103 (7.8) 
Comparison of the percent of patients stopping treatment due to side effects in the four treatment groups: p = 
0.74. 
 
Table 6. Definitive stop of instillations due to side effects in patients who started treatment 
(per treatment type) 
 BCG intervention 
Systemic or local 
side effects   
1/3 D 
(1yr + 3yrs) 
(n=657) 
FD 
(1yr + 3yrs) 
(n=659) 
1 yr 
(1/3D + FD) 
(n=663) 
3 yrs 
(1/3D + FD) 
(n=653) 
 n (%) n (%) n (%) n (%) 
Within the 1st year  41 (6.2) 41 (6.2) 47 (7.1) 35 (5.4) 
After the 1st year  9 (1.4) 12 (1.8) 0 (0.0) 21 (3.2) 
Total 50 (7,6) 53 (8,0) 47 (7,1) 56 (8,6) 
 
DISCUSSION 
Maintenance BCG has been advocated by many investigators as the therapy of choice for 
patients with Ta-T1 high grade urothelial carcinoma of the bladder and/or CIS. This is 
reflected in the various guidelines on NMIBC that include BCG as first line adjuvant therapy 
after TUR in high risk patients [1,2]. 
The most widely used maintenance schedule is based on the SWOG regimen starting with a 
6 weekly induction series followed by three weekly instillations at 3 and 6 months and then 
every 6 months for 3 years [5].  Based on several meta-analyses, the EAU guidelines 
recommend at least 1 year of BCG maintenance therapy [1]. 
However, the side effects of BCG are well known and because of this, many urologists are 
reluctant to administer BCG to their patients, particularly when the disease is not high risk. It 
is therefore important to decrease BCG toxicity while maintaining its efficacy. 
Many strategies have been advocated to reduce the side effects of BCG. In EORTC study 
30911 with 3 years of maintenance BCG in intermediate and high risk patients, the 
prophylactic administration of INH did not decrease BCG’s side effects. On the contrary, 
 
transient liver function disturbances were encountered more frequently when INH was 
administered so the use of prophylactic INH is not recommended. [9, 15]. 
Another possible way to decrease BCG toxicity is by the administration of antibiotics at the 
time of BCG instillation. Colombel et al showed that 2 doses of Ofloxacin given shortly after 
BCG reduced side effects, however its effect on long term efficacy is unknown [12].  
Recently, Johnson et al [17] showed that oxybutynin increased urinary frequency and 
burning on urination as compared to placebo and concluded that it should not be used in the 
routine prophylaxis against urinary symptoms during BCG therapy. 
The most studied option is to decrease the dose. The EORTC-GU Group showed in a phase II 
marker lesion study that ¼ dose of BCG was active. [18]. 
The Club Urológico Español de Tratamiento Oncológico (CUETO) compared 1/3 dose of BCG 
to standard dose in intermediate and high risk patients. Reduced dose of BCG was as 
effective as full dose in intermediate risk patients but in high risk patients full dose provided 
the best results [13]. In a second study, in high risk patients (T1G3 and/or CIS), CUETO 
showed that 1/3 dose BCG was as effective as full dose against recurrence and progression 
but had significantly less toxicity. However, the number of patients who stopped BCG for 
toxicity did not differ significantly between the 2 arms [14].  A third report from CUETO 
found that 1/6 dose was significantly less effective than 1/3 dose for the treatment of 
intermediate-risk NMIBC suggesting that 1/3 dose is the minimum effective dose of BCG in 
these patients [15]. In these 3 reports, the maximum duration of maintenance BCG was only 
5 months whereas in the current study the minimum treatment duration was one year. 
The purpose of EORTC study 30962 was to see if by reducing the dose of BCG to 1/3, the 
toxicity could be reduced while maintaining the same efficacy and to evaluate if 1 year 
maintenance was not inferior to 3 years with respect to efficacy.  
The results of our study have shown that there were no significant differences in toxicity 
according to dose or duration of BCG treatment. 50 (7.6%) patients receiving 1/3 dose 
stopped treatment for toxicity versus 53 (8.0%) patients who received full dose BCG. 47 
(7.1%) patients randomized to 1 yr maintenance stopped BCG for side effects versus 56 
(8.6%) patients randomized to 3 yr. The additional 2 years of maintenance are not associated 
with an appreciable increase in toxicity. 
These results on the discontinuation rate of BCG for toxicity are better than those observed 
in our previous study 30911 where 19.0% of patients had to stop BCG therapy for adverse 
events [19]. Likewise, for the most frequent side effects other than bacterial cystitis, the 
percent of patients reporting side effects tended to be lower in the current trial than in the 
previous study. The reason for this cannot be explained, but may be associated with a 
greater experience of urologists and nurses in administering BCG therapy nowadays. 
Our results confirm the observation from study 30911 that the majority of side effects 
occurred within the first year [19]. This suggests that systemic side effects depend mainly on 
the host and not on the number of instillations. 
The awareness of possible adverse events when administrating BCG together with the 
proper use of antituberculosis drugs can improve local or systemic side effects. In addition, a 
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Table 5. Definitive stop of instillations due to side effects in patients who started treatment 
(per treatment group) 
 BCG treatment arm 
Systemic or local 
side effects   
1/3 D - 1yr 
(n=334) 
FD - 1yr 
(n=329) 
1/3 D - 3yrs 
(n=323) 
FD - 3yrs 
(n=330) 
Total 
(n=1316) 
 n (%) n (%) n (%) n (%) n (%) 
Within 1st year 24 (7.2) 23 (7.0) 17 (5.3) 18 (5.5) 82 (6.2) 
After the 1st year 0 (0.0) 0 (0.0) 9 (2.8) 12 (3.6) 21 (1.6) 
Total  24 (7.2) 23 (7.0) 26 (8.1) 30 (9.1) 103 (7.8) 
Comparison of the percent of patients stopping treatment due to side effects in the four treatment groups: p = 
0.74. 
 
Table 6. Definitive stop of instillations due to side effects in patients who started treatment 
(per treatment type) 
 BCG intervention 
Systemic or local 
side effects   
1/3 D 
(1yr + 3yrs) 
(n=657) 
FD 
(1yr + 3yrs) 
(n=659) 
1 yr 
(1/3D + FD) 
(n=663) 
3 yrs 
(1/3D + FD) 
(n=653) 
 n (%) n (%) n (%) n (%) 
Within the 1st year  41 (6.2) 41 (6.2) 47 (7.1) 35 (5.4) 
After the 1st year  9 (1.4) 12 (1.8) 0 (0.0) 21 (3.2) 
Total 50 (7,6) 53 (8,0) 47 (7,1) 56 (8,6) 
 
DISCUSSION 
Maintenance BCG has been advocated by many investigators as the therapy of choice for 
patients with Ta-T1 high grade urothelial carcinoma of the bladder and/or CIS. This is 
reflected in the various guidelines on NMIBC that include BCG as first line adjuvant therapy 
after TUR in high risk patients [1,2]. 
The most widely used maintenance schedule is based on the SWOG regimen starting with a 
6 weekly induction series followed by three weekly instillations at 3 and 6 months and then 
every 6 months for 3 years [5].  Based on several meta-analyses, the EAU guidelines 
recommend at least 1 year of BCG maintenance therapy [1]. 
However, the side effects of BCG are well known and because of this, many urologists are 
reluctant to administer BCG to their patients, particularly when the disease is not high risk. It 
is therefore important to decrease BCG toxicity while maintaining its efficacy. 
Many strategies have been advocated to reduce the side effects of BCG. In EORTC study 
30911 with 3 years of maintenance BCG in intermediate and high risk patients, the 
prophylactic administration of INH did not decrease BCG’s side effects. On the contrary, 
 
transient liver function disturbances were encountered more frequently when INH was 
administered so the use of prophylactic INH is not recommended. [9, 15]. 
Another possible way to decrease BCG toxicity is by the administration of antibiotics at the 
time of BCG instillation. Colombel et al showed that 2 doses of Ofloxacin given shortly after 
BCG reduced side effects, however its effect on long term efficacy is unknown [12].  
Recently, Johnson et al [17] showed that oxybutynin increased urinary frequency and 
burning on urination as compared to placebo and concluded that it should not be used in the 
routine prophylaxis against urinary symptoms during BCG therapy. 
The most studied option is to decrease the dose. The EORTC-GU Group showed in a phase II 
marker lesion study that ¼ dose of BCG was active. [18]. 
The Club Urológico Español de Tratamiento Oncológico (CUETO) compared 1/3 dose of BCG 
to standard dose in intermediate and high risk patients. Reduced dose of BCG was as 
effective as full dose in intermediate risk patients but in high risk patients full dose provided 
the best results [13]. In a second study, in high risk patients (T1G3 and/or CIS), CUETO 
showed that 1/3 dose BCG was as effective as full dose against recurrence and progression 
but had significantly less toxicity. However, the number of patients who stopped BCG for 
toxicity did not differ significantly between the 2 arms [14].  A third report from CUETO 
found that 1/6 dose was significantly less effective than 1/3 dose for the treatment of 
intermediate-risk NMIBC suggesting that 1/3 dose is the minimum effective dose of BCG in 
these patients [15]. In these 3 reports, the maximum duration of maintenance BCG was only 
5 months whereas in the current study the minimum treatment duration was one year. 
The purpose of EORTC study 30962 was to see if by reducing the dose of BCG to 1/3, the 
toxicity could be reduced while maintaining the same efficacy and to evaluate if 1 year 
maintenance was not inferior to 3 years with respect to efficacy.  
The results of our study have shown that there were no significant differences in toxicity 
according to dose or duration of BCG treatment. 50 (7.6%) patients receiving 1/3 dose 
stopped treatment for toxicity versus 53 (8.0%) patients who received full dose BCG. 47 
(7.1%) patients randomized to 1 yr maintenance stopped BCG for side effects versus 56 
(8.6%) patients randomized to 3 yr. The additional 2 years of maintenance are not associated 
with an appreciable increase in toxicity. 
These results on the discontinuation rate of BCG for toxicity are better than those observed 
in our previous study 30911 where 19.0% of patients had to stop BCG therapy for adverse 
events [19]. Likewise, for the most frequent side effects other than bacterial cystitis, the 
percent of patients reporting side effects tended to be lower in the current trial than in the 
previous study. The reason for this cannot be explained, but may be associated with a 
greater experience of urologists and nurses in administering BCG therapy nowadays. 
Our results confirm the observation from study 30911 that the majority of side effects 
occurred within the first year [19]. This suggests that systemic side effects depend mainly on 
the host and not on the number of instillations. 
The awareness of possible adverse events when administrating BCG together with the 
proper use of antituberculosis drugs can improve local or systemic side effects. In addition, a 
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meticulous discussion with patients receiving BCG on its efficacy and possible adverse events 
has been proven to improve patient compliance [20]. 
Limitations of this study include the lack of a placebo control arm, which is not ethical in this 
patient group, and the absence of standardized criteria to define intravesical BCG toxicity as 
a reason for postponing or stopping treatment. Although side effects were reported 
according to a pre-defined format used in previous studies, the clinical implications of the 
same adverse event could differ among investigators from unacceptable to normal drug 
activity. In the absence of validated international guidelines for the definition and treatment 
of side effects, the description of local and systemic side effects by expert urologists involved 
using pre-defined case report forms across many prospective, randomized EORTC studies 
could be considered as a surrogate standard. 
 
CONCLUSIONS 
No significant differences in toxicity were detected according to dose (1/3 versus FD) or 
duration (1 versus 3 years) of BCG treatment in the 4 arms. Neither reducing the dose nor 
shortening the duration of maintenance decreased the percent of patients who stopped 
treatment due to side effects. Side effects requiring treatment stop were seen more 
frequently in the first year of therapy, preventing some patients from receiving the one to 
three years of treatment recommended in current guidelines. 
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prospective trial comparing a standard 81 mg dose of intravesical bacillus Calmette-
Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671-
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[14]  Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of 
bacillus Calmette-Guerin the same efficacy against recurrence and progression of T1G3 
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meticulous discussion with patients receiving BCG on its efficacy and possible adverse events 
has been proven to improve patient compliance [20]. 
Limitations of this study include the lack of a placebo control arm, which is not ethical in this 
patient group, and the absence of standardized criteria to define intravesical BCG toxicity as 
a reason for postponing or stopping treatment. Although side effects were reported 
according to a pre-defined format used in previous studies, the clinical implications of the 
same adverse event could differ among investigators from unacceptable to normal drug 
activity. In the absence of validated international guidelines for the definition and treatment 
of side effects, the description of local and systemic side effects by expert urologists involved 
using pre-defined case report forms across many prospective, randomized EORTC studies 
could be considered as a surrogate standard. 
 
CONCLUSIONS 
No significant differences in toxicity were detected according to dose (1/3 versus FD) or 
duration (1 versus 3 years) of BCG treatment in the 4 arms. Neither reducing the dose nor 
shortening the duration of maintenance decreased the percent of patients who stopped 
treatment due to side effects. Side effects requiring treatment stop were seen more 
frequently in the first year of therapy, preventing some patients from receiving the one to 
three years of treatment recommended in current guidelines. 
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ABSTRACT 
Objectives: To determine the relationship of age to side effects leading to discontinuation  
of treatment in stage Ta-T1 NMIBC patients treated with maintenance bacillus-Calmette-
Guérin (BCG). 
Patients and Methods: We evaluated toxicity for 487 eligible intermediate or high risk Ta-
T1 (without CIS) non-muscle-invasive bladder cancer (NMIBC) patients randomized to 
receive 3 years of maintenance BCG (247 BCG alone and 240 BCG+INH) in EORTC trial 
30911. The percent of patients who stopped for toxicity and the number of treatment 
cycles that they received were compared in 4 age groups, < 60, 61 - 70, 71 – 75 and > 75 
years of age, using the Mantel-Haenszel chi square test for trend. 
Results: The percent of patients stopping BCG for toxicity was 17.9% in patients < 60, 21.9% 
in patients 61 – 70, 22.9% in patients 71 – 75, and 16.4% in patients > 75 years of age (p = 
0.90). For both systemic and local side effects, there was likewise no significant difference.  
Conclusions: In intermediate and high risk Ta T1 urothelial bladder cancer patients treated 
with BCG, no differences in toxicity as a reason for stopping treatment were observed 
based on age. 
  
 
INTRODUCTION 
In the 2015 European Association of Urology (EAU) guidelines, adjuvant treatment of 
intermediate- and high-risk urothelial non muscle invasive bladder carcinoma (NMIBC) 
patients with bacillus Calmette-Guérin (BCG) is standard of care. The recommended schedule 
consists of an induction course of six weekly instillations followed by a maintenance schedule 
of one year in intermediate-risk patients, in whom intravesical chemotherapy is also an option, 
and one to three years of BCG in high-risk patients [1]. 
Although there isn’t a significant effect of age on time to recurrence in patients receiving BCG, 
patients > 70 years of age do have a significantly shorter time to progression, overall survival 
and disease specific survival compared to patients < 70 years of age. Nevertheless, BCG is still 
more effective than epirubicin even in elderly patients [2].  
Side effects of BCG as a reason for stopping treatment occurred in 19% of the patients in 
EORTC study 30911 [3]. A relationship between side effects and efficacy was not seen [4].  
On the basis of a small retrospective cohort of 58 patients aged 51 to 92 years, Heiner et al. 
suggested that side effects were more common in the elderly [5]. They concluded that one 
should be careful with BCG maintenance treatment in patients over 70 years of age and even 
suggested to avoid it in patients over the age of 80. Other reports on this subject are lacking. 
The median age of bladder cancer patients is 69 years for men and 71 years for women [6]. It 
is expected that with the rising of age of the population, the prevalence of bladder cancer will 
rise too.  
In order to balance the advice to elderly patients for adjuvant BCG treatment, it thus becomes 
increasingly important to be aware of the possible relationship between age and the chances 
of stopping BCG maintenance due to side effects. 
The objective of this paper is to determine if there is a correlation between age and stopping 
treatment due to side effects in NMIBC patients treated with BCG. 
 
MATERIAL AND METHODS 
EORTC GU Group study 30911 is one of the largest prospective randomized studies assessing 
the efficacy and side effects of 3 years of maintenance BCG treatment [3]. Patients with single 
or multiple, primary or recurrent, completely resectable stages Ta and T1, grades 1 to 3, 
histologically proven urothelial NMIBC were included. Exclusion criteria were a primary 
solitary tumor, muscle invasive tumor or carcinoma in situ, age older than 85 years, WHO 
performance status 3 or 4, and previous treatment with doxorubicin, epirubicin or BCG 
intravesical treatment during the previous 3 months. Tumors were classified according to the 
1992 TNM classification of the International Union against Cancer [7].  
Within 24 hours after transurethral resection (TUR), before receiving the definitive histology 
report, patients were randomized to one of three adjuvant treatment arms: epirubicin 50 mg 
in 50 ml of saline weekly for six consecutive weeks starting within 24 hours after transurethral 
resection or BCG (TICE®) weekly +/- isoniazid (INH) for six consecutive weeks starting seven to 
15 days after transurethral resection. In all groups, the initial six instillations were followed by 
three weekly instillations at months 3, 6, 12, 18, 24, 30 and 36. Cytology and cystoscopy were 
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ABSTRACT 
Objectives: To determine the relationship of age to side effects leading to discontinuation  
of treatment in stage Ta-T1 NMIBC patients treated with maintenance bacillus-Calmette-
Guérin (BCG). 
Patients and Methods: We evaluated toxicity for 487 eligible intermediate or high risk Ta-
T1 (without CIS) non-muscle-invasive bladder cancer (NMIBC) patients randomized to 
receive 3 years of maintenance BCG (247 BCG alone and 240 BCG+INH) in EORTC trial 
30911. The percent of patients who stopped for toxicity and the number of treatment 
cycles that they received were compared in 4 age groups, < 60, 61 - 70, 71 – 75 and > 75 
years of age, using the Mantel-Haenszel chi square test for trend. 
Results: The percent of patients stopping BCG for toxicity was 17.9% in patients < 60, 21.9% 
in patients 61 – 70, 22.9% in patients 71 – 75, and 16.4% in patients > 75 years of age (p = 
0.90). For both systemic and local side effects, there was likewise no significant difference.  
Conclusions: In intermediate and high risk Ta T1 urothelial bladder cancer patients treated 
with BCG, no differences in toxicity as a reason for stopping treatment were observed 
based on age. 
  
 
INTRODUCTION 
In the 2015 European Association of Urology (EAU) guidelines, adjuvant treatment of 
intermediate- and high-risk urothelial non muscle invasive bladder carcinoma (NMIBC) 
patients with bacillus Calmette-Guérin (BCG) is standard of care. The recommended schedule 
consists of an induction course of six weekly instillations followed by a maintenance schedule 
of one year in intermediate-risk patients, in whom intravesical chemotherapy is also an option, 
and one to three years of BCG in high-risk patients [1]. 
Although there isn’t a significant effect of age on time to recurrence in patients receiving BCG, 
patients > 70 years of age do have a significantly shorter time to progression, overall survival 
and disease specific survival compared to patients < 70 years of age. Nevertheless, BCG is still 
more effective than epirubicin even in elderly patients [2].  
Side effects of BCG as a reason for stopping treatment occurred in 19% of the patients in 
EORTC study 30911 [3]. A relationship between side effects and efficacy was not seen [4].  
On the basis of a small retrospective cohort of 58 patients aged 51 to 92 years, Heiner et al. 
suggested that side effects were more common in the elderly [5]. They concluded that one 
should be careful with BCG maintenance treatment in patients over 70 years of age and even 
suggested to avoid it in patients over the age of 80. Other reports on this subject are lacking. 
The median age of bladder cancer patients is 69 years for men and 71 years for women [6]. It 
is expected that with the rising of age of the population, the prevalence of bladder cancer will 
rise too.  
In order to balance the advice to elderly patients for adjuvant BCG treatment, it thus becomes 
increasingly important to be aware of the possible relationship between age and the chances 
of stopping BCG maintenance due to side effects. 
The objective of this paper is to determine if there is a correlation between age and stopping 
treatment due to side effects in NMIBC patients treated with BCG. 
 
MATERIAL AND METHODS 
EORTC GU Group study 30911 is one of the largest prospective randomized studies assessing 
the efficacy and side effects of 3 years of maintenance BCG treatment [3]. Patients with single 
or multiple, primary or recurrent, completely resectable stages Ta and T1, grades 1 to 3, 
histologically proven urothelial NMIBC were included. Exclusion criteria were a primary 
solitary tumor, muscle invasive tumor or carcinoma in situ, age older than 85 years, WHO 
performance status 3 or 4, and previous treatment with doxorubicin, epirubicin or BCG 
intravesical treatment during the previous 3 months. Tumors were classified according to the 
1992 TNM classification of the International Union against Cancer [7].  
Within 24 hours after transurethral resection (TUR), before receiving the definitive histology 
report, patients were randomized to one of three adjuvant treatment arms: epirubicin 50 mg 
in 50 ml of saline weekly for six consecutive weeks starting within 24 hours after transurethral 
resection or BCG (TICE®) weekly +/- isoniazid (INH) for six consecutive weeks starting seven to 
15 days after transurethral resection. In all groups, the initial six instillations were followed by 
three weekly instillations at months 3, 6, 12, 18, 24, 30 and 36. Cytology and cystoscopy were 
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performed every three months during the first three years and every six months thereafter. 
In case of a suspected recurrence, pathological confirmation by a TUR was mandatory. The 
primary endpoint was the time to first bladder recurrence with secondary endpoints time to 
progression (muscle invasion or distant metastases), overall duration of survival, and time to 
death due to bladder cancer. Efficacy results and the effect of age and toxicity on efficacy have 
been previously published [2,3,4]. 
At each instillation, patient complaints and symptoms were recorded as were urine cultures. 
Information about the presence or absence of local and systemic side effects and their impact 
on further treatment instillations were collected and reported during each cycle of protocol 
treatment according to a pre-defined format used in previous EORTC studies.  
 
Local side effects included bacterial or chemical cystitis, frequency, hematuria, and other.  
Bacterial cystitis was defined as the occurrence of culture proven (not BCG related) cystitis. 
Irritative bladder symptoms with negative urine culture were classified as BCG induced 
(chemical) cystitis. Other local side effects included granulomatous prostatitis, epididymitis, 
ureteral obstruction and contracted bladder.  
 
Systemic side effects included fever (>39°C), influenza-like symptoms including general 
malaise and chills, BCG induced lung infection, liver toxicity and BCG sepsis. Skin rash, 
arthralgia and arthritis were classified as possible allergic reactions. 
The protocol described treatment recommendations for moderate to severe local and 
systemic BCG-related complications (Table 1). Herein, reasons for stopping or delaying 
treatment are embedded. In the study case report forms, no information was collected about 
treatments given for side effects. The protocol didn’t give recommendations for the use of 
dose reduction or prophylactic distribution of antibiotics in order to prevent side effects. 
 
Table 1. Treatment recommendations for BCG-related complications as in study protocol. 
Complication Recommended treatment 
Fever < 38,5 °C, BCG cystitis, mild malaise No treatment, hold BCG until symptoms resolve 
Fever > 38,5 °C for 12-24 h Isoniazid 300mg daily for 3 mo, may resume BCG 
when asymptomatic 
Allergic reactions (arthralgia, myalgia, rash) Isoniazid 300mg, further BCG is indicated only if 
benefit exceeds risk 
Acute severe illness, local or systemic pneumonitis, 
hepatitis, prostatitis, ureteral obstruction, renal 
abscess, persisting high fever > 39 °C 
Isoniazid 300mg, rifampin 600mg, ethambutol at 
1200 mg daily for 6 months, no further BCG 
BCG sepsis Isoniazid 300mg, rifampin 600mg, ethambutol 
1200mg cycloserine 500mg twice daily orally; 
confider prednisolone 40 mg immediately 
 
 
In earlier reports on BCG and the influence of age, the older group was defined as > 70 years 
of age [2,5,8]. As patients older than 70 years are increasingly seen in daily practice, we 
created 4 age groups, < 60, 61 - 70, 71 - 75 and > 75 years, in order to study the effects of age 
taking into account all age groups. 
To determine the effect of age in relation to stopping treatment due to toxicity, the percent 
of patients stopping BCG for this reason, both overall and also separately due to local or 
systemic side effects, was compared in these 4 age groups using the Mantel-Haenszel chi 
square test for trend on 1 degree of freedom. The number of cycles of treatment in patients 
who stopped treatment for toxicity was compared in the four age groups using the Mantel-
Haenszel chi square test for trend on rank scores with 1 degree of freedom.  
Since we are especially interested in the two groups < 70 years and > 70 years based on 
previous publications, we also compared the percent of patients stopping treatment for 
toxicity in these two groups using a continuity adjusted chi square test on 1 degree of freedom. 
The number of cycles of treatment in patients who stopped treatment for toxicity was 
compared in these two age groups using the Mantel-Haenszel chi square test on rank scores 
with 1 degree of freedom. 
 
RESULTS 
Between January 1992 and February 1997, 957 patients with intermediate or high risk stage 
Ta T1 urothelial bladder cancer were randomized by 44 institutions to receive adjuvant 
intravesical instillations after TUR: 318 to epirubicin and 639 to BCG (320 to BCG alone and 
319 to BCG plus INH). 512 of the 639 patients were eligible with information on age, of whom 
25 patients without information on BCG toxicity were excluded, ranging from four patients 
(2.9%) in the < 60 years old group to five patients (7.6%) in the > 75 years old group.  487 
patients started treatment and had follow up information on BCG toxicity (247 BCG alone and 
240 BCG+INH) and were included in this analysis. Table 2 provides the distribution of patient 
characteristics by age group: 134 patients (27.5%) were < 60 years of age, 187 (38.4%) were 
61 – 70, 105 (21.6%) were 71 – 75 and 61 (12.5%) were > 75 years. Only 17 patients (3.5%) 
were > 80 years of age and were thus included in this last subgroup of patients > 75 years. 
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performed every three months during the first three years and every six months thereafter. 
In case of a suspected recurrence, pathological confirmation by a TUR was mandatory. The 
primary endpoint was the time to first bladder recurrence with secondary endpoints time to 
progression (muscle invasion or distant metastases), overall duration of survival, and time to 
death due to bladder cancer. Efficacy results and the effect of age and toxicity on efficacy have 
been previously published [2,3,4]. 
At each instillation, patient complaints and symptoms were recorded as were urine cultures. 
Information about the presence or absence of local and systemic side effects and their impact 
on further treatment instillations were collected and reported during each cycle of protocol 
treatment according to a pre-defined format used in previous EORTC studies.  
 
Local side effects included bacterial or chemical cystitis, frequency, hematuria, and other.  
Bacterial cystitis was defined as the occurrence of culture proven (not BCG related) cystitis. 
Irritative bladder symptoms with negative urine culture were classified as BCG induced 
(chemical) cystitis. Other local side effects included granulomatous prostatitis, epididymitis, 
ureteral obstruction and contracted bladder.  
 
Systemic side effects included fever (>39°C), influenza-like symptoms including general 
malaise and chills, BCG induced lung infection, liver toxicity and BCG sepsis. Skin rash, 
arthralgia and arthritis were classified as possible allergic reactions. 
The protocol described treatment recommendations for moderate to severe local and 
systemic BCG-related complications (Table 1). Herein, reasons for stopping or delaying 
treatment are embedded. In the study case report forms, no information was collected about 
treatments given for side effects. The protocol didn’t give recommendations for the use of 
dose reduction or prophylactic distribution of antibiotics in order to prevent side effects. 
 
Table 1. Treatment recommendations for BCG-related complications as in study protocol. 
Complication Recommended treatment 
Fever < 38,5 °C, BCG cystitis, mild malaise No treatment, hold BCG until symptoms resolve 
Fever > 38,5 °C for 12-24 h Isoniazid 300mg daily for 3 mo, may resume BCG 
when asymptomatic 
Allergic reactions (arthralgia, myalgia, rash) Isoniazid 300mg, further BCG is indicated only if 
benefit exceeds risk 
Acute severe illness, local or systemic pneumonitis, 
hepatitis, prostatitis, ureteral obstruction, renal 
abscess, persisting high fever > 39 °C 
Isoniazid 300mg, rifampin 600mg, ethambutol at 
1200 mg daily for 6 months, no further BCG 
BCG sepsis Isoniazid 300mg, rifampin 600mg, ethambutol 
1200mg cycloserine 500mg twice daily orally; 
confider prednisolone 40 mg immediately 
 
 
In earlier reports on BCG and the influence of age, the older group was defined as > 70 years 
of age [2,5,8]. As patients older than 70 years are increasingly seen in daily practice, we 
created 4 age groups, < 60, 61 - 70, 71 - 75 and > 75 years, in order to study the effects of age 
taking into account all age groups. 
To determine the effect of age in relation to stopping treatment due to toxicity, the percent 
of patients stopping BCG for this reason, both overall and also separately due to local or 
systemic side effects, was compared in these 4 age groups using the Mantel-Haenszel chi 
square test for trend on 1 degree of freedom. The number of cycles of treatment in patients 
who stopped treatment for toxicity was compared in the four age groups using the Mantel-
Haenszel chi square test for trend on rank scores with 1 degree of freedom.  
Since we are especially interested in the two groups < 70 years and > 70 years based on 
previous publications, we also compared the percent of patients stopping treatment for 
toxicity in these two groups using a continuity adjusted chi square test on 1 degree of freedom. 
The number of cycles of treatment in patients who stopped treatment for toxicity was 
compared in these two age groups using the Mantel-Haenszel chi square test on rank scores 
with 1 degree of freedom. 
 
RESULTS 
Between January 1992 and February 1997, 957 patients with intermediate or high risk stage 
Ta T1 urothelial bladder cancer were randomized by 44 institutions to receive adjuvant 
intravesical instillations after TUR: 318 to epirubicin and 639 to BCG (320 to BCG alone and 
319 to BCG plus INH). 512 of the 639 patients were eligible with information on age, of whom 
25 patients without information on BCG toxicity were excluded, ranging from four patients 
(2.9%) in the < 60 years old group to five patients (7.6%) in the > 75 years old group.  487 
patients started treatment and had follow up information on BCG toxicity (247 BCG alone and 
240 BCG+INH) and were included in this analysis. Table 2 provides the distribution of patient 
characteristics by age group: 134 patients (27.5%) were < 60 years of age, 187 (38.4%) were 
61 – 70, 105 (21.6%) were 71 – 75 and 61 (12.5%) were > 75 years. Only 17 patients (3.5%) 
were > 80 years of age and were thus included in this last subgroup of patients > 75 years. 
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Table 2. Patient Characteristics 
 < 60 years 
n (%) 
61 - 70 years 
n (%) 
71 – 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Sex 
  Male 
  Female 
 
111 (82.8) 
23 (17.2) 
 
147 (78.6) 
40 (21.4) 
 
78 (74.3) 
27 (25.7) 
 
43 (70.5) 
18 (29.5) 
 
379 (77.8) 
108 (22.2) 
Tumor Status 
  Primary 
  Recurrent 
 
56 (41.8) 
78 (58.2) 
 
86 (46.0) 
101 (54.0) 
 
38 (36.2) 
67 (63.8) 
 
27 (44.3) 
34 (55.7) 
 
207 (42.5) 
280 (57.5) 
Tumor Size 
   < 1 cm 
  1 – 3 cm 
  > 3 cm 
  Unknown 
 
67 (50.0) 
42 (31.3) 
19 (14.2) 
6 (4.5) 
 
88 (47.1) 
80 (42.8) 
13 (6.9) 
6 (3.2) 
 
59 (56.2) 
35 (33.3) 
7 (6.7) 
4 (3.8) 
 
28 (45.9) 
26 (42.6) 
6 (9.8) 
1 (1.6) 
 
242 (49.7) 
183 (37.6) 
45 (9.2) 
17 (3.5) 
Number of 
Tumors 
  Single 
  Multiple 
  Unknown 
 
 
27 (20.1) 
105 (78.4) 
2 (1.5) 
 
 
36 (19.3) 
150 (80.2) 
1 (0.5) 
 
 
16 (15.2) 
87 (82.9) 
2 (1.9) 
 
 
4 (6.6) 
56 (91.8) 
1 (1.6) 
 
 
83 (17.0) 
398 (81.7) 
6 (1.2) 
T Category 
  Ta 
  T1 
 
92 (68.7) 
42 (31.3) 
 
113 (60.4) 
74 (39.6) 
 
68 (64.8) 
37 (35.2) 
 
28 (45.9) 
33 (54.1) 
 
301 (61.8) 
186 (38.2) 
1973 WHO 
Grade 
  G1 
  G2 
  G3 
  Unknown 
 
 
70 (52.2) 
50 (37.3) 
13 (9.7) 
1 (0.7) 
 
 
60 (32.1) 
101 (54.0) 
26 (13.9) 
0 
 
 
38 (36.2) 
50 (47.6) 
16 (15.2) 
1 (1.0) 
 
 
15 (24.6) 
38 (62.3) 
8 (13.1) 
0 
 
 
183 (37.6) 
239 (49.1) 
63 (12.9) 
2 (0.4) 
Total 134 187 105 61 487 
 
 
A total of 159 patients (32.6%) completed the maintenance schedule, 99 (20.3%) stopped 
treatment due to BCG toxicity and 80 (16.4%) stopped due to inefficacy. 149 patients (30.6%) 
stopped treatment due to other reasons (Table 3). 
 
The percent of patients stopping BCG for toxicity was similar in the four age groups: 24 
patients (17.9%) < 60 years of age, 41 patients (21.9%) 61 - 70 years, 24 patients (22.9%) 71 - 
75 years, and 10 (16.4%) patients > 75 years, chi square = 0.016, p = 0.90 (Table 3). There was 
likewise no difference in the percent of patients < 70 years (20.2%) and > 70 years (20.5%) 
who stopped for toxicity, chi square = 0.00, p = 1.0.  
 
  
 
Table 3. Reason for stopping treatment 
 < 60 years 
n (%) 
61 – 70 years 
n (%) 
71 – 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Not stopped due 
to toxicity 
110 (82.1) 146 (78.1) 81 (77.1) 51 (83.6) 388 (79.7) 
Stopped due to 
toxicity 
24 (17.9) 41 (21.9) 24 (22.9) 10 (16.4) 99 (20.3) 
Local only 14 (10.4) 24 (12.8) 10 (9.5) 5 (8.0) 53 (10.9) 
Systemic only 5 (3.7) 9 (4.8) 10 (9.5) 2 (3.3) 26 (5.3) 
Local and 
systemic 
5 (3.7) 8 (4.3) 3 (2.9) 3 (4.9) 19 (3.9) 
Type 
unknown 
0 0 1 (0.1) 0 1 
Stopped due to 
inefficacy or 
other reasons  
61 (45.5) 84 (44.9) 48 (45.7) 36 (59.0) 229 (47.0) 
Completed 
treatment 
49 (36.6) 62 (33.2) 33 (31.4) 15 (24.6) 159 (32.6) 
Total 134 187 105 61 487 
 
45 patients stopped treatment due to systemic toxicity, 10 (7.5%) aged < 60 years, 17 (9.1%) 
aged 61 -70 years, 13 (12.4%) aged 71 - 75 years, and 5 (8.2%) > 75 years, chi square = 0.497, 
p = 0.48 (Table 4). Comparing patients < 70 years and patients > 70 years, there was likewise 
no difference with chi square = 0.509, p = 0.48. 
Table 4.  Treatment stopped due to systemic BCG toxicity 
Reason to stop for 
systemic side effects 
< 60 years 
n (%) 
61 - 70 years 
n (%) 
71 - 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Not stopped 124 (92.5) 170 (90.9) 92 (87.6) 56 (91.8) 442 (90.8) 
Fever 4 (3.0) 8 (4.3) 9 (8.6) 2 (3.3) 23 (4.7) 
Lung infection 0 1 (0.5) 0 0 1 (0.2) 
Skin rash 1 (0.7) 0 0 0 1 (0.2) 
General malaise 3 (2.2) 6 (3.2) 3 (2.9) 3 (4.9) 15 (3.1) 
Other systemic side 
effects 
2 (1.5) 2 (1.1) 1 (1.0) 0 5 (1.0) 
Total 134 187 105 61 487 
 
72 patients stopped treatment due to local toxicity, 19 (14.8%) aged < 60 years, 32 (17.1%) 
aged 61 - 70 years, 13 (12.4%) aged 71 – 75 years, and 8 (13.1%) aged > 75 years, chi square = 
0.239, p = 0.62 (Table 5). Comparing patients < 70 years and patients > 70 years, there was 
once again no difference with chi square = 0.671, p = 0.41. 
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Table 2. Patient Characteristics 
 < 60 years 
n (%) 
61 - 70 years 
n (%) 
71 – 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Sex 
  Male 
  Female 
 
111 (82.8) 
23 (17.2) 
 
147 (78.6) 
40 (21.4) 
 
78 (74.3) 
27 (25.7) 
 
43 (70.5) 
18 (29.5) 
 
379 (77.8) 
108 (22.2) 
Tumor Status 
  Primary 
  Recurrent 
 
56 (41.8) 
78 (58.2) 
 
86 (46.0) 
101 (54.0) 
 
38 (36.2) 
67 (63.8) 
 
27 (44.3) 
34 (55.7) 
 
207 (42.5) 
280 (57.5) 
Tumor Size 
   < 1 cm 
  1 – 3 cm 
  > 3 cm 
  Unknown 
 
67 (50.0) 
42 (31.3) 
19 (14.2) 
6 (4.5) 
 
88 (47.1) 
80 (42.8) 
13 (6.9) 
6 (3.2) 
 
59 (56.2) 
35 (33.3) 
7 (6.7) 
4 (3.8) 
 
28 (45.9) 
26 (42.6) 
6 (9.8) 
1 (1.6) 
 
242 (49.7) 
183 (37.6) 
45 (9.2) 
17 (3.5) 
Number of 
Tumors 
  Single 
  Multiple 
  Unknown 
 
 
27 (20.1) 
105 (78.4) 
2 (1.5) 
 
 
36 (19.3) 
150 (80.2) 
1 (0.5) 
 
 
16 (15.2) 
87 (82.9) 
2 (1.9) 
 
 
4 (6.6) 
56 (91.8) 
1 (1.6) 
 
 
83 (17.0) 
398 (81.7) 
6 (1.2) 
T Category 
  Ta 
  T1 
 
92 (68.7) 
42 (31.3) 
 
113 (60.4) 
74 (39.6) 
 
68 (64.8) 
37 (35.2) 
 
28 (45.9) 
33 (54.1) 
 
301 (61.8) 
186 (38.2) 
1973 WHO 
Grade 
  G1 
  G2 
  G3 
  Unknown 
 
 
70 (52.2) 
50 (37.3) 
13 (9.7) 
1 (0.7) 
 
 
60 (32.1) 
101 (54.0) 
26 (13.9) 
0 
 
 
38 (36.2) 
50 (47.6) 
16 (15.2) 
1 (1.0) 
 
 
15 (24.6) 
38 (62.3) 
8 (13.1) 
0 
 
 
183 (37.6) 
239 (49.1) 
63 (12.9) 
2 (0.4) 
Total 134 187 105 61 487 
 
 
A total of 159 patients (32.6%) completed the maintenance schedule, 99 (20.3%) stopped 
treatment due to BCG toxicity and 80 (16.4%) stopped due to inefficacy. 149 patients (30.6%) 
stopped treatment due to other reasons (Table 3). 
 
The percent of patients stopping BCG for toxicity was similar in the four age groups: 24 
patients (17.9%) < 60 years of age, 41 patients (21.9%) 61 - 70 years, 24 patients (22.9%) 71 - 
75 years, and 10 (16.4%) patients > 75 years, chi square = 0.016, p = 0.90 (Table 3). There was 
likewise no difference in the percent of patients < 70 years (20.2%) and > 70 years (20.5%) 
who stopped for toxicity, chi square = 0.00, p = 1.0.  
 
  
 
Table 3. Reason for stopping treatment 
 < 60 years 
n (%) 
61 – 70 years 
n (%) 
71 – 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Not stopped due 
to toxicity 
110 (82.1) 146 (78.1) 81 (77.1) 51 (83.6) 388 (79.7) 
Stopped due to 
toxicity 
24 (17.9) 41 (21.9) 24 (22.9) 10 (16.4) 99 (20.3) 
Local only 14 (10.4) 24 (12.8) 10 (9.5) 5 (8.0) 53 (10.9) 
Systemic only 5 (3.7) 9 (4.8) 10 (9.5) 2 (3.3) 26 (5.3) 
Local and 
systemic 
5 (3.7) 8 (4.3) 3 (2.9) 3 (4.9) 19 (3.9) 
Type 
unknown 
0 0 1 (0.1) 0 1 
Stopped due to 
inefficacy or 
other reasons  
61 (45.5) 84 (44.9) 48 (45.7) 36 (59.0) 229 (47.0) 
Completed 
treatment 
49 (36.6) 62 (33.2) 33 (31.4) 15 (24.6) 159 (32.6) 
Total 134 187 105 61 487 
 
45 patients stopped treatment due to systemic toxicity, 10 (7.5%) aged < 60 years, 17 (9.1%) 
aged 61 -70 years, 13 (12.4%) aged 71 - 75 years, and 5 (8.2%) > 75 years, chi square = 0.497, 
p = 0.48 (Table 4). Comparing patients < 70 years and patients > 70 years, there was likewise 
no difference with chi square = 0.509, p = 0.48. 
Table 4.  Treatment stopped due to systemic BCG toxicity 
Reason to stop for 
systemic side effects 
< 60 years 
n (%) 
61 - 70 years 
n (%) 
71 - 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Not stopped 124 (92.5) 170 (90.9) 92 (87.6) 56 (91.8) 442 (90.8) 
Fever 4 (3.0) 8 (4.3) 9 (8.6) 2 (3.3) 23 (4.7) 
Lung infection 0 1 (0.5) 0 0 1 (0.2) 
Skin rash 1 (0.7) 0 0 0 1 (0.2) 
General malaise 3 (2.2) 6 (3.2) 3 (2.9) 3 (4.9) 15 (3.1) 
Other systemic side 
effects 
2 (1.5) 2 (1.1) 1 (1.0) 0 5 (1.0) 
Total 134 187 105 61 487 
 
72 patients stopped treatment due to local toxicity, 19 (14.8%) aged < 60 years, 32 (17.1%) 
aged 61 - 70 years, 13 (12.4%) aged 71 – 75 years, and 8 (13.1%) aged > 75 years, chi square = 
0.239, p = 0.62 (Table 5). Comparing patients < 70 years and patients > 70 years, there was 
once again no difference with chi square = 0.671, p = 0.41. 
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Table 5.  Treatment stopped due to local BCG toxicity 
Reason to stop 
for local side 
effects 
< 60 years 
n (%) 
61 - 70 years 
n (%) 
71 - 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Not stopped 115 (85.2) 155 (82.9) 92 (87.6) 53 (86.9) 415 (85.2) 
Bacterial cystitis 2 (1.5) 3 (1.6) 1 (1.0) 1 (1.6) 7 (1.4) 
Chemical cystitis 8 (6.0) 19 (10.2) 6 (5.7) 5 (8.2) 38 (7.8) 
Other local side 
effects 
2 (1.5) 3 (1.6) 1 (1.0) 0 6 (1.2) 
Type of local 
toxicity 
unknown 
7 (5.2) 7 (3.7) 5 (4.7) 2 (3.3) 21 (4.3) 
Total 134 187 105 61 487 
 
The duration of treatment in patients who stopped for toxicity is given in Table 6. Although 
there is a suggestion that older patients may have stopped treatment earlier, nether the 
difference between the four age groups (chi square = 3.196 and p = 0.07) nor the difference 
between the two age groups (< 70 versus > 70 years) is statistically significant (chi square = 
3.240 and p = 0.07).  
 
Table 6. Duration of treatment in patients stopping for toxicity 
Treatment Duration < 60 years 
n (%) 
61 - 70 years 
n (%) 
71 - 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Induction only 5 (20.8) 11 (26.8) 9 (37.5) 5 (50.0) 30 (30.3) 
3 – 12 months 11 (45.8) 17 (41.5) 11 (45.8) 3 (30.0) 42 (42.4) 
18 – 24 months 5 (20.8) 6 (14.6) 0 1 (10.0) 12 (12.1) 
> 24 months 3 (12.5) 7 (17.1) 4 (16.7) 1 (10.0) 15 (15.2) 
Total 24 41 24 10 99 
 
The percent of patients who stopped treatment for toxicity was higher in the BCG + INH group 
(58 of 240 patients, 24.2%) as compared to the BCG alone group (41 out of 247 patients, 
16.6%), however the overall conclusions with respect to age did not change when the two 
treatment groups were analyzed separately.
 
DISCUSSION 
This is the largest study on BCG maintenance therapy that focuses on the relationship of age 
and toxicity as a reason for discontinuation of this treatment. Elderly patients have a worse 
outcome on BCG as far as efficacy is concerned [2], but we have now found that the risk of 
stopping treatment for toxicity in elderly patients is similar to that in younger patients. In an 
earlier report on data from the same study, no relationship between toxicity and efficacy, 
regardless of age, was found [4]. 
BCG induces a local immunological reaction inside the bladder wall. This results in secretion 
of various cytokines in urine. The level of cytokines is related to the efficacy of BCG [9-10]. By 
analyzing together the changes in some of these cytokines due to treatment with BCG, a 
nomogram predicting the efficacy of BCG was constructed using of 9 out of 12 selected 
cytokines [11]. Although data for this are lacking, part of the side effects may be related to the 
power of the immune response of the patient. In elderly patients, immunosenescence (the 
decreased capacity for generating an adequate immune response due to age [12,13]) may 
lead to a less pronounced cytokine induction and subsequent a less severe local side effects 
profile.  
Nonetheless, when only local side effects were concerned, no difference related to age was 
observed.  
There are several limitations of this study. Although the data for this analysis were 
prospectively collected and 487 patients were included in the main analyses, the comparison 
of the duration of treatment by age in the patients who stopped due to toxicity has limited 
power since 99 patients stopped due to toxicity and only 34 were > 70 years of age.   Although 
this study is one of the largest in BCG treated patients, the data have been collected in a time 
period when guidelines didn’t yet recommend a reTUR in high risk NMIBC, video cystoscopy 
was not routinely used and additional techniques like photodynamic or narrow band imaging 
cystoscopy were not yet available. Without these surgical improvements, a higher recurrence 
rate could be expected in this study compared to today’s practice. As recurrence as a reason 
for stopping treatment is a competing risk for toxicity as a reason for stopping treatment, this 
could have lowered the risk for stopping due to toxicity. However, we have previously shown 
that age is not a prognostic factor for time to recurrence in this study, so a possible lower risk 
for stopping due to toxicity because of recurrence is not age dependent [2]. Another limitation 
is the eligibility upper age limit of 85 years in this study. This may have limited the number of 
patients in the older age group.  Only 3.5% of the patients were more than 80 years of age.  
This study was done using the TICE® BCG strain. As other strains of BCG may show differences 
in efficacy, there could also be differences in toxicity if another strain had been used. As 
previously reported, the addition of INH to BCG did not reduce either the systemic or local 
side effects. In 11 patients in the BCG + INH group, INH (but not BCG) was stopped due to 
transient liver toxicity [14]. The distribution of patient age was similar in the BCG and BCG + 
INH treatment groups. Although more patients stopped treatment for toxicity in the BCG + 
INH group, 24.2% versus 16.6%, the overall conclusions for age did not change when the two 
treatment groups were analyzed separately. No information about the use of anti-coagulants 
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Table 5.  Treatment stopped due to local BCG toxicity 
Reason to stop 
for local side 
effects 
< 60 years 
n (%) 
61 - 70 years 
n (%) 
71 - 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Not stopped 115 (85.2) 155 (82.9) 92 (87.6) 53 (86.9) 415 (85.2) 
Bacterial cystitis 2 (1.5) 3 (1.6) 1 (1.0) 1 (1.6) 7 (1.4) 
Chemical cystitis 8 (6.0) 19 (10.2) 6 (5.7) 5 (8.2) 38 (7.8) 
Other local side 
effects 
2 (1.5) 3 (1.6) 1 (1.0) 0 6 (1.2) 
Type of local 
toxicity 
unknown 
7 (5.2) 7 (3.7) 5 (4.7) 2 (3.3) 21 (4.3) 
Total 134 187 105 61 487 
 
The duration of treatment in patients who stopped for toxicity is given in Table 6. Although 
there is a suggestion that older patients may have stopped treatment earlier, nether the 
difference between the four age groups (chi square = 3.196 and p = 0.07) nor the difference 
between the two age groups (< 70 versus > 70 years) is statistically significant (chi square = 
3.240 and p = 0.07).  
 
Table 6. Duration of treatment in patients stopping for toxicity 
Treatment Duration < 60 years 
n (%) 
61 - 70 years 
n (%) 
71 - 75 years 
n (%) 
>75 years 
n (%) 
Total 
n (%) 
Induction only 5 (20.8) 11 (26.8) 9 (37.5) 5 (50.0) 30 (30.3) 
3 – 12 months 11 (45.8) 17 (41.5) 11 (45.8) 3 (30.0) 42 (42.4) 
18 – 24 months 5 (20.8) 6 (14.6) 0 1 (10.0) 12 (12.1) 
> 24 months 3 (12.5) 7 (17.1) 4 (16.7) 1 (10.0) 15 (15.2) 
Total 24 41 24 10 99 
 
The percent of patients who stopped treatment for toxicity was higher in the BCG + INH group 
(58 of 240 patients, 24.2%) as compared to the BCG alone group (41 out of 247 patients, 
16.6%), however the overall conclusions with respect to age did not change when the two 
treatment groups were analyzed separately.
 
DISCUSSION 
This is the largest study on BCG maintenance therapy that focuses on the relationship of age 
and toxicity as a reason for discontinuation of this treatment. Elderly patients have a worse 
outcome on BCG as far as efficacy is concerned [2], but we have now found that the risk of 
stopping treatment for toxicity in elderly patients is similar to that in younger patients. In an 
earlier report on data from the same study, no relationship between toxicity and efficacy, 
regardless of age, was found [4]. 
BCG induces a local immunological reaction inside the bladder wall. This results in secretion 
of various cytokines in urine. The level of cytokines is related to the efficacy of BCG [9-10]. By 
analyzing together the changes in some of these cytokines due to treatment with BCG, a 
nomogram predicting the efficacy of BCG was constructed using of 9 out of 12 selected 
cytokines [11]. Although data for this are lacking, part of the side effects may be related to the 
power of the immune response of the patient. In elderly patients, immunosenescence (the 
decreased capacity for generating an adequate immune response due to age [12,13]) may 
lead to a less pronounced cytokine induction and subsequent a less severe local side effects 
profile.  
Nonetheless, when only local side effects were concerned, no difference related to age was 
observed.  
There are several limitations of this study. Although the data for this analysis were 
prospectively collected and 487 patients were included in the main analyses, the comparison 
of the duration of treatment by age in the patients who stopped due to toxicity has limited 
power since 99 patients stopped due to toxicity and only 34 were > 70 years of age.   Although 
this study is one of the largest in BCG treated patients, the data have been collected in a time 
period when guidelines didn’t yet recommend a reTUR in high risk NMIBC, video cystoscopy 
was not routinely used and additional techniques like photodynamic or narrow band imaging 
cystoscopy were not yet available. Without these surgical improvements, a higher recurrence 
rate could be expected in this study compared to today’s practice. As recurrence as a reason 
for stopping treatment is a competing risk for toxicity as a reason for stopping treatment, this 
could have lowered the risk for stopping due to toxicity. However, we have previously shown 
that age is not a prognostic factor for time to recurrence in this study, so a possible lower risk 
for stopping due to toxicity because of recurrence is not age dependent [2]. Another limitation 
is the eligibility upper age limit of 85 years in this study. This may have limited the number of 
patients in the older age group.  Only 3.5% of the patients were more than 80 years of age.  
This study was done using the TICE® BCG strain. As other strains of BCG may show differences 
in efficacy, there could also be differences in toxicity if another strain had been used. As 
previously reported, the addition of INH to BCG did not reduce either the systemic or local 
side effects. In 11 patients in the BCG + INH group, INH (but not BCG) was stopped due to 
transient liver toxicity [14]. The distribution of patient age was similar in the BCG and BCG + 
INH treatment groups. Although more patients stopped treatment for toxicity in the BCG + 
INH group, 24.2% versus 16.6%, the overall conclusions for age did not change when the two 
treatment groups were analyzed separately. No information about the use of anti-coagulants 
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is available, which may have been used more frequently in older patients and thus be 
protective for side effects as was suggested by Heiner [5]. 
 
CONCLUSION 
In the treatment debate for patients with intermediate or high-risk NMIBC, the efficacy of BCG 
must be balanced against its risk of toxicity. This study shows that toxicity in elderly patients 
is not a valid reason for omitting BCG treatment. 
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is available, which may have been used more frequently in older patients and thus be 
protective for side effects as was suggested by Heiner [5]. 
 
CONCLUSION 
In the treatment debate for patients with intermediate or high-risk NMIBC, the efficacy of BCG 
must be balanced against its risk of toxicity. This study shows that toxicity in elderly patients 
is not a valid reason for omitting BCG treatment. 
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SUMMARY (EN) 
In the adjuvant treatment of non-muscle invasive bladder cancer, instillations with bacille 
Calmette-Guérin reduce the chance of recurrence of bladder cancer. This effect is especially 
valid when a schedule is used of 27 instillations over a period of 3 years. This scheme is build 
up by six weekly instillations, followed by 3 weekly instillations with an interval of 3 and 
afterwards 6 months of time. The adverse effects of BCG are a mayor disadvantage. They often 
occur and can be a reason to interrupt or even discontinue treatment. 
Although it is possible to treat patients for these side effects if they remain after pausing 
treatment with tuberculostatic agents like isoniazid (INH), measures to prevent side effects 
are needed. By the the European Organization for Research and Treatment of Cancer Genito-
Urinary group (EORTC-GU), trial 30911 was conducted in order to determine whether the 
combination of INH and BCG would decrease side effects as compared to BCG alone. Both 
study arms using BCG were compared to a third arm with treatment of the chemotherapeutic 
drug epirubicin. The initial and long term results were published in 2001 and 2010 respectively 
by Van der Meijden and Sylvester and showed no beneficial effect of INH on adverse effects 
and a significant lower recurrence rate in both BCG arms compared to the epirubicin arm. 
Challenged by this result the EORTC-GU group designed Trial 30962, further focusing on 
reduction of adverse events. By reducing the delivered dose to 1/3, or by shortening the length 
of maintenance treatment from 3 years to 1 year, it was postulated that side effects could be 
reduced without compromising the efficacy. 
In this thesis the final results on trial 30962 are presented, together with analyses done with 
the data of BCG treatment in trial 30911. 
 
In chapter 1, the field of bladder cancer treatment is described. The difference between non-
muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer is explained. Also 
the place of transurethral resection as important first step is discussed. A description of the 
role of adjuvant treatment with maintenance BCG in NMIBC is given. 
 
In part 1, the focus is on efficacy of maintenance BCG treatment. 
 
Chapter 2 presents the important final efficacy results of trial 30962. It described the analyses 
done and the conclusions in terms of efficacy results of the regime of dose reduction and 
shortening of the maintenance period. The study was designed to show no difference in 
efficacy, assuming that such a difference wasn’t existing. However, due to a lower than 
expected event rate (there were less recurrences in the study population as expected 
beforehand), such a conclusion could not be drawn. Fortunately, we were able to draw some 
other important conclusions on the separate risk groups, showing that in intermediate risk 
patients treatment with normal dose BCG for a period of 1 year is sufficient. Furthermore, the 
reduced dose during 1 year was for both intermediate and high risk patients insufficient 
treatment. Finally, for high risk patients, full dose during 3 years was better compared to 
either 1 year or reduced dose. 
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reduced without compromising the efficacy. 
In this thesis the final results on trial 30962 are presented, together with analyses done with 
the data of BCG treatment in trial 30911. 
 
In chapter 1, the field of bladder cancer treatment is described. The difference between non-
muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer is explained. Also 
the place of transurethral resection as important first step is discussed. A description of the 
role of adjuvant treatment with maintenance BCG in NMIBC is given. 
 
In part 1, the focus is on efficacy of maintenance BCG treatment. 
 
Chapter 2 presents the important final efficacy results of trial 30962. It described the analyses 
done and the conclusions in terms of efficacy results of the regime of dose reduction and 
shortening of the maintenance period. The study was designed to show no difference in 
efficacy, assuming that such a difference wasn’t existing. However, due to a lower than 
expected event rate (there were less recurrences in the study population as expected 
beforehand), such a conclusion could not be drawn. Fortunately, we were able to draw some 
other important conclusions on the separate risk groups, showing that in intermediate risk 
patients treatment with normal dose BCG for a period of 1 year is sufficient. Furthermore, the 
reduced dose during 1 year was for both intermediate and high risk patients insufficient 
treatment. Finally, for high risk patients, full dose during 3 years was better compared to 
either 1 year or reduced dose. 
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Chapter 3 is focusing on efficacy results related to the age of patients. Because the life 
expectancy of the general population is increasing, the amount of older patients with NMIBC 
is increasing as well. The working mechanism of BCG is using the host’s immune response. As 
in older people the quality of their immune response is lower compared to younger people, it 
is expected that BCG is less effective in the elderly. With the data set of trial 30911, we showed 
that older age is indeed related with a higher recurrence rate. Because in the study also 
epirubicin was tested, we concluded that although people older than 70 years of age had a 
worse prognosis compared to younger ones, BCG still is superior to epirubicin; also in the 
elderly. 
 
In chapter 4 the results on efficacy of BCG maintenance treatment of both trials were used in 
order to investigate prognostic factors in NMIBC patients treated with BCG. We were able to 
do this analysis in a large data set containing 1812 patients. We identified by multivariable 
analyses the following prognostic factors for recurrence: prior recurrence rate and number of 
tumors. For progression and death: tumor stage and grade. Patients with T1G3 showed the 
highest 1 and 5 years progression rate: 11.4% and 19.8% respectively. Disease specific death 
rates for this group at 1 and 5 years were 4.8% and 11.3% respectively. With these data we 
were able to create a nomogram predicting overall survival when treated with maintenance 
BCG.  
 
In part 2, side effects of maintenance BCG are discussed. 
 
Chapter 5 gives the results of side effect analysis of trial 30962. We present the amount and 
severity of side effects. Trial 30962 tried to find a way of reducing side effects by decreasing 
treatment time or dose. In the groups with reduced dose, the same amount of side effects 
was reported compared with full dose. It was also shown that effects were most prominent 
within the first year of treatment without a significant contribution of prolonged maintenance 
to 3 years. 
 
In chapter 6 we investigated the effect of age on the occurrence of side effects. In the data 
set of trial 30911, side effects that resulted in stopping treatment definitively, were linked to 
patients age. In this analysis we weren’t able to show a relation between age and stopp ing 
treatment due to side effects. We concluded that older age is not a valid reason for omitting 
BCG to patients by the fear of more intense side effects. 
 
  
 
SAMENVATTING (NL) 
Bij de behandeling van niet-spierinvasieve blaaskanker (NMIBC) reduceren blaasspoelingen 
met bacille Calmette-Guérin (BCG) de kans op de terugkeer van blaaskanker. Dit effect is het 
grootst wanneer een schema wordt gehanteerd van 27 spoelingen gedurende 3 jaar. Dit 
onderhoudsschema bestaat uit een cyclus van 6 wekelijkse spoelingen, gevolgd door 3 
wekelijkse spoelingen die eerst om de 3 en later om de 6 maanden worden gegeven. Een groot 
nadeel van BCG is de kans op neveneffecten: deze is vrij groot en kan dan leiden tot het 
moeten onderbreken of stoppen van de behandeling. 
Het is weliswaar mogelijk om de neveneffecten te behandelen met tuberculostatica zoals 
isoniazide (INH) indien patiënten ondanks het staken van de behandelingen toch symptomen 
blijven houden, maar maatregelen die neveneffecten kunnen voorkomen zijn uiterst welkom. 
Trial 30911 van de European Organization for Research and Treatment of Cancer Genito-
Urinary group (EORTC-GU groep), was erop gericht om te onderzoeken of de het geven van 
INH tijdens de behandeling met BCG het aantal neveneffecten zou doen afnemen, in 
vergelijking met de behandeling met BCG alleen. De beide studie armen waarin BCG werd 
gebruikt, werden vergeleken met een derde arm waarin het chemotherapeuticum epirubicine 
werd gebruikt. De eerste en de lange termijn resultaten van deze studie werden 
respectievelijk in 2001 en 2010 gepubliceerd door Van der Meijden en Sylvester en lieten geen 
voordeel zien van het toevoegen van INH aan de behandeling met BCG in het optreden van 
neveneffecten en daarnaast een significant kleinere kans op ziekte terugkeer in de beide BCG 
studie-armen in vergelijking met epirubicine. 
Als gevolg van deze uitkomst ontwierp de EORTC-GU groep Trial 30962, die verder inzoomt op 
het terugdringen van neveneffecten. Nu door de gebruikte BCG dosis tot 1/3 te verlagen en/ 
of de behandelduur te verkorten van 3 tot 1 jaar. De aanname bij deze studie was dat deze 
aanpassingen het optreden van neveneffecten kon terugdringen zonder de effectiviteit van 
de behandeling nadelig te beïnvloeden. 
In dit proefschrift worden de resultaten van trial 30962 gepresenteerd en tevens aanvullende 
onderzoeken die uitgevoerd zijn met de gegevens van trial 30911. 
 
In hoofdstuk 1 wordt een overzicht gegeven van de behandeling van blaaskanker. Het verschil 
tussen niet-spierinvasieve blaaskanker en spierinvasieve blaaskanker is uitgelegd, samen met 
de rol van de trans-urethrale (blaas)tumor-resectie (TURT-operatie) als belangrijke eerste stap 
in de analyse en behandeling. Ook wordt de rol van aanvullende blaasspoelingen beschreven. 
 
In deel 1 wordt aandacht besteed aan de effectiviteit van een onderhoudsschema met BCG. 
 
Hoofdstuk 2 geeft de resultaten weer ten aanzien van de effectiviteit van de behandeling zoals 
deze in trial 30962 bleek. We beschrijven welke analyses hiervoor zijn uitgevoerd en wat de 
conclusies zijn ten aanzien van de effectiviteit van de behandeling indien de dosis wordt 
gereduceerd of het interval van een onderhoudsbehandeling met BCG wordt verkort. Het 
ontwerp van de studie was erop gericht dat aangetoond zou kunnen worden dat er geen 
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highest 1 and 5 years progression rate: 11.4% and 19.8% respectively. Disease specific death 
rates for this group at 1 and 5 years were 4.8% and 11.3% respectively. With these data we 
were able to create a nomogram predicting overall survival when treated with maintenance 
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Chapter 5 gives the results of side effect analysis of trial 30962. We present the amount and 
severity of side effects. Trial 30962 tried to find a way of reducing side effects by decreasing 
treatment time or dose. In the groups with reduced dose, the same amount of side effects 
was reported compared with full dose. It was also shown that effects were most prominent 
within the first year of treatment without a significant contribution of prolonged maintenance 
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In chapter 6 we investigated the effect of age on the occurrence of side effects. In the data 
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moeten onderbreken of stoppen van de behandeling. 
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blijven houden, maar maatregelen die neveneffecten kunnen voorkomen zijn uiterst welkom. 
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Urinary group (EORTC-GU groep), was erop gericht om te onderzoeken of de het geven van 
INH tijdens de behandeling met BCG het aantal neveneffecten zou doen afnemen, in 
vergelijking met de behandeling met BCG alleen. De beide studie armen waarin BCG werd 
gebruikt, werden vergeleken met een derde arm waarin het chemotherapeuticum epirubicine 
werd gebruikt. De eerste en de lange termijn resultaten van deze studie werden 
respectievelijk in 2001 en 2010 gepubliceerd door Van der Meijden en Sylvester en lieten geen 
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neveneffecten en daarnaast een significant kleinere kans op ziekte terugkeer in de beide BCG 
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Als gevolg van deze uitkomst ontwierp de EORTC-GU groep Trial 30962, die verder inzoomt op 
het terugdringen van neveneffecten. Nu door de gebruikte BCG dosis tot 1/3 te verlagen en/ 
of de behandelduur te verkorten van 3 tot 1 jaar. De aanname bij deze studie was dat deze 
aanpassingen het optreden van neveneffecten kon terugdringen zonder de effectiviteit van 
de behandeling nadelig te beïnvloeden. 
In dit proefschrift worden de resultaten van trial 30962 gepresenteerd en tevens aanvullende 
onderzoeken die uitgevoerd zijn met de gegevens van trial 30911. 
 
In hoofdstuk 1 wordt een overzicht gegeven van de behandeling van blaaskanker. Het verschil 
tussen niet-spierinvasieve blaaskanker en spierinvasieve blaaskanker is uitgelegd, samen met 
de rol van de trans-urethrale (blaas)tumor-resectie (TURT-operatie) als belangrijke eerste stap 
in de analyse en behandeling. Ook wordt de rol van aanvullende blaasspoelingen beschreven. 
 
In deel 1 wordt aandacht besteed aan de effectiviteit van een onderhoudsschema met BCG. 
 
Hoofdstuk 2 geeft de resultaten weer ten aanzien van de effectiviteit van de behandeling zoals 
deze in trial 30962 bleek. We beschrijven welke analyses hiervoor zijn uitgevoerd en wat de 
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verschil in effectiviteit tussen de behandelde groepen zou zijn. Gaandeweg de studie bleek 
echter dat het aantal patiënten dat recidieven van blaaskanker kreeg in de gehele studie lager 
uit viel dan van tevoren was ingeschat, wat ertoe leidde dat een harde conclusie over het al 
dan niet even goed zijn van de behandelingen in het algemeen toch niet getrokken mocht 
worden. Gelukkig bleken we met alle verzamelde gegevens wel in staat een aantal andere 
conclusies te trekken. Deze waren geldig voor de verschillende risicogroepen van patiënten 
ten aanzien van de kans op terugkeer van blaaskanker. We lieten zien dat voor de patiënten 
met een intermediair risico, de behandeling met een normale dosis BCG gedurende 1 jaar 
goed is en niet nog 2 jaar langer hoeft te duren. Ook bleek de gereduceerde dosis gedurende 
1 jaar voor alle risicogroepen onvoldoende te zijn. En ten slotte dat voor de hoog-
risicopatiënten de volledige dosis gedurende 3 jaar de beste behandeling is. 
 
Hoofdstuk 3 behandelt de resultaten van een studie naar de effectiviteit van BCG in oudere 
patiënten. De levensverwachting van de gehele bevolking wordt steeds hoger en daarmee 
stijgt ook het aantal oudere patiënten met NMIBC. Het effect van BCG verloopt via activatie 
van het afweersysteem. Omdat bij oudere patiënten het afweersysteem minder goed 
functioneert dan bij jongere mensen, ligt het in de lijn der verwachting dat het effect van BCG 
afneemt naarmate de patiënt ouder is. Met behulp van de gegevens uit trial 30911 toonden 
we inderdaad aan dat de kans op terugkeer van blaaskanker in oudere patiënten die 
behandeld worden met BCG groter is dan in jongere patiënten, waarbij overigens ook bleek 
dat in deze groep ouder dan 70 jaar BCG toch nog beter werkte dan epirubicine. 
 
In hoofdstuk 4 worden de resultaten van de effectiviteit van BCG zoals die uit beide studies 
naar voren kwamen gebruikt om na te gaan welke prognostische factoren er zijn bij patiënten 
met NMIBC die behandeld worden met BCG. Met gegevens van 1812 patiënten konden we 
door middel van multivariabele analyses diverse prognostische factoren vaststellen. Voor de 
kans op terugkeer van blaaskanker waren dat: het aantal eerdere keren dat blaaskanker was 
opgetreden en het aantal blaastumoren. Voor de kans dat de blaaskanker voortschrijdt of leidt 
tot overlijden waren dat: het tumor stadium en de tumorgraad. Patiënten met een T1G3 
tumor lieten de hoogste kans op voortschrijding zien na 1 en na 5 jaar van respectievelijk 
11,4% en 19,8%. De aan de ziekte gerelateerde kans om te overlijden na 1 en 5 jaar waren 
voor deze groep respectievelijk 4,8% en 11,3%. Met behulp van deze gegevens creëerden we 
een nomogram die de algehele overlevingskans kan voorspellen van patiënten die met 
onderhouds-BCG worden behandeld. 
 
In deel 2 van het proefschrift wordt stilgestaan bij de neveneffecten van de behandeling met 
onderhouds-BCG. 
 
In hoofdstuk 5 worden de aantallen en soorten neveneffecten beschreven zoals die werden 
gerapporteerd in trial 30962. De studie was erop gericht om met een gereduceerde dosis of 
een korter behandelschema het aantal neveneffecten terug te dringen. In de groep die 
 
behandeld werd met een gereduceerde dosis bleek het aantal neveneffecten niet te 
verschillen ten opzichte van de groep die met de volledige dosis werd behandeld. Omdat de 
meeste neveneffecten al in het eerste jaar van de behandeling optraden, leidde het geven van 
meer dan 1 jaar BCG niet tot duidelijk meer gerapporteerde neveneffecten in deze periode. 
 
Hoofdstuk 6 beschrijft het onderzoek naar het mogelijke effect van de leeftijd op de kans op 
het optreden van neveneffecten. Op basis van de gegevens van trial 30911 keken we hoe vaak 
neveneffecten leidden tot voortijdig staken van de behandeling en of dit gerelateerd was aan 
de leeftijd van de patiënt. We concluderen dat BCG niet vaker door neveneffecten gestaakt 
wordt op oudere leeftijd dan op jongere leeftijd en dat oudere leeftijd mede daardoor geen 
extra reden is de behandeling niet aan te bieden. 
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we inderdaad aan dat de kans op terugkeer van blaaskanker in oudere patiënten die 
behandeld worden met BCG groter is dan in jongere patiënten, waarbij overigens ook bleek 
dat in deze groep ouder dan 70 jaar BCG toch nog beter werkte dan epirubicine. 
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met NMIBC die behandeld worden met BCG. Met gegevens van 1812 patiënten konden we 
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FUTURE PERSPECTIVES 
BCG in a maintenance schedule is the most investigated compound so far as adjuvant 
treatment of intermediate- to high risk bladder cancer and has proven to be one of the most 
effective drugs to prevent recurrences. Information about the most appropriate treatment 
schedule for intermediate and high risk NMIBC derived from trial 30962 [Chapter 2] are 
adopted into the EAU guidelines on non muscle invasive bladder cancer (NMIBC): it is advised 
to treat patients at high risk with 3 years, full dose, in contrast with patients with intermediate 
risk, who can safely omit treatment after 1 year [1]. The latter includes patients with recurrent 
disease despite chemotherapeutic instillations who may well benefit from BCG. Also the 
conclusions of chapter 3, that BCG is less effective in patients > 70 years of age but still more 
than epirubicin is adopted by these guidelines. We can state that the research presented in 
this thesis is in this way already valorized.  
 
However, 3 aspects of maintenance BCG are bothersome:  
(1) The side effects of the treatment are frequently seen (62,8%) and have implications for 
the patients, regularly leading to discontinuation of the treatment (7,8%) [Chapter 5]. 
(2) The recurrence and progression despite maintenance BCG: we confirmed that patients 
with T1G3 do the worst with a 5 years’ progression rate of nearly 20% [chapter 4]. For 
these patients, other strategies are mandatory. 
(3) The world-wide and long lasting production problem leading to a shortage of BCG. 
All of the above mentioned aspects demand alternative adjuvant treatment options for 
patients with intermediate to high risk NMIBC. 
One of the most effective alternative treatments for very high risk patients is a cystectomy 
with subsequent creation of a bladder substitute (ilial conduit or neobladder). Other less 
rigorous strategies use other or a combination of compounds as bladder instillations and/or 
device assisted chemotherapeutic instillations. In this respect, promising data are available on 
the use of gemcitabine, Radiofrequency-Induced Thermo-chemotherapy (RITE) with 
mitomycin-C (MMC), and Electromotive drug administration (EMDA) with MMC combined 
with BCG. 
 
THE ROLE OF EARLY CYSTECTOMY AND SELECTION TOOLS FOR THIS APPROACH 
In very high risk cases (large or multifocal T1G3 tumors, recurrent T1G3 tumors or combined 
with CIS) it is advised to discuss the option of early cystectomy with the patient, according to 
the European guidelines of NMIBC [1]. Within the group of recurrent patients some progress 
to muscle invasive bladder cancer, making a cystectomy the gold standard therapy [2]. For 
these patients, prognosis is worse compared to primary muscle invasive bladder cancer (MIBC) 
as was first described by Schrier et al. [3]. This underlines again that we urgently need a 
thorough tool in order to make a proper and timely selection of patients for this intensive 
surgical approach. Could bladder cancer markers be used for this? Several markers that give 
information about bladder cancer recurrence have been developed. However, even for this 
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purpose none of the urinary markers were able to do better than cystoscopy and cytology in 
diagnosing recurrent disease [4]. For example, a recently tested marker in bladder cancer 
patients, urinary tyrosine-phosphorylated proteins, showed a sensitivity of 80% and a 
specificity of 79% for the presence of bladder cancer using a certain cut-off level compared to 
healthy people. [5]. This results are comparable with other available urinary tests [6]. 
Combining several tests may improve the sensitivity and specificity. For example, by 
combining epithelial membrane antigen (EMA) and nuclear matrix protein 52 (NMP-52), the 
sensitivity and specificity increased to 94% and 80%, respectively [7]. Nevertheless, the 
ultimate goal in creating and testing panels of markers will not only be predicting a recurrence 
but prognosticate progression despite adjuvant treatment. For this purpose, marker panels 
aren’t available yet. In this respect, some attention may go to circulating tumor cells (CTC). 
These have been linked to metastatic MIBC, but in 6 of 16 of patients with T1 non metastatic 
disease, CTC were also present [8]. 
 
GEMCITABINE 
Although BCG is superior to the mostly used chemotherapeutic agents MMC and epirubicin, 
in the past years another chemotherapeutic drug has been tested as adjuvant treatment in 
NMIBC. In a randomized phase 2 study patients recurring after BCG treatment were treated 
with Gemcitabine 2000mg in 50-100 cc NaCl,9%. The results showed a recurrence rate 
comparable with initial BCG treatment with acceptable side effects. Several schemes were 
used. An example is the schedule used by Di Lorenzo et al, who studied bi-weekly instillations 
of 2000mg Gemcitabine in 50 ml during in 6 weeks, followed by 3 weekly instillations after 3, 
6 and 12 months [9]. Another example is derived from a phase 2 trial by Skinner, that used a 
scheme of Gemcitabine 2000mg/ 100 ml of once a week during 6 weeks, followed by 10 
monthly instillations [10]. Despite these positive results and the need for an alternative for 
BCG, no registration studies are conducted currently. In October 2014, the Dutch Urology 
Association sent out a communication and advised it as alternative treatment in case of BCG 
shortage [11]. In 2015, Mostafid et al. published a comparable advice [12]. 
 
DEVICE ASSISTED CHEMOTHERAPEUTIC INSTILLATIONS 
The superior effect of RITE compared to MMC was initially shown by Colombo [13]. The report 
on a randomized phase 3 trial on BCG vs. RITE in intermediate and high risk NMIBC patients is 
submitted. An abstract on this study showed that RITE resulted in a lower RFS, at least in 
intermediate risk NMIBC patients compared to BCG in a maintenance schedule of 1 year [14]. 
By creating a field of electrical current inside the bladder using a surface electrode at the 
abdominal wall and an electrode inside the bladder, EMDA causes iontophoresis which causes 
a more thorough penetration of MMC inside the bladder mucosa. In a study by Di Stasi this 
instillation technique was combined with BCG instillations that were given alternately and 
gave a higher disease free interval by the combination as compared to 1 year of maintenance 
BCG alone in high risk patients [15]. 
 
 
MYCOBACTERIAL CELL WALL PARTICLES 
A potentially promising development is the isolation of surface proteins of Mycobacteria. 
Derived from BCG, cell wall skeleton (CWS), showed a negative response on viability of bladder 
cancer cells in vitro [16]. In animal studies using CWS, the effect was only seen when the 
particles were packed inside liposomes [17]. This strategy, that still demands BCG as a 
compound, could lower side effects, especially the risk of BCG sepsis but is no answer for 
recurrence rates or BCG shortage. Another approach is by the use of cell wall parts of 
Mycobacterium phlei. In 2015 Morales et al. published a phase 2 study in high risk patients 
who relapsed on BCG. The disease free rate at 2 years was 19%. Side effects were mild and 
mainly local [18]. 
 
REDUCING BCG DOSE ON INDICATION OF SIDE EFFECTS 
In trial 30962, reduction of the dose to 1/3 was investigated in a randomized fashion. This lead 
to the conclusion that in high risk patients this was insufficient treatment [chapter2]. On the 
other hand, it was not confirmed that a reduced dose lead to significantly less side effects 
[chapter 5]. What we do not know is the effect of reducing the dose only in patients that are 
experiencing side effects. When side effects otherwise would have resulted in a complete stop 
of the treatment, continuing with 1/3 dose can be considered after a clear and open discussion 
with the patient about the pro-‘s and con’s. 
 
BCG FAILURE IN INTERMEDIATE RISK PATIENTS 
Despite BCG maintenance therapy in intermediate risk patients, recurrent disease will occur 
in 5-20 percent of patients [chapter4]. The EAU guidelines on NMIBC give the advice to either 
repeat BCG, to start chemotherapeutic instillations or to do a cystectomy. Because 
maintenance BCG is superior to chemotherapeutic instillations in all RCT’s , it seems logical to 
upscale treatment to cystectomy unless the patient is not fit for this extensive surgery. 
However, on an individual basis, some patients can react poorly on BCG while reacting very 
well on e.g. MMC. Aspects of time to first recurrence, multiplicity and size of tumor recurrence 
and the quality of the transurethral resection has to be weighted against the impact of a 
cystectomy on the quality of life of the individual patient. 
 
IMPROVEMENTS IN RESECTION OF BLADDER TUMORS 
The expected recurrence rates in the treatment arms of trial 30962 [chapter2] were initially 
estimated at a higher level than eventually appeared during the lead time of the study. This 
resulted in less events as defined in the protocol when finally closing the trial.  One of the 
factors that may have contributed to the lower recurrence rate could be the improvement in 
visualisation leading to better transurethral resections. In the past 20 years, video cystoscopy 
has replaced direct cystoscopy, both in the outpatient clinic as in the operation theatre. 
Further improvements in video resolution to High Definition (HD) are expected to add to the 
accuracy although no research is done to evaluate this. Other technical improvements in 
cystoscopy include the introduction of photodynamic diagnostics (PDD). This technique uses 
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aminolevulinic acid that binds to cells that leads to the accumulation of fluorescent 
porphirines. With the ability to use a blue light source (380-470nm wavelength) and a 
computer that compensates the low luminous efficacy, altered tissue can be recognised and 
resected [19]. Another application of a filtered light source is Narrow Band Imaging (NBI). By 
using only blue and green light (excluding red), blood vessels will become black. Altered 
patterns of vessels can be recognized easier, leading to an improved resection rate of 
cancerous tissue [20]. Both techniques will stimulate the urologist to do a thorough inspection 
of the bladder wall before starting the resection. This aspect is suggested to be an important 
factor for better resection, as discussed in the study by O’Brien et al. that showed equally well 
results in white light resections as well some time after implementation of PDD [21]. 
 
A CLOUDY FUTURE? 
In searching for better treatment of NMIBC one aspect is easily overlooked. All efforts in 
solving an existing disease could be redundant if bladder cancer prevalence will drop 
dramatically. One of the most important risk factors is cigarette smoking This habit leads to a 
relative risk (RR) of developing bladder cancer of 3.49 and a RR of dying from bladder cancer 
of 1.48 for current smokers [22]. In the policy to discourage cigarette smoking by warnings on 
the packages, bladder cancer is not mentioned at all. By informing potential patients and 
prohibiting smoking a significant reduction of bladder cancer can be established, potentially 
reducing bladder cancer burden far more efficient than by the discussed adjuvant treatments. 
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DANKWOORD. 
Een dankwoord in een proefschrift weerspiegelt nog meer dan de lijst van auteurs wie het tot 
stand brengen van het manuscript mede mogelijk hebben gemaakt. En het eindigt steevast 
met het noemen van de levenspartner en eventuele kinderen, ook al zijn zij meestal meer 
belemmerend dan bijdragend geweest. Maar niet belemmerend genoeg, blijkbaar… 
Dit proefschrift heb ik te danken aan de visie van Dr. Adriaan van der Meijden, uroloog en een 
van mijn opleiders in het Bosch Medicentrum/ Jeroen Bosch Ziekenhuis. Hij was destijds ook 
één van de leidende urologen binnen de EORTC-GU groep en introduceerde me bij hun 
vergaderingen en congressen. Daar ontmoette ik Richard Sylvester, met wie Van de Meijden 
veelvuldig samenwerkte en publiceerde. Door deze introductie kreeg ik de kans om binnen 
deze groep taken op me te nemen en uiteindelijk hoofdonderzoeker te worden van een van 
de in dit proefschrift beschreven studies (samen met Professor Brausi).  
From that moment on I frequently went to Brussels to discuss the study-data with Richard. An 
American statistician in Brussels, who knows more of bladder cancer than most urologists do. 
In discussing and interpreting the results of the studies, Richard was of great help. Also in 
writing the articles and correcting my English sentences, Richard contributed a lot. Many, 
many thanks! The data of the trial were collected by Ms Linda Deprijck, at the EORTC 
headquarters. We checked a lot of datasheets together. Due to her very precise preparation 
of these meetings, we could be efficient and were able to guarantee an output of solid data. 
Thanks a lot, Linda! In trial 30962 was professor Brausi the eminent co-principal investigator. 
His efforts at the start to launch the study in 1996 and in the end to collect some of the missing 
data were important in order to finalize the study. The analyses of chapter 6 were performed 
by Samantha Cambier, as a statistician-trainee at the EORTC. Together we bridged the gap 
between calculations and medical relevance.  
Om te bereiken wat er nu voor u ligt is, naast onderzoek en tijd, ook een stok achter de deur 
nodig die op niveau de voortgang bewaakt en op cruciale momenten mee denkt. In dit kader 
heb ik grote bewondering voor de no-nonsens ondersteuning van Professor Witjes. Fred, dank 
daarvoor!  Voorts zijn er de overige mede-auteurs van de hoofdstukken, zonder wie het niet 
was gelukt ze te schrijven. De meesten van hen hebben door inclusie van patiënten 
bijgedragen aan het onderzoek, een aantal van hen daarbij ook door de manuscripten kritisch 
te lezen en te corrigeren. Met name Professor de Reijke, Professor Oosterlinck en Professor 
Gontero hebben zich daarin van hun opbouwende kant laten zien.  
In het gezin waarin ik opgroeide is nu bijna iedereen gepromoveerd. En dat hebben we 
allemaal aan mijn moeder te danken. Dat is jouw bijdrage, lieve Ans. En dan als laatste, 
onvermijdelijk, zoals reeds aangekondigd, wil ik mijn complimenten maken aan mijn eigen 
gezin: Ilone de Bruijn en Wessel en Reimer Oddens. Ilone, ik hoop dat je geduld wordt beloond, 
maar ik heb het zeker gewaardeerd. Wessel, jouw doorzettingsvermogen is al net zo groot als 
dat van mij. Dus je kan nog heel wat voor elkaar krijgen! Reimer, de uren dat we samen achter 
de computers zaten, waren voor jou heel wat speelser dan voor mij, al was het voor ons allebei 
hobby. 
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